Anesthesiological strategies to modulate the surgical stress response : a focus on the cardiovascular consequences

Citation for published version (APA):

Willigers, H. M. (2007). *Anesthesiological strategies to modulate the surgical stress response : a focus on the cardiovascular consequences*. [Doctoral Thesis, Maastricht University]. Datawyse / Universitaire Pers Maastricht. <https://doi.org/10.26481/dis.20071018hw>

Document status and date:

Published: 01/01/2007

DOI:

[10.26481/dis.20071018hw](https://doi.org/10.26481/dis.20071018hw)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Anesthesiological strategies to
modulate the surgical stress response

A focus on the cardiovascular consequences

ISBN 978 90 5278 658 2

© Copyright HMM Willigers, Maastricht 2007

Layout en druk: Datawyse bv / Universitaire Pers Maastricht

Anesthesiological strategies to modulate the surgical stress response

A focus on the cardiovascular consequences

PROEFSCHRIFT

ter verkrijging van de graad van doctor aan de Universiteit Maastricht,
op gezag van de Rector Magnificus, Prof. mr. G.P.M.F. Mols
volgens het besluit van het College van Decanen,
in het openbaar te verdedigen
op donderdag 18 oktober 2007 om 12.00 uur

door

Henriëtte Maria Margaretha Willigers

Promotor

Prof. dr. M. van Kleef

Copromotores

Dr. P.M.H.J. Roekaerts

Dr. F.W. Prinzen

Beoordelingscommissie

Prof. dr. H.J.G.M. Crijns (voorzitter)

Prof. dr. H. ten Cate

Prof. dr. M.E. Durieux (University of Virginia, USA)

Prof. dr. G.J. Scheffer (Universitair Medisch Centrum St Radboud, Nijmegen)

Prof. dr. H.A.J. Struijker Boudier

Contents

<i>Chapter 1</i>	Introduction	7
<i>Chapter 2</i>	The anesthesiologist and optimising cardiac outcome: <i>Strategies to modulate the perioperative stress response</i>	15
<i>Chapter 3</i>	Homeostatic responses after cardiac surgery: <i>Effect of anaesthesia management</i>	37
<i>Chapter 4</i>	Dexmedetomidine decreases perioperative myocardial lactate release in dogs	51
<i>Chapter 5</i>	Comparison of the effects of dexmedetomidine and esmolol on myocardial oxygen consumption in dogs	69
<i>Chapter 6</i>	The effects of esmolol and dexmedetomidine on myocardial oxygen consumption during sympathetic stimulation in dogs	87
<i>Chapter 7</i>	Contrasting baroreceptor effects of esmolol and dexmedetomidine in dogs	103
<i>Chapter 8</i>	General discussion	119

CHAPTER 1

Introduction

Introduction

A main goal of anesthesiologists is to protect their patients from risks associated with surgery. The stress response to tissue injury is a natural response which generally restores tissue homeostasis. However, the physiological effects associated with a large stress response or a defective stress response may be a major risk for patients having surgery. Therefore, anesthesiologists should further refine their strategies to control the surgical stress response. However, this is not an easy task.

Surgical procedures such as reposition of fractured bones and trepanation of the skull have been performed since prehistoric times¹. However, it is only for about one century that the systemic adaptive response associated with these procedures has attracted the interest of scientists. First, physiologists introduced terms related to adaptive systems in general such as: “milieu interieur” (Claude Bernard, 1898) “homeostasis” and “fight or flight” (Walter Cannon, 1929). Later, terms in relation to the stress of tissue injury were introduced like “metabolic stress response” (D. Cuthbertson, 1932), “general adaptation syndrome” (Hans Selye, 1936) and “wound hormones” (Egdahl, 1959). Since then a growing number of studies continue to reveal the enormous complexity of the stress response to tissue injury. This complexity is not surprising because there are data indicating that this response is also present in fish and therefore has evolved over more than 400 million years². Our current understanding of this response may be summarized as follows (fig. 1). Tissue trauma initiates a local inflammatory response that, through blood-borne and neuro-sensory signals, initiates a systemic stress response with the ultimate goal to restore homeostasis. In general, the stress response to tissue trauma may be divided into an immunological component and a neuro-endocrine component³. The immunological component, which includes activation of the inflammatory response and amplification of the innate (natural) immune system, is important for tissue healing and prevention of infections. The neuro-endocrine component, which consists of activation of the autonomic nervous system and of the hypothalamic-pituitary-adrenal (HPA) axis, has an important role in providing energy sources for the injured tissue. Additionally it helps to prevent an overreaction of the inflammatory-immunological response. It is important to realise that these two components of the systemic stress response are tightly interconnected³⁻⁵. For example, cytokines, important mediators of the inflammatory-immune response, are known to stimulate the HPA axis. Conversely, immune cells contain receptors for hormones and transmitters of the HPA axis. In addition to this hormonal interaction between both systems there is exciting evidence that the nervous system may directly control the immune system⁵.

Figure 1 Schematic representation of the stress response to tissue injury.
 Symp NS: sympathetic nervous system; Parasymp NS: parasympathetic nervous system.

Homeostasis may not be restored if the stress response is too weak or too strong in relation to the stressor or in relation to the patient. If the stress response is too weak the patient suffers from infections and impaired tissue healing. In contrast, excessive inflammatory or neuro-endocrine responses may result in the systemic inflammatory response syndrome or excessive cardiovascular activation respectively. Especially in patients at the extremes of ages and in patients having co-morbidity this may cause significant morbidity.

The introduction of anesthetic techniques in the 19th century was a key event in surgical practice because the associated sedation and tissue relaxation allowed for increasingly invasive surgical procedures. However, patients frequently died after major surgical procedures. Later, a study in neonates showed the importance of attenuation of the neuro-endocrine stress response in reducing postoperative morbidity and mortality⁶. Also, various studies in adults suggested an important relation between the neuro-endocrine stress response and adverse cardiac outcome after surgery. So, diminishing the neuro-endocrine stress response to surgery became a major goal for anesthesiologists.

Recently, evidence has emerged that inflammatory immunological phenomena underlie postoperative complications such as the systemic inflammatory response syndrome, postoperative infections, and coronary thrombotic events^{7,8}. Additionally, there is evidence that anesthesiological techniques can affect these immunological phenomena⁹. So, anesthesiological techniques may improve outcome from their effect on both the neuro-endocrine and the immunological component of the stress response.

Various recent developments in health care have created a renewed interest in strategies to modulate the surgical stress response. Also, the research questions in this thesis may be seen as part of this renewed interest. The main focus of these questions is on modulation of the stress response in relation to the cardiovascular system. This is because cardiovascular complications have an important effect on postoperative outcome.

A first development in health care is that economic forces have resulted in surgical programs aiming at a faster recovery from anesthesia and surgery. However, these fast track surgical programs incorporate the use of short-acting anesthetic drugs, and thus may leave the patient relatively unprotected from potential harmful stress responses during the early period after major surgery¹⁰. One fast track anesthetic strategy for cardiac surgery is a technique based on the short-acting opioid remifentanyl, which allows for the intra-operative use of high dose opioids without delaying extubation¹¹. Alternatively, an anesthetic technique based on thoracic epidural analgesia can be used. This is because this technique has additional potential benefits such as profound attenuation of the neuro-endocrine stress response and thoracic cardiac sympathectomy¹². There are indications that an epidural-based anesthetic technique results in superior analgesia and haemodynamic stability compared to a remifentanyl based technique¹³. However, the simultaneous effects of these fast-track anesthetic techniques on both the neuro-endocrine and the immunological component the surgical response have not been studied. Therefore, our first research question was: "How does the choice of anesthesiological techniques affect homeostatic responses to fast track coronary artery bypass surgery?"

Another development in health care is that there are increasingly less restrictions regarding age and comorbidity in surgical patients. This has resulted in an increased incidence of coronary artery disease, an important risk factor for myocardial ischemia, in surgical patients¹⁴. Currently, the most important strategy to decrease the risk at myocardial ischemia in these patients is to suppress the stress response to surgery. However, many basal questions in relation to this strategy are still unanswered. We decided to focus at pharmacological modulation of the autonomic nervous system and the associated cardiovascular

effects. This resulted in two research questions which were studied in dogs because this species allowed for detailed measurements in a controlled experimental setting and because our laboratory has extensive experience with cardiovascular studies in dogs.

First, there is uncertainty regarding the exact pathophysiology of postoperative myocardial ischemia. Postoperative myocardial ischemia may result from myocardial oxygen supply-demand mismatch or from thrombosis on coronary plaques. It is generally believed that sympatholytic therapy may decrease myocardial ischemia purely from its effect on myocardial oxygen supply-demand balance. However, this remains unknown from clinical studies because in these studies it cannot be excluded that sympatholytic therapy reduces myocardial ischemia by decreasing shear stress on plaques⁸. Therefore, our research question was: “Has pharmacological sympatholysis the potential to decrease myocardial ischemia during emergence from anesthesia purely from its effect on myocardial oxygen balance?”

The next question was related to choosing the optimal drug for modulation of autonomic nervous system. The American Heart Association advises to use either beta-adrenergic antagonists or α_2 -adrenergic receptor agonists for perioperative pharmacological sympatholysis¹⁵. These are fundamentally different classes of drugs. The principal action of beta-adrenergic blockade is to decrease beta-adrenoreceptor signalling at the end-organ receptor level. α_2 -agonists lower central sympathetic tone via activation of α_2 -receptors in the medullary dorsal motor complex and in the nucleus tractus solitarius. However, few studies concentrated on differences between both classes of sympatholytic drugs. Therefore we studied differences between beta-blockers and α_2 -agonists on myocardial oxygen demand and on autonomic nervous system mediated cardiovascular control. This is because these two variables seem to have an important role in the anti-ischemic effects of sympatholytic drugs.

In summary, the following three research questions have been addressed in this thesis:

1. How does the choice of anesthesiological techniques affect homeostatic responses to fast track coronary artery bypass surgery?
2. Has pharmacological sympatholysis potential to decrease myocardial ischemia during emergence from anesthesia purely from its effect on myocardial oxygen balance?
3. Do fundamentally different classes of sympatholytic drugs have different effects on:
 - A. Myocardial oxygen demand?
 - B. Autonomic nervous system mediated cardiovascular control mechanisms?

Overview of the thesis

We started with an overview of the literature on anesthesiological strategies to decrease myocardial ischemia associated with the stress response to surgery (**chapter 2**).

The first research question has been addressed in **chapter 3**. In this chapter we compare the effects of two different anesthetic techniques on the inflammatory and the sympathetic stress response after fast-track coronary bypass surgery. We studied an epidural-based fast track technique and a technique based on the short-acting opioid remifentanyl.

To answer our second research question we applied a critical coronary stenosis in dogs that were instrumented for detailed measurements of myocardial oxygen balance. Then either a sympatholytic drug (the α_2 -agonist dexmedetomidine) or a placebo drug was infused and the dogs were allowed to emerge from anesthesia. Myocardial lactate release was measured as a gold standard indicator of myocardial ischemia (**chapter 4**).

The short acting β_1 -blocker esmolol and the α_2 -agonist dexmedetomidine were compared to study our third research question. The effects of both classes of sympatholytic drugs on changes in myocardial oxygen demand and in cardiovascular variables were measured both in absence (**chapter 5**) and in presence of a sympathetic stimulus (**chapter 6**). A selective decrease in carotid artery pressure from bilateral carotid artery occlusion was used as a sympathetic stimulus. Differences in the effects of esmolol and dexmedetomidine on autonomic nervous system function and associated hemodynamic stability have been studied in **chapter 7**. Autonomic nervous system tone and baroreceptor mediated cardiovascular control was evaluated from; the power of frequency spectra of heart rate and aortic pressure variability, plasma norepinephrine concentrations, the response to a decrease in carotid artery pressure, and cardiac baroreflex sensitivity. Our findings are discussed and suggestions for future research are proposed in **chapter 8**. Finally, the previous chapters are summarized in **chapter 9**.

References

- 1 Ellis H. *A history of surgery*. London: Greenwich Medical Media Limited, 2001.
- 2 Metz JR, Huising MO, Leon K, Verburg van Kemenade BM, Flik G. Central and peripheral interleukin-1 β and interleukin-1 receptor I expression and their role in the acute stress response of common carp, *Cyprinus carpio* L. *J Endocrinol* 2006; **191**: 25-35.
- 3 Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. *Ann N Y Acad Sci* 1998; **851**: 311-35.
- 4 Molina PE. Neurobiology of the stress response: contribution of the sympathetic nervous system to the neuroimmune axis in traumatic injury. *Shock Augusta, Ga.* 2005; **24**: 3-10.

- 5 Tracey KJ. The inflammatory reflex. *Nature* 2002; **420**: 853-9.
- 6 Anand K, Hickey P. Halothane-morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. *N Engl J Med* 1992; **326**: 1-9.
- 7 Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. *Anesthesiology* 2002; **97**: 215-52.
- 8 Landesberg G. The pathophysiology of perioperative myocardial infarction: facts and perspectives. *Journal of cardiothoracic and vascular anesthesia* 2003; **17**: 90-100.
- 9 Homburger JA, Meiler SE. Anesthesia drugs, immunity, and long-term outcome. *Current opinion in anaesthesiology* 2006; **19**: 423-8.
- 10 Myles PS, Daly DJ, Djaiani G, Lee A, Cheng DC. A systematic review of the safety and effectiveness of fast-track cardiac anesthesia. *Anesthesiology* 2003; **99**: 982-7.
- 11 Royston D. Patient selection and anesthetic management for early extubation and hospital discharge: CABG. *J Cardiothorac Vasc Anesth* 1998; **12**: 11-9.
- 12 Chaney MA. Intrathecal and Epidural Anesthesia and Analgesia for Cardiac Surgery. *Anesth Analg* 2006; **102**: 45-64.
- 13 Kessler P, Aybek T, Neidhart G et al. Comparison of three anesthetic techniques for off-pump coronary artery bypass grafting: general anesthesia, combined general and high thoracic epidural anesthesia, or high thoracic epidural anesthesia alone. *J Cardiothorac Vasc Anesth* 2005; **19**: 32-9.
- 14 Mahla E, Vicenzi MN, Schrottner B et al. Coronary artery plaque burden and perioperative cardiac risk. *Anesthesiology* 2001; **95**: 1133-40.
- 15 Eagle KA, Berger PB, Calkins H et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Anesth Analg* 2002; **94**: 1052-64.

CHAPTER 2

The anesthesiologist and optimising cardiac outcome: *Strategies to modulate the perioperative stress response*

Perioperative myocardial ischemia, a serious problem

Cardiac complications are a major cause of morbidity and mortality after surgery¹. Early postoperative myocardial ischemia is the most important predictor of these cardiac complications, increasing their relative risk 9 to 21 times. It is important to realize that myocardial ischemia and cardiac complications constitute a continuum of biological processes. With a shortage of myocardial oxygen supply, anaerobic glycolysis replaces oxidative phosphorylation as the primary source for ATP. This results in an increase in lactate, ADP, AMP, glucose-6-phosphate, and fructose-6-phosphate. After one minute the function of the ischemic area starts to deteriorate proportionally to the decrease in myocardial blood flow². Thereafter electrophysiological abnormalities start as reflected by ECG changes. Irreversible myocardial damage (i.e. myocardial infarction) occurs after approximately 30 minutes cessation of myocardial blood flow. Congestive heart failure and cardiac death may result from changes in myocardial function and electrical stability during or after this process.

The incidence of myocardial infarction is approximately 0.06% in one month in a population-based cohort of men and women aged 55 years and older³. In contrast, the incidence of in-hospital myocardial infarction after surgery varies between 1.4% in relatively unselected patients, and 5.6% in cardiac risk patients⁴. These figures suggest that surgery increases the risk for myocardial infarction more than ten-fold. Why is this?

The stress response to surgery

The most important reason for the increased incidence of myocardial infarction after surgery is related to the stress response associated with tissue trauma. This response incorporates profound immunological and neuro-endocrine changes with the ultimate goal to restore tissue homeostasis. A simplified picture of this response and its feedback mechanisms is shown in fig. 1.

The immunological part of the surgical stress response starts as a tissue based reaction to trauma and is designed to decrease infections and promote healing. As far back as AD 40, Celsus defined this response as rubor, calor, dolor, and tumor. Currently we know that this response includes complex cascades, such as the complement, cytokine, and the coagulation-fibrinolytic cascades, and changes in cellular components of the immune system.

The cytokine cascade is of key importance and starts with the release of the cytokines IL-1 and TNF- α from activated macrophages and monocytes in injured tissue⁵. These cytokines stimulate the release of IL-6 which is mainly a pro-inflammatory cytokine and responsible for inducing the production of

Figure 1. Some of the hormonal and neural pathways involved in the neuro-endocrine and the immunological response to tissue injury. TNF: tissue necrosis factor; IL-1: interleukine-1; IL-6: interleukine-6.

acute phase proteins such as C-reactive protein, fibrinogen and α_2 -macroglobulin in the liver. These acute phase proteins act as inflammatory mediators and as anti-proteinases, and promote tissue repair. To prevent a systemic overreaction of this pro-inflammatory response, tissue trauma also stimulates the production and release of anti-inflammatory cytokines such as IL-10, IL-1ra, and TNF soluble receptors. There are indications that it is this balance, between pro- and anti-inflammatory cytokine responses, which is most important for the clinical prognosis after surgery⁶. Closely interconnected with this cytokine cascade are changes in the coagulation-fibrinolytic cascades⁷. Proinflammatory cytokines increase the expression of tissue factor and of intravascular leukocyte

adhesion molecules, activate the endothelium, and stimulate the production of platelet activation factors. Also, the fibrinolytic and protein-C anticoagulant pathways are down regulated. As a result, the immune response to tissue injury is associated with a marked procoagulant state.

The immune response to tissue injury also includes profound changes in the cellular components of the immune system. There is an immunoconversion from the acquired immune response to the natural immune response⁸. This increased activity of the natural immune system assures the highest level of host defence because it is capable of instantaneously attacking pathogenenic agents and detecting infected and injured cells. The down-side of this immunoconversion manifests as anergy in response to skin testing and failure to produce specific antibodies. Theoretically, this may result in an increased risk of sepsis and increased metastatic tumour spread after surgery^{9,10}.

The neuro-endocrine part of the surgical stress response is a central nervous system mediated response. It peaks early after surgery, when the effects of anesthesia wear off. Its magnitude and duration are influenced by factors such as the amount and location of tissue damage, pain, anxiety, infection, hypovolemia, and hypoxemia. The most important function of the neuro-endocrine response is to promote an adaptive redirection of oxygen and nutrients to the stressed body sites and the central nervous system¹¹. Additionally, it has a role in preventing an overreaction of the immune response. Neural and cytokine signalling of tissue trauma results in activation of the paraventricular nucleus of the hypothalamus. The increase in hypothalamic releasing factors in turn stimulate the pituitary to release vasopressin, growth hormone, prolactin and propiomelanocortin. Propiomelanocortin is metabolised to ACTH, which stimulates the secretion of corticosteroids, and to beta-endorphin, an endogenous opioid. Hypothalamic activation also changes the activity of autonomic nervous centre towards an increased sympathetic tone and a decreased parasympathetic tone. Clinical consequences are: 1) down-regulation of the beta-adrenoreceptor system related to increased plasma concentrations of catecholamines and 2) a decrease in vagal mediated heart rate variability in patients after major surgery¹². In this way changes in autonomic nervous balance may explain increased blood pressure fluctuations after surgery¹³.

The immunological and the neuro-endocrine parts of the stress response are no separate entities. Instead, the system is designed as a neuro-endocrine-immune feedback loop which allows regulation of host defence mechanisms¹⁴⁻¹⁸. For example, immune mediators and cytokines activate the neuro-endocrine stress response because they can pass the blood-brain barrier and because they can stimulate vagal and sensory afferent nerves¹⁹. Simultaneously, glucocorticoids and catecholamines activate receptors on immune cells which

results in a negative-feedback control of the immune response. The dynamic nature of mediators of the stress response adds to the complexity of the stress response. For example, the actions of some cytokines switch from pro-inflammatory to anti-inflammatory, depending on timing and context¹⁶.

In conclusion, surgery leaves the patient with much more than a tissue scar. Studies focussing on homeostatic responses to tissue injury continue to reveal the enormous complexity of these responses. It is this increase in basic knowledge on homeostatic responses which offers exciting opportunities to increase our knowledge on the relation between homeostatic responses and perioperative morbidity.

Linking the surgical stress response to myocardial ischemia

The atherosclerotic coronary plaque is the common morphological risk factor of perioperative myocardial ischemia and infarction. Over the past decade we have learned that the immune response occupies a central position in the pathophysiology of these plaques²⁰. We have also appreciated the dynamic nature of inflammatory-immune processes in these plaques which may be divided into two extremes. At one end of the spectrum is the structural vulnerable plaque, which has a central lipid core, many inflammatory cells and a thin cap. At the other end of the spectrum is the stable plaque which has few inflammatory cells and a thick fibrous cap.

Parallel to this variability of inflammatory-immune processes in plaques the aetiology of perioperative myocardial infarction may be divided into the following two common mechanisms²¹ (Fig. 2).

First, myocardial infarction may result from thrombosis on, or rupture of, coronary plaques. Potential triggers of this mechanism are: increased systemic inflammatory and procoagulant activity, increased sympathetic mediated shear stress on plaques, and increased sympathetic or local mediated coronary vasoconstriction. This mechanism accounts for less than 50% of perioperative myocardial infarctions and the timing of these infarctions has no specific correlation to the end of surgery.

Another mechanism for perioperative myocardial infarction is prolonged myocardial oxygen supply-demand mismatch in the presence of severe, but stable, coronary stenosis. The postoperative increase in sympathetic tone seems to be central to this type of myocardial infarction. Myocardial oxygen demand may increase from associated increases in heart rate, arterial pressure, and myocardial contractility. Simultaneously, myocardial oxygen supply may decrease from coronary vasoconstriction and a decreased diastolic filling time. These changes in myocardial oxygen demand and supply may result in

Figure 2. Two common pathophysiological mechanisms of perioperative myocardial infarction. These are; 1) long-term mismatch in myocardial oxygen demand and supply in presence of a severe stable coronary artery stenosis and, 2) rupture and thrombosis in presence of an unstable coronary plaque. Adapted with permission from Libby *et al* (Circulation 2005; 111: 3481-8.)

subendocardial ischemia, and if prolonged, in circumferential myocardial infarction. Typically, this ST-depression type of myocardial ischemia occurs within 8 to 24 hours from the end of surgery, and the peak incidence of associated cardiac death is in the first 1-3 postoperative days.

However, although these two pathophysiological mechanisms are clearly associated with perioperative myocardial infarction, the exact mechanism of perioperative myocardial ischemia remains unknown. To date, it remains unknown if myocardial infarction can result purely from mismatches in myocardial oxygen supply and demand. This is because the coronary plaque is the common morphological lesion in patients having perioperative myocardial infarction. Rupture of, and thrombosis on, coronary plaques may resolve spontaneously and therefore it can never be excluded that this mechanism contributed to the etiology of perioperative myocardial infarction. Another problem in studying the pathophysiological mechanisms of perioperative myocardial infarction is that methodological limitations prevent accurate measurement of myocardial oxygen consumption and demand. Finally, the diagnosis of myocardial ischemia and infarction is very difficult. Selecting ST-segment changes as an outcome measure may not always be clinically relevant because they also result

from changes in temperature, serum electrolytes, position of electrodes, and from administration of drugs²². A more precise measure of myocardial ischemia, but difficult to obtain in patients, is the presence of lactate release from the myocardial area at risk. For the diagnosis of myocardial infarction several combinations of criteria such as typical ischemic chest pain, typical ECG findings, and increases in plasma concentrations of biochemical markers of myocardial injury are used. However, chest pain is often masked by analgesics in patients recovering from surgery and there is no generalised accepted standardization of these criteria¹.

It is likely that both inflammatory mediated coronary thrombotic events and sympathetic mediated mismatches in myocardial oxygen balance contribute to myocardial infarction in the perioperative period. This implicates that multimodal strategies are needed to decrease the incidence or severity of perioperative myocardial infarction.

Strategies to decrease the surgical stress response

The surgeon may decrease the immunological response to tissue injury by further developing surgical techniques with lesser tissue trauma. However, these techniques seem to have relatively little effect on the neuro-endocrine response²³. Also, there seems to be no immunologic advantage of laparoscopic surgery in relatively uncomplicated operations such as inguinal herniorrhaphies and in advanced procedures such as colectomies²⁴.

The anesthesiologist may decrease the neuro-endocrine response to surgery by carefully choosing anesthetic strategies. In contrast to earlier beliefs, there are recent indications that these techniques also affect the immune response to surgery²⁵. Anesthetic strategies may affect the immune response to surgery indirectly by modulating the neuro-endocrine response or directly by affecting the functions of immune competent cells. In addition to choosing anesthetic strategies, the anesthesiologist may implement pharmacological strategies to modulate the perioperative stress response. Of these, sympatholytic drugs receive most attention because of their potential to decrease cardiac complications.

1. Anesthetic and analgesic strategies to decrease the surgical stress response.

In general, either an epidural based or an opioid based anesthetic strategy may be used to decrease the stress response to major surgery.

Epidural anesthesia and analgesia

Epidural analgesia involves the administration of local anesthetics through a catheter placed in the epidural space thus interrupting peripheral nerve traffic. The level of the catheter tip and the infusion rate of local anesthetics determine

the extend and spinal level of nerve blockade. Epidural analgesia has profound sympatholytic effects because it decreases the afferent neural input from the site of injury and because it may decrease the efferent neural input to the adrenal gland. Additionally, epidural anesthesia may also suppress the response of the hypothalamic-pituitary-adrenal (HPA)-axis to surgical stress. However, this suppression of the HPA axis applies mainly to patients having surgery below the umbilicus. In high abdominal and thoracic surgery epidural analgesia does not consistently suppress the HPA-axis response. The reason for this is unknown, but afferent neural input may not be blocked adequately or the inflammatory response may have an important role in activation of the HPA-axis in this type of surgery²⁶.

The cardiovascular effects of epidural anesthesia depend on the extend and level of epidural blockade and associated sympatholysis²⁷. The heart is innervated by sympathetic nerves from thoracic level 2 to 4. Blockade of cardiac sympathetic fibers associated with a high level epidural block (above the fifth thoracic level) may therefore decrease myocardial oxygen demand. Additionally, the diameter of stenotic coronary arteries and the endo- to epicardial blood flow ratio may increase as a result of a decrease in sympathetic mediated coronary vasoconstriction. In contrast, during lumbar epidural anesthesia a reflex compensatory increase in thoracic sympathetic nerve activity may compromise myocardial oxygen balance.

In addition to these neuro-endocrine effects there are indications that epidural techniques also modulate the immunological response to surgery. This seems to be an indirect effect because epidural infusion of local anesthetics alone, in the absence of surgery, seems to have only transient and minor effects on human immune function²⁸. In contrast, in presence of surgery epidural anesthesia does have immunological effects. Epidural analgesia decreased IL-6 production after low abdominal surgery²⁹ and decreased circulating levels of the anti-inflammatory cytokine IL-10 in patients having coronary artery bypass³⁰. Also, epidural analgesia attenuated post surgical lymphocyte depression in patients having spine surgery³¹. The exact mechanism of these immunological effects remains unknown. They may be related to the neuro-endocrine effects of epidural anesthesia or to direct effects of local anesthetics on neutrophils³².

Clinically, an epidural technique has profound analgetic effects and reduces many of the potential adverse physiological consequences of surgery. However, the impact of epidural analgesia on postoperative mortality and morbidity remains uncertain. In a large randomised controlled trial in high-risk patients undergoing major intra-abdominal surgery an epidural technique improved analgesia, and reduced respiratory failure³³. However, this trial failed to show an effect of epidural analgesia on cardiovascular morbidity. Further, it is important

to realise that potentially serious complications of an epidural technique include epidural hematoma, epidural abscess, and post-dural puncture headache.

Opioid anesthesia and analgesia

As alternative to an epidural based anesthetic strategy, an opioid based strategy may be used to modulate surgical stress responses. Opioids exert their effects through the μ , κ , and δ – opioid receptors which belong to the family of G-protein coupled receptors. These receptors are present on various cells involved in the stress response, including central neurons and immune cells.

Opioids modulate neuro-endocrine stress responses because of their analgesic effects and because of their effects on receptors in the hypothalamus and brainstem^{17,34}. It has been known for many years that stimulation of μ -opioid receptors in the hypothalamus suppresses the response of the HPA-axis. Stimulation of central μ -opioid receptors also affects autonomic nervous system activity. Vagal outflow increases, but variable effects on sympathetic outflow have been reported. It has been suggested that these effects on sympathetic outflow depend on which hypothalamic nucleus is stimulated³⁴. In the surgical patient opioids favour a sympatholytic effect. However, this effect does not seem to be very strong because high doses of morphine are needed to suppress the increase in catecholamines during thoracic and upper abdominal surgery³⁵. Also, further increasing the dose of opioids has no additional sympatholytic effect³⁶.

Opioids also modulate the immunological stress response. This may result from direct interaction with opioid receptors on cells of the immune system, or indirectly from their effect on neuro-endocrine stress response. Stimulation of opioid receptors on immune cells results in a suppression of numerous components of the immune system such as natural killer cell activity, neutrophil complement and immunoglobulin receptor expression, chemokine induced chemotaxis, and phagocytosis³⁷. Also most clinical studies point toward an overall immunosuppressive effect and an increased susceptibility to infections of chronic administration of opioids³⁸. However, the immunological consequences of short-term opioid analgesia are less clear.

Opioids may have a beneficial effect on cardiac outcome. In a study in cardiac surgical patients intensive postoperative opioid analgesia decreased the severity of myocardial ischemia³⁹. Also, there are indications that direct stimulation of opioid receptors on cardiac myocytes may limit myocardial ischemic injury⁴⁰. However, no definite data are available on the effects of opioids on cardiac outcome.

2. Pharmacological strategies

In addition to choosing anesthetic strategies the anesthesiologist may also modulate perioperative stress responses by adding drugs. Of these, beta-blockers

and α_2 -agonists, two fundamentally different classes of sympatholytic drugs, are most commonly used.

Beta-blockers

The principle action of beta-adrenergic blockade is to decrease beta-adrenoreceptor signalling at the end-organ receptor level⁴¹. Beta-1 selective beta-blockers have been used in most studies on perioperative beta blockade. However, the clinical importance of beta1-receptor selectivity on cardiac mortality remains to be determined⁴². Esmolol, a beta-1 selective blocker, has been advocated for use in the perioperative period because of its extremely short elimination half-life of approximately 9 minutes⁴³.

In general, beta-blockers seem to have no major effects on the neuro-endocrine stress response. They have been found to either increase or to have no effect on the activity of the sympathetic and parasympathetic nervous system⁴⁴⁻⁴⁶. These differences in findings may be explained from differences in methods of measurements, and from differences in route and in duration of the administration of the beta-blocker. The effect of beta-adrenergic blockade on the HPA-response is largely unknown. In a study in healthy adults the beta-blocker propranolol had no effect on the HPA-response associated with a pentagastrine induced panic attack⁴⁷. Also, a study in volunteers showed that the adrenal beta-receptor plays no major role in steroid secretion⁴⁸.

There is increasing evidence that beta-adrenergic receptors on immune cells have a central role in the connection between sympathetic activation and immune function⁴⁹. However, there are very few studies focussing on the immunological effects of beta-blockers. In studies in mice beta blockade changed cellular immune functions and reduced survival from septic or hemorrhagic shock^{50, 51, 52}.

The effect of perioperative beta-blockade on cardiac outcome has been intensively studied. Mangano and colleagues showed that perioperative atenolol administration decreased long term overall mortality by 55% and cardiac mortality by 65% in patients having or being at risk for coronary artery disease and undergoing major surgery⁵³. Poldermans and colleagues showed in a placebo controlled study that bisopropol significantly decreased perioperative cardiac morbidity and mortality in a very high cardiac risk group⁵⁴. Based on this evidence the American Heart Association guidelines strongly support the perioperative use of beta-blockers in patients having an increased cardiac risk⁵⁵. However, there are also indications that this evidence is too optimistic. In the study of Mangano and colleagues the in-hospital deaths were excluded, beta-blockers were stopped in the control group, and there were more diabetic patients in the control group. The study of Poldermans and colleagues has been criticized for the lack of blinding and the implausibly large treatment effects.

More recent trials did not demonstrate any benefit from perioperative beta-blocker therapy⁵⁶. Very recently, a meta-analysis of 69 controlled trials showed that beta-blockers reduce myocardial ischemia, but have no effect on myocardial infarction or mortality⁵⁷.

The exact mechanism by which beta blockers reduce myocardial ischemia remains unknown²¹. In general, suppression of sympathetic beta-receptor mediated cardiovascular responses is believed to be their most important anti-ischemic mechanism. In this way beta-blockers may prevent prolonged, stress induced mismatches in myocardial oxygen balance. More specifically, there is quite convincing evidence that the protective effect of beta blockers is related to their heart rate lowering effect. Controlling the heart rate below the individual ischemic threshold for 48 hour after surgery reduced myocardial ischemia in patients at high risk of cardiac complications⁵⁸. Also, high doses of beta-blockers and tight heart rate control were associated with reduced perioperative myocardial ischemia and troponin-T release in vascular surgery patients⁵⁹.

Alpha₂-agonists

The principal action of alpha₂-agonists is to decrease central sympathetic outflow. Other well-documented effects of alpha₂-agonists include anxiolysis, sedation, and analgesia. Clonidine is the prototypical alpha₂-agonist to which all other alpha₂-agonists are compared, and has been used for more than 40 years in treatment of hypertension and in opioid and alcohol withdrawal syndromes. The alpha₂-agonist dexmedetomidine is very selective for alpha₂-receptors (dexmedetomidine: α_2 / α_1 selectivity: 1600, versus clonidine: α_2 / α_1 selectivity: 40) and its shorter plasma half live makes titration to effect more easy (dexmedetomidine plasma half life: 2 hours, versus clonidine plasma half life: 9 hours). In 1999 the US Food and Drug Administration approved dexmedetomidine for sedation of intensive care patients. Since that time the number of studies focussing on this drug has increased enormously. A recent study in human volunteers showed that dexmedetomidine has a profound sympatholytic effect which is already clinically significant at the lowest plasma concentration⁶⁰.

Alpha₂-agonists affect mainly the autonomic nervous system mediated effects of the neuro-endocrine stress response. They lower central sympathetic tone via activation of alpha₂-receptors in the medullary dorsal motor complex and in the nucleus tractus solitarius. These central sympatholytic effects of alpha₂-agonists are augmented by inhibition of peripheral ganglionic transmission⁶¹. Additionally, there are indications that alpha₂-agonists enhance parasympathetically mediated heart rate control from their effects on alpha₂-receptors in the vagal nuclei of the medulla oblongata⁶². A recent study demonstrated the clinical importance of central alpha₂-receptors on autonomic responses to stress⁶³. It

showed that persons which have a genetic polymorphism of the central α_2 -adrenergic receptor have an increased autonomic responsiveness to various stressors. In addition to their direct sympatholytic effects, α_2 -agonists may decrease sympathetic responses from their analgetic, anxiolytic, and sedative effects. These effects are mediated by stimulation of α_2 -receptors in the locus coeruleus and nucleus reticularis lateralis. In contrast to their profound autonomic nervous system effects, α_2 -agonists do not seem to have an important effect on the HPA-axis mediated effects. Clonidine did not affect cortisol release in patients undergoing pancreatico- biliary surgery⁶⁴ or CABG surgery⁶⁵. Also, dexmedetomidine infusion had no effect on serum cortisol or ACTH concentrations after major surgery⁶⁶.

There are few data on the immunological effect of α_2 -agonists. In an in vitro study, clonidine and dexmedetomidine did not affect chemotaxis, phagocytosis, or superoxide production by human neutrophils⁶⁷. The immunological effects of α_2 -agonists in the presence of surgery are equivocal. Clonidine reduced the interleukin-6 production in response to total abdominal hysterectomy⁶⁸. In contrast, clonidine had no effect on the IL-6 response after pancreatico- biliary surgery⁶⁴. Also, a postoperative sedative infusion of dexmedetomidine had no significant effects on IL-6 plasma concentrations⁶⁶. A study focussing on the cellular immunological response of clonidine after CABG surgery showed that this α_2 -agonist changed the T-lymphocyte subpopulation in favour of a pro-inflammatory response⁶⁹. However, the clinical relevance of these data remains to be determined.

α_2 -agonists have been less well studied than beta-blockers for perioperative myocardial protection; 6 versus 11 randomized controlled trials up to November 2002⁷⁰. The potential benefit of α_2 -agonists on myocardial ischemia was initially controversial because of their direct coronary vascular effects. α_2 -agonists may jeopardize coronary flow reserve from stimulation of vascular smooth muscle α_{2B} -receptors⁷¹. However, activation of α_2 -adrenoreceptors on vascular endothelial cells may cause vasodilatation. Also, multiple clinical studies and two meta-analyses have shown that α_2 -agonists decrease perioperative myocardial ischemia in cardiac risk patients^{72,73}. In the largest study this beneficial effect resulted mainly from the effect of an α_2 -agonist in a subgroup of patients with known coronary heart disease and undergoing vascular surgery⁷⁴. Recently, a prospective double blind trial in 190 patients showed that clonidine reduces perioperative ischemia and postoperative mortality in patients undergoing non-cardiac surgery and having or being at risk for coronary artery disease⁷⁵.

It is important to realise that studies on the effect of an intervention on the stress response are very difficult to interpret. Firstly, this is because the stress response is part of a feedback system. Another difficulty is that there is a paucity of basal data on “normal” quantitative relationships between the type and duration of stressor and sequential changes in plasma concentrations of mediators of the stress response⁷⁶. Studies having perioperative myocardial ischemia or myocardial infarction as an outcome measure are even more difficult to interpret. This is because these outcome measures are difficult to diagnose and have a low incidence¹. It has been calculated that more than 6000 patients are needed to detect an effect of an intervention on myocardial infarction⁷⁷.

In conclusion, anesthesiological strategies and sympatholytic pharmacological strategies have the potential to decrease perioperative myocardial ischemia. Also, all of these strategies seem to affect both the immune and the neuro-endocrine component of the stress response. However, these strategies have different locations of action within the pathways of the stress response (fig. 3). This seems to result in important qualitative and quantitative differences in their potential to modify various components of the stress response (table 1).

Different strategies to modulate the perioperative stress response: comparative studies

It is important to focus on differences between the various stress modulating strategies because this knowledge may help to define the optimal strategy for an individual patient. For example, a patient at risk for developing an excessive inflammatory response after surgery may benefit from a strategy which is known to reduce this inflammatory response. With the exception of studies comparing epidural based to opioid based strategies, there is a paucity of comparative data on how various strategies affect different components of the stress response (Table 2). From these data a speculative ranking can only be made for the potential of the various strategies to decrease sympathetic outflow: Epidural > α_2 -agonist > opioid > beta-blocker. Below we will discuss differences of frequently used anesthesiological and sympatholytic strategies into more detail.

Differences in modulation of the stress response of two important anesthesiological strategies

Differences between the neuro-endocrine effects of an epidural based and an opioid based anesthetic technique have been studied extensively^{78,79}. Collectively, the available studies indicate that an epidural-based technique reduces sympathetic and cortisol responses more effectively than an opioid technique,

Table 1. General effect of different strategies on various components of the surgical stress response. ↓: decrease; ↑: increase; ↔ : no effect; ?: unknown because of very few studies.

	Thoracic Epidural	Opioid	Beta blocker	Alpha ₂ -agonist
Sympathetic outflow	↓↓	↑↓	↑↔	↓
Parasympathetic outflow	↔↑	↑	↑↔	↑
HPA-axis hormones	↓↔	↓	↔	↔
Activity immune cells	↑?	↓	↓?	?

Figure 3. Strategies to decrease the stress response to tissue injury and their main location of action within the pathways of the stress response. 1: opioids; 2: alpha₂-adrenergic agonists; 3: epidural; 4: beta-adrenergic antagonist. TNF: tissue necrosis factor; IL-1: interleukine-1; IL-6: interleukine-6.

Table 2 . Studies in which the effects of different strategies on the stress response are directly compared

	Neuro-endocrine response	Immune response
Epidural <i>vs</i> opioid	Epidural suppresses sympathetic and cortisol response more effectively ^{78,79}	Epidural maintains lymphocyte function after surgery better than opioid ^{29,31} . Epidural has no effect on IL-6 response ^{26,30,80}
Alpha ₂ -agonist <i>vs</i> beta-blocker	α ₂ -agonist suppressed the increase in plasma catecholamines to intubation ⁸⁵ and to a rapid increase in desflurane ⁸⁶ more than the beta-blocker. Cortisol response: not determined	Not determined
Epidural <i>vs</i> alpha ₂ -agonist	Addition of epidural analgesia decreased plasma epinephrine concentrations compared to addition of clonidine in patients having CABG surgery ⁶⁵ . Cortisol response: not different.	Not determined
Epidural <i>vs</i> beta-blocker	Addition of epidural anesthesia to beta-blocked patients suppressed the increase in myocardial oxygen consumption related to surgery ⁸⁷ . A high thoracic epidural decreased angina pectoris in beta-blocked patients ⁸⁸ . Cortisol response: not determined	Not determined
Opioid <i>vs</i> alpha ₂ -agonist	In CABG surgery the addition of clonidine to a general anesthetic resulted lower plasma catecholamine levels compared to a high dose opioid regimen ⁸⁹ . Cortisol response: not determined	Not determined
Opioid <i>vs</i> beta-blocker	Opioids suppressed the neuro-endocrine stress response to laryngeal stimulation more profoundly than beta-blockers ^{90,91} . Cortisol response: not determined	Not determined

especially in surgery below the umbilicus. However, less data are available on immunological differences between these two techniques. Epidural analgesia seems to maintain postoperative lymphocyte function better than opioid analgesia^{29,31}. However, no effect of epidural analgesia on the IL-6 response has been found^{26,30,80}. There are tight feedback connections between the immunological and neuro-endocrine components of the stress response. Therefore, it seems logical to study the effect of an intervention on both components of the stress response. However, most studies concentrate on only one of these components. The short-acting opioid remifentanyl is increasingly used since the introduction of fast track surgical programs. These programs aim at shortening recovery time

and therefore incorporate the use of short-acting anesthetic drugs or the combination of a regional anesthetic technique with a low dose general anesthetic. The fear is that these techniques thus may leave the patient relatively unprotected from potential harmful stress responses during the early period after major surgery⁸¹. Recently, it has been shown that an epidural-based anesthetic technique results in superior analgesia and haemodynamic stability compared to a remifentanyl based technique⁸².

Differences in modulation of the stress response of two pharmacological sympatholytic therapies.

Only a few studies have compared the effects of an α_2 -agonist and a beta-blocker on the neuro-endocrine stress response and the related cardiovascular effects. This is surprising because it is very likely that these fundamentally different classes of sympatholytic drugs have different effects on the neuro-endocrine stress response. α_2 -agonists have a central sympatholytic effect, thus decreasing both α - and β -receptor mediated sympathetic effects. In contrast, β -blockers decrease only β -receptor mediated sympathetic effects. Knowing differences between both classes of drugs on autonomic nervous system mediated cardiovascular control is important. This is because of its relation to myocardial oxygen balance and because evidence has emerged that cardiovascular control as such may be important in decreasing cardiac complications⁸³. An example of this evidence is that heart rate variability, one of the indicators of impaired cardiovascular control, is an independent predictor of adverse cardiac outcome in certain groups of patients⁸⁴. The few comparative studies on the neuro-endocrine effects of α_2 -agonists and β -blockers showed that the α_2 -agonist clonidine suppressed the increase in plasma catecholamines to intubation⁸⁵ and to a rapid increase in desflurane⁸⁶ more than the β -blocker esmolol. However, to date, differences in parasympathetic nervous system activation and baroreceptor mediated cardiovascular control of these groups of drugs have not been studied.

To conclude, the stress response to surgery consists of an immunological component and a neuro-endocrine component which interact closely. Each of these components seems to be involved in increasing the risk at perioperative myocardial ischemia. The anesthesiologist has a pivotal role in modulating the stress response to surgery and thus decreasing the risk at perioperative myocardial ischemia. To this, several anesthesiological techniques and pharmacological sympatholytic therapies may be used. There are indications that these various options affect the perioperative stress response differently. Knowing these differ-

ences may help to define the optimal stress response modulating strategy. However, these differences and the associated cardiovascular effects are largely unknown because they have not been studied into detail. The studies presented in this thesis were designed to fill parts of these gaps in our knowledge.

References

- 1 Priebe HJ. Triggers of perioperative myocardial ischaemia and infarction. *Br J Anesth* 2004; **93**: 9–20.
- 2 Vatner SE. Correlation between acute reductions in myocardial blood flow and function in conscious dogs. *Circ Res* 1980; **47**: 201–7.
- 3 de Torbal A, Boersma E, Kors JA et al. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study *Eur Heart J* 2006; **27**: 729–36.
- 4 Devereaux PJ, Goldman L, Cook DJ et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk *CMAJ* 2005; **173**: 627–34.
- 5 Mastorakos G, Ilias I. Interleukin-6: A Cytokine and/or a Major Modulator of the Response to Somatic Stress. *Ann N Y Acad Sci* 2006; **1088**: 373–81.
- 6 Nathan N, Preux PM, Feiss P, Denizot Y. Plasma interleukin-4, interleukin-10, and interleukin-13 concentrations and complications after coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth* 2000; **14**: 156–60.
- 7 Cirino G, Napoli C, Bucci M, Cicala C. Inflammation-coagulation network: are serine protease receptors the knot? *Trends Pharmacol Sci* 2000; **21**: 170–2.
- 8 Berczi I, Bertok L, Chow DA. Natural immunity and neuroimmune host defense. *Ann N Y Acad Sci* 2000; **917**: 248–57.
- 9 Vallejo R, Hord ED, Barna SA, Santiago-Palma J, Ahmed S. Perioperative immunosuppression in cancer patients. *J Environ Pathol Toxicol Oncol* 2003; **22**: 139–46.
- 10 Tsuchiya Y, Sawada S, Yoshioka I et al. Increased surgical stress promotes tumor metastasis. *Surgery* 2003; **133**: 547–55.
- 11 Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. *Ann N Y Acad Sci* 1998; **851**: 311–35.
- 12 Amar D, Fleisher M, Pantuck CB et al. Persistent alterations of the autonomic nervous system after noncardiac surgery. *Anesthesiology* 1998; **89**: 30–42.
- 13 Wray DW, Formes KJ, Weiss MS et al. Vagal cardiac function and arterial blood pressure stability. *Am J Physiol Heart Circ Physiol* 2001; **281**: H1870–80.
- 14 Tracey KJ. The inflammatory reflex. *Nature* 2002; **420**: 853–9.
- 15 Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. *Nat Rev Immunol* 2006; **6**: 318–28.
- 16 Nathan C. Points of control in inflammation. *Nature* 2002; **420**: 846–52.
- 17 Desborough JP. The stress response to trauma and surgery. *Br J Anesth* 2000; **85**: 109–17.
- 18 Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. *Endocr Rev* 1996; **17**: 64–102.
- 19 Molina PE. Neurobiology of the stress response: contribution of the sympathetic nervous system to the neuroimmune axis in traumatic injury. *Shock Augusta, Ga.* 2005; **24**: 3–10.
- 20 Libby P. Inflammation in atherosclerosis. *Nature* 2002; **420**: 868–74.

- 21 Landesberg G. The pathophysiology of perioperative myocardial infarction: facts and perspectives. *J Cardiothorac Vasc Anesth* 2003; **17**: 90-100.
- 22 Fleisher LA, Zielski MM, Schulman SP. Perioperative ST-segment depression is rare and may not indicate myocardial ischemia in moderate-risk patients undergoing noncardiac surgery. *J Cardiothorac Vasc Anesth* 1997; **11**: 155-9.
- 23 Kehlet H. Manipulation of the metabolic response in clinical practice. *World J Surg* 2000; **24**: 690-5.
- 24 Novitsky YW, Litwin DE, Callery MP. The net immunologic advantage of laparoscopic surgery. *Surg Endosc* 2004; **18**: 1411-9.
- 25 Bauer M. Anästhesie und perioperative Immundefunktion. *Anesthetist, Der* 1998; **47**: 939.
- 26 Naito Y, Tamai S, Shingu K et al. Responses of plasma adrenocorticotrophic hormone, cortisol, and cytokines during and after upper abdominal surgery. *Anesthesiology* 1992; **77**: 426-31.
- 27 Waurick R, Van Aken H. Update in thoracic epidural anesthesia. *Best Pract Res Clin Anesthesiol* 2005; **19**: 201-13.
- 28 Procopio MA, Rassias AJ, DeLeo JA et al. The in vivo effects of general and epidural anesthesia on human immune function. *Anesth Analg* 2001; **93**: 460-5.
- 29 Beilin B, Shavit Y, Trabekín E et al. The effects of postoperative pain management on immune response to surgery. *Anesth Analg* 2003; **97**: 822-7.
- 30 Volk T, Dopfner UR, Schmutzler M et al. Stress induced IL-10 does not seem to be essential for early monocyte deactivation following cardiac surgery. *Cytokine* 2003; **24**: 237-43.
- 31 Volk T, Schenk M, Voigt K et al. Postoperative epidural anesthesia preserves lymphocyte, but not monocyte, immune function after major spine surgery. *Anesth Analg* 2004; **98**: 1086-92.
- 32 Hollmann MW, Durieux ME. Local anesthetics and the inflammatory response: a new therapeutic indication? *Anesthesiology* 2000; **93**: 858-75.
- 33 Rigg JR, Jamrozik K, Myles PS et al. Epidural anesthesia and analgesia and outcome of major surgery: a randomised trial. *Lancet* 2002; **359**: 1276-82.
- 34 Feuerstein G, Siren AL. Hypothalamic mu-opioid receptors in cardiovascular control: a review. *Peptides* 1988; **9 Suppl 1**: 75-8.
- 35 Mistraretti G, Donatelli F, Carli F. Metabolic and endocrine effects of sedative agents. *Curr Opin Crit Care* 2005; **11**: 312-7.
- 36 Philbin DM, Rosow CE, Schneider RC, Koski G, D'Ambra MN. Fentanyl and sufentanil anesthesia revisited: how much is enough? *Anesthesiology* 1990; **73**: 5-11.
- 37 Molina PE. Opioids and opiates: analgesia with cardiovascular, haemodynamic and immune implications in critical illness. *J Intern Med* 2006; **259**: 138-54.
- 38 Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. *Am J Ther* 2004; **11**: 354-65.
- 39 Mangano DT, Siliciano D, Hollenberg M et al. Postoperative myocardial ischemia. Therapeutic trials using intensive analgesia following surgery. The Study of Perioperative Ischemia (SPI) Research Group. *Anesthesiology* 1992; **76**: 342-53.
- 40 Lessa MA, Tibirica E. Pharmacologic evidence for the involvement of central and peripheral opioid receptors in the cardioprotective effects of fentanyl. *Anesth Analg* 2006; **103**: 815-21.
- 41 Zaugg M, Schaub MC, Pasch T, Spahn DR. Modulation of β -adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action. *Br J Anesth* 2002; **88**: 103-23.
- 42 Gottlieb SS, McCarter RJ. Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction. *Am J Cardiol* 2001; **87**: 823-6.
- 43 Wiest D. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. *Clin Pharmacokinet* 1995; **28**: 190-202.

- 44 Hayano J, Sakakibara Y, Yamada A et al. Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. *Am J Cardiol* 1991; **67**: 199-204.
- 45 Melenovsky V, Simek J, Sperl M, Malik J, Wichterle D. Relation between actual heart rate and autonomic effects of beta blockade in healthy men. *Am J Cardiol* 2005; **95**: 999-1002.
- 46 Cogliati C, Colombo S, Ruscone TG et al. Acute beta-blockade increases muscle sympathetic activity and modifies its frequency distribution. *Circulation* 2004; **110**: 2786-91.
- 47 Khan S, Liberzon I, Abelson JL. Effects of propranolol on symptom and endocrine responses to pentagastrin. *Psychoneuroendocrinology* 2004; **29**: 1163-71.
- 48 Nonell A, Kerk S, Lederbogen F et al. No major effect of orciprenaline and propranolol upon ACTH-induced cortisol secretion. *Exp Clin Endocrinol Diabetes* 2004; **112**: 59-61.
- 49 Wong J, Murthy A, Patterson M. Beta-adrenergic receptors (BAR): role in modulating the host immune response. *Seminars in anesthesia, Perioperative Medicine and Pain* 2007: 10-6.
- 50 Schmitz D, Wilsenack K, Lendemanns S, Schedlowski M, Oberbeck R. beta-Adrenergic blockade during systemic inflammation: Impact on cellular immune functions and survival in a murine model of sepsis. *Resuscitation* 2006.
- 51 Oberbeck R, van Griensven M, Nickel E et al. Influence of beta-adrenoceptor antagonists on hemorrhage-induced cellular immune suppression. *Shock* 2002; **18**: 331-5.
- 52 Oberbeck R, Schmitz D, Wilsenack K et al. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. *Neuroimmunomodulation* 2004; **11**: 214-23.
- 53 Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. *N Engl J Med* 1996; **335**: 1713-20.
- 54 Poldermans D, Boersma E, Bax JJ et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med* 1999; **341**: 1789-94.
- 55 Eagle KA, Berger PB, Calkins H et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Anesth Analg* 2002; **94**: 1052-64.
- 56 Wetterslev J, Juul AB. Benefits and harms of perioperative beta-blockade. *Best Pract Res Clin Anesthesiol* 2006; **20**: 285-302.
- 57 Wiesbauer F, Schlager O, Domanovits H et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity: a systematic review and meta-analysis. *Anesth Analg* 2007; **104**: 27-41.
- 58 Raby KE, Brull SJ, Timimi F et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. *Anesth Analg* 1999; **88**: 477-82.
- 59 Feringa HH, Bax JJ, Boersma E et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. *Circulation* 2006; **114**: I344-9.
- 60 Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinto MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. *Anesthesiology* 2000; **93**: 382-94.
- 61 McCallum JB, Boban N, Hogan Q et al. The mechanism of alpha2-adrenergic inhibition of sympathetic ganglionic transmission. *Anesth Analg* 1998; **87**: 503-10.
- 62 Robertson HA, Leslie RA. Noradrenergic alpha 2 binding sites in vagal dorsal motor nucleus and nucleus tractus solitarius: autoradiographic localization. *Can J Physiol Pharmacol* 1985; **63**: 1190-4.

- 63 Finley JC, Jr., O'Leary M, Wester D et al. A genetic polymorphism of the alpha2-adrenergic receptor increases autonomic responses to stress. *J Appl Physiol* 2004; **96**: 2231-9.
- 64 Dorman T, Clarkson K, Rosenfeld BA et al. Effects of clonidine on prolonged postoperative sympathetic response. *Crit Care Med* 1997; **25**: 1147-52.
- 65 Loick HM, Schmidt C, Van Aken H et al. High thoracic epidural anesthesia, but not clonidine, attenuates the perioperative stress response via sympatholysis and reduces the release of troponin T in patients undergoing coronary artery bypass grafting. *Anesth Analg* 1999; **88**: 701-9.
- 66 Venn RM, Bryant A, Hall GM, Grounds RM. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit. *Br J Anesth* 2001; **86**: 650-6.
- 67 Nishina K, Akamatsu H, Mikawa K et al. The effects of clonidine and dexmedetomidine on human neutrophil functions. *Anesth Analg* 1999; **88**: 452-8.
- 68 Kim MH, Hahn TH. The effect of clonidine pretreatment on the perioperative proinflammatory cytokines, cortisol, and ACTH responses in patients undergoing total abdominal hysterectomy. *Anesth Analg* 2000; **90**: 1441-4.
- 69 von Dossow V, Baehr N, Moshirzadeh M et al. Clonidine attenuated early proinflammatory response in T-cell subsets after cardiac surgery. *Anesth Analg* 2006; **103**: 809-14.
- 70 Stevens RD, Burri H, Tramer MR. Pharmacologic Myocardial Protection in Patients Undergoing Noncardiac Surgery: A Quantitative Systematic Review. *Anesth Analg* 2003; **97**: 623-33.
- 71 Indolfi C, Piscione F, Villari B et al. Role of alpha 2-adrenoceptors in normal and atherosclerotic human coronary circulation. *Circulation* 1992; **86**: 1116-24.
- 72 Nishina K, Mikawa K, Uesugi T et al. Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature. *Anesthesiology* 2002; **96**: 323-9.
- 73 Wijeyundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. *Am J Med* 2003; **114**: 742-52.
- 74 Oliver MF, Goldman L, Julian DG, Holme I. Effect of mivazerol on perioperative cardiac complications during non- cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). *Anesthesiology* 1999; **91**: 951-61.
- 75 Wallace AW, Galindez D, Salahieh A et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. *Anesthesiology* 2004; **101**: 284-93.
- 76 Pruett SB. Quantitative aspects of stress-induced immunomodulation. *Int Immunopharmacol* 2001; **1**: 507-20.
- 77 Devereaux PJ, Leslie K, Yang H. The effect of perioperative beta-blockers on patients undergoing noncardiac surgery - is the answer in? *Can J Anesth* 2004; **51**: 749-55.
- 78 Liu S, Carpenter RL, Neal JM. Epidural anesthesia and analgesia. Their role in postoperative outcome. *Anesthesiology* 1995; **82**: 1474-506.
- 79 Guay J. The benefits of adding epidural analgesia to general anesthesia: a metaanalysis. *J Anesth* 2006; **20**: 335-40.
- 80 Brix Christensen V, Tonnesen E, Sorensen IJ et al. Effects of anesthesia based on high versus low doses of opioids on the cytokine and acute-phase protein responses in patients undergoing cardiac surgery. *Acta Anaesthesiol Scand* 1998; **42**: 63-70.
- 81 Myles PS, Daly DJ, Djaiani G, Lee A, Cheng DC. A systematic review of the safety and effectiveness of fast-track cardiac anesthesia. *Anesthesiology* 2003; **99**: 982-7.
- 82 Kessler P, Aybek T, Neidhart G et al. Comparison of three anesthetic techniques for off-pump coronary artery bypass grafting: general anesthesia, combined general and high

- thoracic epidural anesthesia, or high thoracic epidural anesthesia alone. *J Cardiothorac Vasc Anesth* 2005; **19**: 32-9.
- 83 Parlow JL, Begou G, Sagnard P et al. Cardiac baroreflex during the postoperative period in patients with hypertension: effect of clonidine. *Anesthesiology* 1999; **90**: 681-92.
- 84 Filipovic M, Jeger R, Probst C et al. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. *J Am Coll Cardiol* 2003; **42**: 1767-76.
- 85 Zalunardo MP, Zollinger A, Szelloe P et al. Cardiovascular stress protection following anesthesia induction. Comparison of clonidine and esmolol. *Anesthesist* 2001; **50**: 21-5.
- 86 Weiskopf RB, Eger Eid, Noorani M, Daniel M. Fentanyl, esmolol, and clonidine blunt the transient cardiovascular stimulation induced by desflurane in humans. *Anesthesiology* 1994; **81**: 1350-5.
- 87 Reiz S, Haggmark S, Rydval A, Ostman M. Beta-blockers and thoracic epidural analgesia. Cardioprotective and synergistic effects. *Acta Anesthesiol Scand Suppl* 1982; **76**: 54-61.
- 88 Gramling B, P., Miller MJ, Reeves ST, Roy RC, Zile MR. Treatment of medically and surgically refractory angina pectoris with high thoracic epidural analgesia: initial clinical experience. *American heart journal* 1997; **133**: 648-55.
- 89 Gerlach K, Uhlig T, Huppe M et al. Remifentanyl-clonidine-propofol versus sufentanil-propofol anesthesia for coronary artery bypass surgery. *Cardiothorac Vasc Anesth* 2002; **16**: 703-8.
- 90 Maguire A, Thompson JP, Guest C et al. Comparison of the effects of intravenous alfentanil and esmolol on the cardiovascular response to double-lumen endobronchial intubation. *Anesthesia* 2001; **56**: 319-25.
- 91 Magnusson J, Werner O, Carlsson C, Norden N, Pettersson KI. Metoprolol, fentanyl and stress responses to microlaryngoscopy. Effects on arterial pressure, heart rate and plasma concentrations of catecholamines, ACTH and cortisol. *Br J Anesth* 1983; **55**: 405-14.

CHAPTER 3

Homeostatic responses after cardiac surgery *Effect of anaesthesia management*

Henriëtte M. Willigers, John H. Heijmans, Jos G. Maessen and
Paul M.H.J. Roekaerts

Submitted to *European journal of anaesthesiology*

Abstract

Background and objective. Epidural-based and remifentanyl-based anaesthetic techniques have different effects on the haemodynamic and analgetic responses after cardiac surgery. The purpose of this study was to compare their effects on sympathetic and inflammatory responses during the first day after surgery.

Methods. Patients received propofol anaesthesia combined with either thoracic epidural anaesthesia and low dose remifentanyl (TEA group) or with high dose remifentanyl (REMI group). Postoperative analgesia consisted of epidural bupivacaine and morphine (TEA group) or intravenous piritramide (REMI group).

Results. Plasma catecholamines and the pro-inflammatory interleukin-6 (IL-6) were measured as measures of sympathetic and inflammatory responses respectively. Additionally, bactericidal permeability increasing protein, lipopolysaccharide binding protein, and C-reactive protein, and white blood cell count were measured. Ventilator dependency and analgesia were also evaluated. Plasma concentrations of epinephrine were less in the TEA group compared to the REMI group (300 (100 – 1300) *versus* 1000 (600 – 1600) pmol L⁻¹, median (interquartile range), $P < 0.05$) during the first 4 hours after surgery. In contrast, release of IL-6 was less in the REMI group (140 (100 – 290) *versus* (400 (200 – 500) pg ml⁻¹, $P < 0.05$). Analgesia was superior and ventilator dependency shorter in the TEA group. All other variables were not different.

Conclusions. The epidural-based anaesthetic technique had a superior sympatholytic effect and was associated with an increased IL-6 response, indicating the immunologic modulatory effects of anaesthesia management.

Keywords. Epidural, immune response, surgery – cardiovascular, opioid, sympathetic nervous system.

Introduction

Recently, there has been much discussion about the safety of fast track cardiac anaesthesia because it may leave the patient relatively unprotected from potential harmful homeostatic stress responses during the early postoperative period [1]. Traditionally, there was much attention for the neuro-endocrine responses to cardiac surgery, which resulted in the concept of high-dose opioid anaesthesia. Over the past decades there is increasing interest in modulating the immune response to cardiac surgery with the expectation to decrease postoperative complications such as the systemic inflammatory response syndrome and infections [2].

Several different fast track anaesthetic strategies for cardiac surgery have been described. One is a technique based on the short-acting opioid remifentanyl, which allows for the intra-operative use of high dose opioids without delaying extubation [3]. Alternatively, a thoracic epidural-based anaesthetic technique can be used because this technique has additional potential benefits such as profound stress response attenuation and thoracic cardiac sympathectomy [4]. Recently, it has been shown that an epidural-based anaesthetic technique results in superior analgesia and haemodynamic stability compared to a remifentanyl based technique [5]. However, to our knowledge, studies comparing the early postoperative neuro-endocrine and the immunological effects of these two techniques are lacking. Therefore, we prospectively studied indicators of these homeostatic stress responses in patients managed with either an epidural-based or a remifentanyl-based fast-track technique during the first day after elective on-pump coronary artery bypass surgery (CABG).

Methods

After local ethics committee approval and written informed consent from the patients, 30 adult patients undergoing elective on-pump CABG were allocated to this prospective trial. The sample size was chosen on the basis of power calculation from a pilot study. It was calculated that a sample size of 15 in each group would provide 80% power using a Student's *t*-test with a significance level of 0.05 for detecting a difference in IL-6 and in catecholamines of at least 100%. The current trial consisted of the following two anaesthetic treatment groups; 1) Thoracic Epidural Analgesia (TEA group), 2) high dose remifentanyl (REMI group). Exclusion criteria included left ventricular ejection fraction less than 25%, recent myocardial infarction, pre-operative inotropic or intra-aortic balloon pump support, and significant pulmonary, endocrine, renal, or neurolog-

ical disease. Patients who were not suitable for epidural blockade according to our National Guidelines were also excluded.

Experimental design

All patients continued their usual medications and received standardized premedication with oral midazolam $0.1 - 0.2 \text{ mg kg}^{-1}$. After arrival in the induction room, the radial artery was cannulated and blood was sampled for baseline (BL) measurements. In the TEA group, the epidural catheter was inserted more than one hour before surgery at the C7 - T1 level. It was tested with 2 ml of lidocaine 2%. A loading dose of 10 ml bupivacaine 0.25% and 2.5 mg morphine was infused over 1 hour, and sensible block heights were tested with application of cold. Anaesthesia was induced using target-controlled infusion (TCI) of propofol with the target at $2 \mu\text{g ml}^{-1}$ (BD Master Diprifusor TCI system, Brezins, France), remifentanyl (GlaxoSmithKline, Zeist, The Netherlands) $2.5 \mu\text{g kg}^{-1}$ in 4 minutes, and pancuronium 0.1 mg kg^{-1} to facilitate orotracheal intubation. The patients were ventilated with oxygen-enriched air (40% oxygen) and a pulmonary artery catheter was inserted into the right internal jugular vein. Anaesthesia was maintained with TCI propofol (target $1-2 \mu\text{g ml}^{-1}$) and a remifentanyl infusion protocol, which was different for both groups (REMI group $0.5 \mu\text{g kg}^{-1} \text{ min}^{-1}$, TEA group $0.125 \mu\text{g kg}^{-1} \text{ min}^{-1}$). Additionally, an epidural infusion of bupivacaine [3.75 mg ml^{-1}] and morphine [0.2 mg ml^{-1}] was started at a rate of 1.5 ml hour^{-1} in the TEA group. Cardiopulmonary bypass was standardized and performed using a hollow fibre membrane oxygenator, haemodilution, and moderate hypothermia (34°C).

At arrival in the intensive care unit (ICU) patients were kept sedated with propofol ($0.5 \text{ mg kg}^{-1} \text{ h}^{-1}$) and remifentanyl ($0.025 \mu\text{g kg}^{-1} \text{ min}^{-1}$) for four hours. If necessary, propofol was increased to achieve moderate sedation (Ramsay sedation score 3-5) [6]. Acetaminophen, 1 gram every 6 hours was started as a basic analgesic. In the TEA group bupivacaine 0.125% and morphine 0.2 mg ml^{-1} were infused into the epidural catheter at a rate of 1.5 ml h^{-1} for 48 hours. The REMI group received 0.15 mg kg^{-1} intravenous piritramide, a μ -receptor agonist with a potency of 0.7 compared with morphine, 15 minutes before stopping the sedative infusion. Tracheal extubation was performed when the patients had stable haemodynamics, were normothermic (core temperature $> 36.5^\circ\text{C}$), not bleeding (chest tube drainage $< 100 \text{ mL h}^{-1}$), and had adequate spontaneous ventilation (tidal volume $> 5 \text{ mL kg}^{-1}$, respiratory rate $> 10 \text{ breaths min}^{-1}$, minute ventilation $> 90 \text{ mL kg}^{-1} \text{ min}^{-1}$, $\text{FiO}_2 < 40\%$, peak end-expiratory pressure $< 5 \text{ cm H}_2\text{O}$, and arterial $\text{PO}_2 > 12 \text{ kPa}$). Time to extubation from stop sedation was recorded.

The nursing staff evaluated pain scores every 30 minutes on a 5-point scale from “no pain” to “very severe pain” after stopping the sedative infusion.

Piritramide 0.3 mg kg^{-1} was injected intramuscularly as an escape analgesic if the patient had more than slight pain. Quality of postoperative analgesia was evaluated from the number of piritramide administrations during the first 18 hours in the ICU. Then the patients were discharged to a step-down unit.

Plasma Sampling and Measurements

Plasma concentrations of catecholamines (norepinephrine and epinephrine) were measured as indicators of sympathetic tone, and interleukin-6 (IL-6) as a key mediator in the inflammatory response. Additionally, we measured bactericidal permeability increasing protein (BPI), as an indicator of neutrophil activation, lipopolysaccharide binding protein (LPB) and C-reactive protein (CRP) as indicators of the acute phase response, and leukocyte numbers and percentage of lymphocytes as indicators of the immunological cell response.

Samples for measurement of catecholamines and of BPI, LPB, and IL-6 were taken at five time-points: BL (baseline, before start of epidural or anaesthesia), T-0 (at arrival in the ICU), T-4 (four hours after arrival in the ICU), T-8 (eight hours in ICU), and T-18 (eighteen hours in ICU). Blood samples for CRP and white blood cell count were taken on day 1, 2, 4, and 6 after surgery. Arterial plasma epinephrine and norepinephrine concentrations were analysed with high-performance liquid chromatography with colorimetric electrochemical detection [7]. Plasma levels of BPI, IL-6 and LBP were measured using sandwich enzyme linked immunosorbent assays (Elisa's) as described previously [8]. CRP concentrations were measured using a turbidimetric method; the white blood cell count and the percentage of lymphocytes were measured with an automated white blood cell differential count according to the standard practice of our hospital laboratory.

Statistical Analysis

The SPSS (SPSS Inc., Chicago, IL) software for Windows, version 11.5 was used for statistical analysis. Differences between groups were analysed using the unpaired Student's *t*-test for patient characteristics, and the non-parametric Mann-Whitney *U*-test for all other data. Within group differences were analysed with the non-parametric Wilcoxon Matched-Pairs Signed-Ranks test followed by Bonferroni correction to allow for multiple comparisons as appropriate. Incidence of variables (the number of blood transfusions and of piritramide doses) were analysed using the chi-square test. A *P*-value of < 0.05 was considered statistically significant. Results are presented as mean (SD) or median (interquartile range).

Results

All 30 patients completed the study, had stable haemodynamic values without inotropic support throughout the study period, and had no postoperative complications necessitating prolonged hospitalization (data not shown). The epidural bolus dose resulted in sensory blockade from thoracic level 2 to 10 in all patients of the TEA group. Patient and perioperative data were similar in both groups (Table 1).

Plasma concentrations of epinephrine were about 80% less in the TEA group compared to the REMI group during the first 4 postoperative hours ($P < 0.05$ at T-0 and T-4, Fig. 1). Plasma concentrations of norepinephrine did not change and were similar in both groups (Fig. 1)

IL-6 remained unchanged in the REMI group, in contrast, epidural analgesia was associated with an approximately five-fold increase from baseline of this cytokine ($P < 0.01$, Fig. 2). As a result plasma concentrations of IL-6 were different between both study groups ($P < 0.05$ at T-0, T-4 and T-8, Fig. 2) during the first eight postoperative hours. Neutrophil activation, as indicated by the BPI response, peaked at arrival in the ICU (200 – 300% increase from baseline, $P < 0.01$) and was the same in both groups ($P > 0.1$ between both groups at all time points, Fig. 2). The increase in plasma concentrations of LBP and CRP, later markers of the inflammatory response, was also not different between both

Table 1 Patient characteristics and perioperative data of the two patient groups.

	REMI group	TEA group
Age (yrs)	57 (11)	61 (10)
Height (cm)	172 (8)	171 (9)
Weight (kg)	76 (13)	78 (10)
Male : Female	13: 2	12: 3
Aortic Cross clamp time (min)	57 (25)	46 (17)
Cardiopulmonary bypass duration (min)	80 (31)	74 (23)
Coronary grafts (number)	4 (1)	4 (1)
Packed Cells:		
Number of patients transfused	7	10
Number of packed cells transfused	24	26
Number of patients needing escape analgesia	7	0 *
Ventilator dependency time (min from stop sedation)	315 (169)	153 (101) *

REMI group = remifentanyl group. TEA = thoracic epidural group. Data are presented as mean (SD). Statistical significance: * $P < 0.001$

Figure 1. Time course of plasma catecholamines in the thoracic epidural group (○) and in the remifentanyl group (●) during the first 18 hours after coronary artery bypass surgery. Dots and error lines indicate median and corresponding interquartile range of plasma concentrations of epinephrine and norepinephrine. * = $P < 0.05$ vs. corresponding baseline value (BL), # = $P < 0.05$ thoracic epidural group vs. remifentanyl group. T-0, T-4, T-8, T-18 = 0, 4, 8, 18 hours after arrival in the intensive care unit. Plasma epinephrine was significantly less in the epidural group during the first four postoperative hours.

groups ($P > 0.1$ at all time points, Fig. 2 and 3). White blood cell count and the relative fraction of lymphocytes, as indicators of the cellular immune response was also not different between both groups (Fig. 3). Epidural analgesia decreased pain and ventilator dependency more effectively than opioid analgesia (Table 1).

Discussion

The present data show that the choice of anaesthetic technique affects the inflammatory response to CABG surgery in addition to the well-known effect of anaesthesia on the neuro-humoral limb of the homeostatic stress response. We found that epidural analgesia had superior sympatholytic effects compared to

Figure 2. Time course of inflammatory mediators in the thoracic epidural group (O) and in the remifentanyl group (●) during the first 18 hours after coronary artery bypass surgery. Dots and error lines indicate median and corresponding interquartile range of plasma concentrations of Bactericidal Permeability Increasing Protein, Interleukin-6, and Lipopolysaccharide Binding Protein. * = $P < 0.05$ vs. corresponding baseline value (BL), # = $P < 0.05$ thoracic epidural group vs. remifentanyl group. T-0, T-4, T-8, T-18 = 0, 4, 8, 18 hours after arrival in the intensive care unit. Interleukin-6 was significantly less in the remifentanyl group during the first eight postoperative hours.

Figure 3. Time course of C-reactive Protein, number of leukocytes, and number fraction of Lymphocytes in the thoracic epidural group (○) and in the remifentanyl group (●) during the first 6 days after coronary artery bypass surgery. Dots and error lines indicate median values and corresponding interquartile range. ★ = $P < 0.05$ *vs.* corresponding baseline value (BL), # = $P < 0.05$ thoracic epidural group *vs.* remifentanyl group. PO1, POD2, POD4, POD6 = 1, 2, 4, and 6 days after surgery. No significant differences between groups of these immunological parameters were measured.

opioid analgesia as indicated by decreased plasma epinephrine concentrations in the TEA group. These data confirm the findings of previous studies [9,10], and can be explained from a decreased neural afferent input from the site of injury from epidural analgesia. In contrast, even large doses of opioids cannot completely prevent increases in plasma catecholamines during cardiac surgery [11,12], and it has been shown that the sympatholytic effect of the new opioid remifentanyl is similar to that of the more traditional opioids [13]. The finding that epidural analgesia did not affect plasma norepinephrine concentrations is not in contradiction with its sympatholytic effect because it has been shown that high thoracic epidural analgesia decreases cardiac norepinephrine spill over from sternotomy without affecting plasma norepinephrine concentrations [14]. The relatively short duration of difference in sympatholytic effect may be explained by a decrease in the amount of the neural blockade associated with the use of a relatively small dose of local anaesthetics.

An important finding in this study is that the anaesthetic technique modulates the proinflammatory cytokine response after on-pump CABG. This can be concluded from the increased plasma concentration of IL-6 in the EPI group compared to the REMI group during the first eight hours after surgery. It is likely that intra-operative factors caused this difference because this cytokine is known to be produced 2 to 4 hours after tissue damage. Of these intra-operative factors, the anaesthetic technique most likely caused this difference because most other factors controlling the IL-6 response; surgical procedure, duration of bypass, and the amount of blood transfused [15], were similar in both groups. In accordance with our findings, there is growing evidence that anaesthetic techniques, and epidural anaesthesia in particular, modulate immunity of the surgical patient [16]. However, epidural analgesia, in general, does not affect the inflammatory IL-6 response to surgery. A possible explanation for the increased IL-6 response in our EPI group may be related to the improved sympatholysis in this group, because sympathetic activation is known to inhibit the production of proinflammatory cytokines [17]. However, in a previous study in CABG patients, differences in sympathetic tone were not translated into differences in IL-6 release [18]. Alternatively, a direct suppressive effect of remifentanyl on the inflammatory cascade may explain the difference in IL-6. The IL-6 plasma concentrations of 100 pg mL^{-1} measured in our REMI group are similar to those measured previously after remifentanyl anaesthesia [19]. These values are less than one fourth of those measured in presence of either epidural-based or long-acting opioid-based cardiac anaesthetic techniques [18,20]. There is growing evidence that opioids have a suppressive effect on cells of the immune system, either indirectly from their central nervous system mediated hormonal effects or from direct interactions with the $\mu 3$ opioid receptors on cells of the

immune system [2]. Theoretically, opioids should affect also the IL-6 response to surgery because monocytes, which secrete IL-6, have opioid receptors [21]. However, the evidence for this theory is equivocal. Crozier and colleagues [22] showed that the opioid alfentanil diminished the IL-6 response compared to inhalational anaesthesia, whereas Taylor and colleagues [23] showed no effect of fentanyl on IL-6 release. These contrasting results may be explained because there is evidence that opioids have differentiated immunological effects [24]. In accordance with a suppressive effect of remifentanil on inflammatory responses, it has been shown that this opioid suppresses natural killer function [25] and inhibits the early local inflammatory response in rats [26]. However, to date there are no studies which measure its effect on IL-6 release.

The clinical implications of this difference in IL-6 response remain uncertain, as the immune system is complex and difficult to assess from individual tests. It is important to stress that, in the current study, this effect of anaesthetic technique on IL-6 was not accompanied by differences in LBP, CRP, and number of leukocytes and leukocytes subsets, which are later markers of the immune response. An intriguing first implication of our finding could be a decreased likelihood for adverse outcome after remifentanil anaesthesia, because there are reports linking increased IL-6 levels with adverse outcome [27]. However, analgesia was superior, and ventilator dependency was shorter in the TEA group. Also, the association between IL-6 and adverse outcome seems to be only valid in the presence of an overwhelming systemic release of this cytokine, such as in sepsis. A second implication of the decreased IL-6 response during remifentanil anaesthesia is a potential increased risk at infectious complications. This is because IL-6 is necessary for initiating an effective inflammatory response against infection. In the current study there were no infectious complications in neither group but our study was underpowered to investigate such an effect.

A limitation of the current investigation is that the study period of approximately 24 hours was rather short, because neuro-endocrine and inflammatory changes after cardiac surgery are known to last about three days. However the peak change of most measured variables in the current study had already occurred within the study period. Another limitation is that this study could not be blinded, which could have influenced the results on detubation time and on pain measurement. However, the moment of detubation and administration of analgesics were strictly protocolized and performed by nurses not involved in the study.

In conclusion, this is the first study in which the effects of two different fast track anaesthetic techniques on both sympathetic and inflammatory responses during the early postoperative period after coronary artery surgery were evaluated. We showed that the epidural-based anaesthetic technique resulted in supe-

rior sympatholysis and that the remifentanil-based technique was associated with a decreased proinflammatory cytokine response. Therefore, this study adds to the growing evidence that anaesthetic techniques affect immunological homeostatic responses in addition to their well-known effect on neurohumoral responses.

References

- 1 Myles PS, Daly DJ, Djaiani G, Lee A, Cheng DC. A systematic review of the safety and effectiveness of fast-track cardiac anesthesia. *Anesthesiology* 2003; **99**: 982-7.
- 2 Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. *Anesthesiology* 2002; **97**: 215-52.
- 3 Royston D. Patient selection and anesthetic management for early extubation and hospital discharge: CABG. *J Cardiothorac Vasc Anesth* 1998; **12**: 11-9.
- 4 Chaney MA. Intrathecal and Epidural Anesthesia and Analgesia for Cardiac Surgery. *Anesth Analg* 2006; **102**: 45-64.
- 5 Kessler P, Aybek T, Neidhart G et al. Comparison of three anesthetic techniques for off-pump coronary artery bypass grafting: general anesthesia, combined general and high thoracic epidural anesthesia, or high thoracic epidural anesthesia alone. *J Cardiothorac Vasc Anesth* 2005; **19**: 32-9.
- 6 Barr J, Zomorodi K, Bertaccini EJ, Shafer SL, Geller E. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. *Anesthesiology* 2001; **95**: 286-98.
- 7 Hoorn van der FAJ, Boomsma, Man in het Veld AJ, Schalekamp MADH. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. *Journal of Chromatography* 1989; **487**: 17-28.
- 8 Fransen E, Maessen J, Dentener M et al. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. *Chest* 1998; **113**: 1290-5.
- 9 Liem TH, Booij LH, Gielen MJ, Hasenbos MA, van Egmond J. Coronary artery bypass grafting using two different anesthetic techniques: Part 3: Adrenergic responses. *J Cardiothorac Vasc Anesth* 1992; **6**: 162-7.
- 10 Loick HM, Schmidt C, Van Aken H et al. High thoracic epidural anesthesia, but not clonidine, attenuates the perioperative stress response via sympatholysis and reduces the release of troponin T in patients undergoing coronary artery bypass grafting. *Anesth Analg* 1999; **88**: 701-9.
- 11 Philbin DM, Rosow CE, Schneider RC, Koski G, D'Ambra MN. Fentanyl and sufentanil anesthesia revisited: how much is enough? *Anesthesiology* 1990; **73**: 5-11.
- 12 Duncan HP, Cloote A, Weir PM et al. Reducing stress responses in the pre-bypass phase of open heart surgery in infants and young children: a comparison of different fentanyl doses. *Br J Anaesth*. 2000; **84**: 556-64.
- 13 Howie MB, Cheng D, Newman MF et al. A randomized double-blinded multicenter comparison of remifentanil versus fentanyl when combined with isoflurane/propofol for early extubation in coronary artery bypass graft surgery. *Anesth Analg* 2001; **92**: 1084-93.
- 14 Kirno K, Friberg P, Grzegorzczak A et al. Thoracic epidural anesthesia during coronary artery bypass surgery: effects on cardiac sympathetic activity, myocardial blood flow and metabolism, and central hemodynamics. *Anesth Analg* 1994; **79**: 1075-81.

- 15 Fransen E, Maessen J, Dentener M, Senden N, Buurman W. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. *Chest* 1999; **116**: 1233-9.
- 16 Bauer M. Anästhesie und perioperative Immundefunktion. Ergänzende Bemerkungen zur Übersicht von M. Bauer, H. Rensing und T. Ziegenfuss. *Anaesthesist* 1998; **47**: 538-56.
- 17 Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. *Nat Rev Immunol* 2006; **6**: 318-28.
- 18 Volk T, Dopfner UR, Schmutzler M et al. Stress induced IL-10 does not seem to be essential for early monocyte deactivation following cardiac surgery. *Cytokine* 2003; **24**: 237-43.
- 19 Bauer M, Wilhelm W, Kraemer T et al. Impact of bispectral index monitoring on stress response and propofol consumption in patients undergoing coronary artery bypass surgery. *Anesthesiology* 2004; **101**: 1096-104.
- 20 Brix Christensen V, Tonnesen E, Sorensen IJ et al. Effects of anaesthesia based on high versus low doses of opioids on the cytokine and acute-phase protein responses in patients undergoing cardiac surgery. *Acta Anaesthesiol Scand* 1998; **42**: 63-70.
- 21 Bidlack JM. Detection and function of opioid receptors on cells from the immune system. *Clin Diagn Lab Immunol* 2000; **7**: 719-23.
- 22 Crozier TA, Muller JE, Quittkat D et al. Effect of anaesthesia on the cytokine responses to abdominal surgery. *Br J Anaesth* 1994; **72**: 280-5.
- 23 Taylor NM, Lacoumenta S, Hall GM. Fentanyl and the interleukin-6 response to surgery. *Anaesthesia* 1997; **52**: 112-5.
- 24 Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ. Opioid Agonists Have Different Efficacy Profiles for G Protein Activation, Rapid Desensitization, and Endocytosis of Mu-opioid Receptors. *J. Biol. Chem.* 2003; **278**: 18776-84.
- 25 Sacerdote P, Gaspani L, Rossoni G, Panerai AE, Bianchi M. Effect of the opioid remifentanyl on cellular immune response in the rat. *Int Immunopharmacol* 2001; **1**: 713-9.
- 26 Taylor BK, Peterson MA, Roderick RE et al. Opioid inhibition of formalin-induced changes in plasma extravasation and local blood flow in rats. *Pain* 2000; **84**: 263-70.
- 27 Pinsky M, Vincent J, Deviere J et al. Serum cytokine levels in human septic shock. Relation to multiple- system organ failure and mortality. *Chest* 1993; **103**: 565-75.

CHAPTER 4

Dexmedetomidine decreases perioperative myocardial lactate release in dogs

Henriëtte M. Willigers, Frits W. Prinzen, Paul M. Roekaerts, Simon de Lange and Marcel E. Durieux.

Anesth Analg 2003; **96**: 657-64.

Abstract

The sympatholytic effect of the α_2 -adrenergic agonist dexmedetomidine may decrease emergence-related myocardial ischemic load in patients. However, a direct measure of myocardial ischemia such as myocardial lactate release is difficult to obtain in patients. Therefore, we studied mongrel dogs and measured myocardial lactate release, myocardial oxygen supply, hemodynamic parameters, and neurohumoral indices of the stress response. After induction of a standardized degree of borderline myocardial ischemia, either dexmedetomidine (Dexmed group, $n = 9$) or normal saline (Control group, $n = 9$) was infused. Measurements were repeated at the end of the anesthetic period, and every 10 minutes during the 90-minutes emergence period. In the Dexmed group cumulative emergence-related lactate release was 46% lower than in the Control group (95% CI = 20 to 80%, $P = 0.02$). Simultaneously, dexmedetomidine increased the endo-/epicardial blood flow ratio by 35% (Control group: 0.4 ± 0.1 , Dexmed group: 0.6 ± 0.1 endo/epi ratio, $P = 0.03$). These anti-ischemic effects of dexmedetomidine were accompanied by lower plasma concentrations of norepinephrine (126 *vs.* 577 pg/ml) and epinephrine (158 *vs.* 1909 pg/ml), and a lower heart rate (123 ± 6 *vs.* 160 ± 10 beats/min, Dexmed *vs.* Control). The anti-ischemic effect of dexmedetomidine started prior to emergence as evidenced by a lower prevalence of myocardial lactate release at that time (Dexmed: 0/8, Control 4/7 dogs lactate release prior to emergence, $P = 0.03$). *Implications:* Dexmedetomidine decreases plasma catecholamines and heart rate during emergence from anesthesia. In dogs with a coronary stenosis these sympatholytic effects decrease myocardial lactate release, and therefore minimize emergence-related myocardial ischemia.

Key Words: myocardial ischemia, postoperative complications, α_2 -adrenergic agonists, sympatholysis.

Introduction

Early postoperative myocardial ischemia is one of the most important risk factors for adverse cardiac outcome in surgical patients with coronary artery disease¹. Because this risk factor appears related to the stress response associated with surgery and emergence from anesthesia, methods to reduce this stress response have been studied. Examples include epidural analgesia, profound opioid analgesia, and administration of β -adrenoceptor antagonists or α_2 -adrenergic agonists². The last modality in particular seems promising because, in contrast to β -adrenoceptor antagonists, α_2 -agonists reduce overall tonic sympathetic action, reduce anesthetic requirements, and induce analgesia and anxiolysis³.

It is well known that α_2 -adrenergic agonists can attenuate the stress response associated with emergence from anesthesia⁴⁻⁶. However, whether this translates to less postoperative myocardial ischemia is unknown. This is partly because until now only 2 studies have focused directly on this issue^{7, 8}. And, although these studies show that α_2 -agonists decrease the incidence of emergence-related ST-depression and postoperative cardiac deaths in high-risk surgical patients, no effect on myocardial infarction has been demonstrated.

One of the main reasons for the paucity of information on the effect of α_2 -agonists on postoperative myocardial ischemia, is the difficulty to select a practical and clinical relevant outcome measure. The outcome measure myocardial infarction has a low incidence, necessitating studying a large number of patients. Selecting ST-segment changes as an outcome measure may not always be clinically relevant because they also result from changes in temperature, serum electrolytes, position, and from administration of drugs⁹. A more precise measure of myocardial ischemia, but difficult to obtain in patients, is the presence of lactate release from the myocardial area at risk. Also, it has been shown that not the incidence but the load (i.e. duration) of myocardial ischemia is most significantly associated with adverse cardiac outcome¹⁰, and therefore may be a more appropriate outcome measure.

Therefore, our aim was to determine in a placebo-controlled study if dexmedetomidine, the most specific α_2 -agonist available, can decrease cumulative myocardial lactate release in dogs having a coronary stenosis and emerging from surgery and anesthesia. To obtain more insight in potential mechanisms we also measured the effects of dexmedetomidine on hemodynamic parameters, neurohumoral indices of the stress response, and on indices of myocardial oxygen supply and demand.

Methods

Animal preparation

With the approval of the Animal Care and Use Committee at the University of Maastricht we studied 18 adult mongrel dogs. After induction of anesthesia with 20 mg/kg sodium thiopental intravenously, the dogs were intubated and ventilated with halothane in oxygen / nitrous oxide. After thoracotomy, a screw-driven plastic occluder was placed non-constrictively distal to the first diagonal branch of the left anterior descending coronary artery (LAD). This occluder allows producing a fixed stenosis from controllable narrowing of coronary arteries. Catheters were inserted into the left femoral artery, the left anterior coronary vein, and a distal pulmonary artery for arterial (A), coronary venous (CV), and mixed venous (MV) blood sampling. To measure regional myocardial blood flow, a catheter for injection of microspheres was implanted in the left atrial appendage. Pressure sensors (Sentron 180 S, Cordis, Roden, the Netherlands) were inserted through the right femoral artery into the ascending aorta and left ventricle (LV). Ultrasonic transit-time flow probes (Transonic Systems, Ithaca, NY) were placed around the aortic root and just proximal to the coronary occluder. Heart rate was monitored using limb lead II of the electrocardiogram. To measure regional myocardial shortening, a pair of 1.5 mm-diameter piezoelectric crystals was inserted parallel to circumferential midwall fibers in the area perfused by the LAD and connected to a digital sonomicrometer (Sonometrics Corporation, London, Ontario, Canada)

Throughout the experiment, all signals were continuously displayed on monitors, and the corresponding values were stored every minute. During each period of measurement, digitized signals (12 bit A/D interface, sample frequency 200 Hz) and corresponding beat-to-beat values were stored for 5 minutes. During off-line processing, all data of a 2-minute stable period (i.e. less than 5% heart rate variation) within this 5-minute acquisition period were averaged.

All blood samples were collected on ice. Those to be analyzed afterwards were centrifuged within 15 min at 4°C to separate plasma, and stored at -70°C.

Study protocol (Fig. 1)

At the start of the study protocol anesthesia was standardized to 1% halothane in oxygen / nitrous oxide (33% / 66%). After 20 minutes a stenosis of the LAD was applied, standardized as the tightest stenosis not resulting in myocardial lactate release during stable anesthesia. We aimed to increase the probability of myocardial lactate release from emergence-related stress responses by creating comparable degrees of borderline ischemia, and used lactate release as primary outcome variable.

Figure 1. Schematic representation of the study protocol. Black arrows represent periods of measurements of hemodynamic variables; hemoglobin content; arterial and coronary venous blood gases; poststenotic coronary flow, lactate release, and regional myocardial contractile function. Stress hormones (SH) and regional myocardial blood flow (MBF) were measured less frequently. Time axis shows exact number of minutes from start spontaneous breathing (first emergence period measurement), and approximate number of minutes before this event. Note that baseline stenosis measurements were performed BEFORE study drug administration. P = before coronary stenosis. St = coronary Stenosis. S = Stop anesthesia. R = first emergence period measurement at start of spontaneous Respiration. 2,3,4,... = emergence period measurements

To create similar borderline ischemia in both groups, the coronary artery was narrowed step by step at 5-minutes intervals until the poststenotic myocardium released lactate, i.e. [(CV-A) lactate] > 0. Then the occluder was released step by step until lactate release just ceased. During this procedure, lactate concentrations were measured within 3 minutes using an absorption photometric method (DR Lange cuvette test LKM 140, Berlin, Germany). After a stabilization period of 15 minutes the following baseline variables were measured: 1) hemodynamic variables (heart rate, aortic pressure, end-diastolic and maximum first derivative of LV pressure (dPdT_{max}), and aortic flow); 2) stress hormones (arterial plasma concentrations of norepinephrine, epinephrine, and cortisol); 3) indicators of myocardial oxygen balance (LAD flow, regional myocardial blood flow, fractional oxygen extraction, and poststenotic myocardial lactate release).

After these baseline stenosis measurements the study-drug was administered. Animals were randomly assigned to one of 2 groups: those receiving dexmedetomidine (loading dose $0.5 \mu\text{g kg}^{-1}$ followed by a continuous infusion of $0.6 \mu\text{g.kg}^{-1}.\text{hour}^{-1}$, Dexmed group, $n = 9$), or those receiving placebo (0.9% NaCl, Control Group, $n = 9$). We did not blind administration of the study-drug because the marked bradycardic effect of dexmedetomidine makes this virtually impossible. The target plasma concentration of dexmedetomidine was 0.5 ng ml^{-1} because this concentration does not have major vasoconstrictive effects (11), and reduces sympathetic tone effectively in dogs(12) and in humans (4). The corresponding infusion scheme (timing and dose) was obtained from pharmacokinetic data of our pilot study.

About 10 minutes after starting the study-drug, the chest wall was closed and care was taken to maintain the position of the occluder by observing coronary flow and myocardial shortening signals. The pneumothorax was evacuated by careful manual inflation of the lungs. To mimic perioperative blood loss and to decrease the number of animals needed in our study, blood was collected from the femoral artery and replaced simultaneously with a colloid solution (Haemacel[®], Behringwerke AG, Marburg) until a hemoglobin value of approximately 6.5 mmol L^{-1} was reached. After completion of surgery, 0.01 mg kg^{-1} buprenorphine was injected intramuscularly for postoperative analgesia (13), the dogs were restrained, and measurements were repeated. Then the emergence period was started by changing the inspiratory gas to 100% oxygen. The first emergence period measurement was made at the moment the dogs first breathed spontaneously. This was done to standardize the level of consciousness during the emergence period. Then, measurements were repeated every 10 minutes during 90 minutes. By protocol no interventions were made if ventricular fibrillation (VF) occurred. At the end of the experiment, the dogs were euthanized by pentobarbital overdose, and their hearts were stored at -20°C for regional blood flow analysis.

Measurements and calculations

Myocardial ischemic load: Plasma lactate concentrations were determined spectrophotometrically (Cobas Bio System, Hoffman La Roche, Basel, Switzerland) afterwards, and the presence of myocardial lactate release ($[(\text{CV} - \text{A}) \text{ lactate}] > 0$) was identified. Of each dog the cumulative myocardial ischemic load of the emergence period, our primary outcome measure, was calculated as the percentage of measurements indicating myocardial lactate release. In dogs that died from VF, missing lactate measurements were added to the myocardial ischemic load provided that VF occurred during a period of lactate release. We consider this appropriate because VF is a more severe consequence of myocar-

dial ischemia than is myocardial lactate release, and not coding these measurements would have underestimated myocardial ischemia in these dogs.

Myocardial oxygen extraction and consumption: Hemoglobin content (Hb (mmol/L)) and oxygen saturation (SaO_2 (%)) of A, CV, and MV samples were measured with a hemoxymeter (OSM-2, Radiometer, Copenhagen, Denmark), and oxygen tension (PO_2 (kPa)) was measured with a blood gas analyzer (Radiometer ABL 3). The O_2 content (CaO_2 (mmol/L)) was calculated as: $\text{Hb} \times \text{SaO}_2 + 0.0102 \times \text{PO}_2$. From this, oxygen extraction and consumption were calculated using standard formulas.

Regional myocardial shortening: Myocardial circumferential segment lengths at begin ejection (Be sl) and end ejection (Ee sl) were measured using the aortic flow signal to delineate the ejection period. From these, percentage systolic shortening during the ejection period (Sse) was calculated as $\text{Sse} (\%) = 100 \times (\text{Be sl} - \text{Ee sl}) / \text{Be sl}$.

Regional myocardial blood flow: Regional myocardial blood flow was measured with fluorescent labeled microspheres (polystyrene, diameter: $15.5 \mu\text{m} \pm 2\%$, Molecular Probes, Eugene, OR) of 6 different colors (blue-green, yellow-green, orange, red, crimson, and scarlet) as described in detail elsewhere (14). Briefly, for each measurement approximately 4×10^6 microspheres of a single color were injected into the left atrium; simultaneously a reference arterial blood sample was withdrawn. Afterwards, several adjacent myocardial samples were taken from the poststenotic myocardial wall and from the remote non-ischemic myocardial wall, and divided into subendo- and subepicardial samples. Microspheres were isolated, their fluorescence determined, and regional myocardial flow was calculated. Of the poststenotic myocardial wall, the area with lowest flow immediately after application of the stenosis was used for analysis.

Plasma concentrations of stress hormones and dexmedetomidine: Catecholamines were measured fluorimetrically (15). Serum cortisol concentration was determined using solid-phase, chemiluminescent enzyme immunoassay (Immulite[®], Cortisol kit, DPC, Los Angeles). Plasma concentrations of dexmedetomidine were determined by gas chromatography-mass spectrometry (16) at Farnos Research, Turku, Finland.

Pressure work index: The pressure work index (PWI, equivalent to $\mu\text{mol} \cdot \text{min}^{-1} \cdot \text{g}^{-1}$) was calculated as a measure of myocardial oxygen demand (17) $\text{PWI} = \text{C1} (\text{SBP} \times \text{HR}) + \text{C2} (0.8 \text{ SBP} + 0.2 \text{ DBP}) \times \text{HR} \times \text{SV} / \text{BW} + 0.57$

Where

SV = stroke volume (ml)

SBP = systolic blood pressure (mmHg)

DBP = diastolic blood pressure (mmHg)

BW = body weight (kg)

C1 = 1.63×10^{-4}

C2 = 1.30×10^{-4}

Statistical analysis

From the 18 dogs, 1 dog from each group was not included in the statistical analysis; in the control group because of VF before administration of the study-drug, in the dexmed group because of severe postoperative hemorrhage. Of some variables data from at most 1 experiment were missing due to technical problems. Data are presented as mean $\pm$ SEM, unless stated otherwise.

Emergence period values of each experiment were summarized as median values. This was done because the use of a summary measure is considered the most appropriate approach to analyze serial measurements (18). Differences between groups were evaluated by Mann-Whitney U test, within group changes by Wilcoxon Signed Rank Test with Bonferroni correction, and differences between ratios by Fisher's Exact Test. A P-value < 0.05 was considered statistically significant. Additionally, individual timepoints were analyzed using Two Way Repeated Measures Anova followed by Tukey test for multiple comparisons.

Results

Effects of dexmedetomidine during the emergence period.

The cumulative myocardial ischemic load was 46% lower in the Dexmed group than in the Control group (95% CI = 20 to 80%, $P = 0.02$, Fig. 2). Simultaneously, dexmedetomidine increased total coronary blood flow distal to the stenosis (figure 3), especially in the endocardial layers, as indicated by a 35% higher endo- / epicardial blood flow ratio (Table 1). The other determinants of myocardial oxygen supply, hemoglobin concentration and partial arterial oxygen pressure, were similar in both groups (Table 1). Regarding demand, dexmedetomidine decreased heart rate during the emergence period by approximately 23%, but it did not affect aortic flow, aortic pressure and PWI (Table 2). In neither group myocardial ischemia was preceded by a change in heart rate, blood pressure, or coronary flow (data not shown). The differences in incidence (%) between both groups of (1) myocardial lactate release (95% CI = -19% to 65%); and (2) VF (95% CI = -5 to +62%) were not statistically significant (Fig. 2B).

With regard to the emergence-related stress response, plasma catecholamines, heart rate, and oxygen consumption of the body were lower in the Dexmed group than in the Control group (Table 2, Fig. 3). Of these, dexmedetomidine

Figure 2. Effect of dexmedetomidine on poststenotic myocardial lactate release in dogs emerging from anesthesia. **Panel A:** Time course of individual coronary venous (CV) to arterial (A) lactate differences in the Control group (left panel) and Dexmed group (right panel). In 1 dog of the Control group no lactate data were obtained because of technical problems. **Panel B:** Data from panel A represented as either presence (●) or absence (○) of episodes myocardial lactate release. **Panel C:** Mean values ± SEM of the cumulative myocardial ischemic load during the emergence period (= (episodes lactate release or VF / total emergence period measurements) X 100%). P = before coronary stenosis. St = coronary Stenosis. S = Stop anesthesia. R = first emergence period measurement at start of spontaneous Respiration. 2,3,4,... = emergence period measurements. #: P < 0.02; Dexmed vs. Control group.

Figure 3. Changes in time in hemodynamics, plasma norepinephrine concentration, and poststenotic myocardial oxygenation in the Dexmed group (●) and Control group (○). Values are plotted as mean percentages of baseline stenosis measurements. Error bars indicate SEM. For plasma norepinephrine concentrations median values are plotted. Arrow indicates start administration of study drug. P = before coronary stenosis. St = coronary Stenosis. S = Stop anesthesia. R = first emergence period measurement at start of spontaneous Respiration. 2,3,4,... = emergence period measurements. Absolute values of these data are given in table 1 and 2. * $P < 0.05$, Control group vs. Dexmed group (Two Way Repeated Measures Anova on absolute values followed by Tukey test for multiple comparisons).

Table 1. Changes in Indices of Myocardial Oxygen Supply

Variable	Area	Group	Pre-stenosis (Pre- drug)	Stenosis (Pre- drug)	Stop (Drug)	Emergence (Drug)
Endocardial flow $\text{ml} \cdot \text{min}^{-1} \cdot \text{g}^{-1}$	Stenotic	Control	1.0 ± 0.1	$0.3 \pm 0.1^*$	0.3 ± 0.1	0.4 ± 0.1
		Dexmed	$0.8 \pm 0.1^\#$	$0.3 \pm 0.1^*$	0.5 ± 0.1	0.6 ± 0.1
Epicardial flow $\text{ml} \cdot \text{min}^{-1} \cdot \text{g}^{-1}$	Stenotic	Control	1.2 ± 0.1	$0.8 \pm 0.1^*$	0.8 ± 0.1	1.0 ± 0.1
		Dexmed	0.9 ± 0.1	0.9 ± 0.2	0.7 ± 0.1	1.0 ± 0.1
Endo-/epicardial blood flow ratio	Stenotic	Control	1.0 ± 0.1	$0.5 \pm 0.1^*$	0.4 ± 0.1	0.4 ± 0.1
		Dexmed	0.8 ± 0.1	$0.4 \pm 0.1^*$	$0.7 \pm 0.1^{*\#}$	$0.6 \pm 0.1^\#$
Endocardial flow $\text{ml} \cdot \text{min}^{-1} \cdot \text{g}^{-1}$	Remote	Control	1.2 ± 0.1	1.1 ± 0.2	1.1 ± 0.1	1.4 ± 0.2
		Dexmed	0.9 ± 0.1	1.2 ± 0.2	0.9 ± 0.1	1.3 ± 0.1
Epicardial flow $\text{ml} \cdot \text{min}^{-1} \cdot \text{g}^{-1}$	Remote	Control	1.1 ± 0.1	1.0 ± 0.2	1.0 ± 0.1	$1.4 \pm 0.1^*$
		Dexmed	0.9 ± 0.1	1.2 ± 0.2	0.8 ± 0.1	1.2 ± 0.1
Endo-/epicardial bloodflow ratio	Remote	Control	1.1 ± 0.1	1.1 ± 0.1	1.1 ± 0.1	1.1 ± 0.1
		Dexmed	1.0 ± 0.1	1.0 ± 0.1	1.1 ± 0.0	1.0 ± 0.0
Fractional O_2 extraction	Stenotic	Control	0.55 ± 0.03	$0.73 \pm 0.01^*$	0.77 ± 0.02	0.79 ± 0.03
		Dexmed	0.60 ± 0.04	$0.75 \pm 0.04^*$	0.70 ± 0.05	$0.76 \pm 0.04^*$
LAD flow $\text{ml}/\text{min}(\text{flow probe})$	Stenotic	Control	33 ± 4	$16 \pm 2^*$	14 ± 3	14 ± 3
		Dexmed	27 ± 4	$12 \pm 2^*$	14 ± 2	$20 \pm 4^*$
Hemoglobin (A) mmol/L		Control	8.5 ± 0.3	9.0 ± 0.3	$6.2 \pm 0.3^*$	6.5 ± 0.6
		Dexmed	8.2 ± 0.3	7.7 ± 0.6	6.7 ± 0.5	6.9 ± 0.4
$\text{pO}_2(\text{A})$ kPa		Control	13 ± 1	12 ± 1	$18 \pm 1^*$	16 ± 2
		Dexmed	16 ± 2	16 ± 1	18 ± 2	$11 \pm 2^*$

Data are mean $\pm$ SEM. Pre-stenosis and Stenosis values are measured just before, and just after application of the coronary stenosis. Stop values are measured just prior to stopping the anesthetics, Emergence values are median values of all time points during emergence. Pre- drug = before starting study drug (dexmedetomidine or NaCl). Drug = in presence of study drug. LAD = left anterior descending coronary artery. A = Arterial, $*$ = $P < 0.05$ compared to preceding measurement in the same group, $\#$ = $P < 0.05$, Control group vs. Dexmed group.

Table 2. Changes in Hemodynamic Variables and Stress Hormones.

Variable	Group	Pre-stenosis (Pre- Drug)	Stenosis (Pre- Drug)	Stop (Drug)	Emergence (Drug)
Heart Rate	Control	139 ± 4	145 ± 6	148 ± 9	160 ± 10 [*]
beats/minute	Dexmed	125 ± 4 [#]	131 ± 5	104 ± 3 ^{*#}	123 ± 6 ^{*#}
Systolic Aortic Pressure mmHg	Control	109 ± 4	109 ± 5	100 ± 5	113 ± 8
	Dexmed	99 ± 5	97 ± 4	90 ± 5	113 ± 5
dPdT _{max}	Control	1365 ± 97	1368 ± 90	1384 ± 123	2153 ± 185 [*]
mmHg/sec	Dexmed	1323 ± 79	1270 ± 76	1012 ± 42 ^{*#}	1781 ± 152 [*]
Enddiastolic LVP	Control	11 ± 2	12 ± 1	10 ± 1	5 ± 1
mmHg	Dexmed	8 ± 1	8 ± 1 [#]	9 ± 1	4 ± 1 [*]
Aortic Flow	Control	3.5 ± 0.3	2.8 ± 0.3	2.4 ± 0.2	2.8 ± 0.3
L/min	Dexmed	2.8 ± 0.2	2.4 ± 0.1	1.9 ± 0.1 ^{*#}	2.5 ± 0.1 [*]
Pressure Work Index	Control	4.7 ± 0.2	4.5 ± 0.3	4.0 ± 0.2	5.1 ± 0.5
μmol.min ⁻¹ .g ⁻¹	Dexmed	3.8 ± 0.2	3.7 ± 0.2	2.9 ± 0.1 ^{*#}	4.2 ± 0.3 [*]
SSE	Control	5 ± 1	6 ± 1	4 ± 1	5 ± 1
%	Dexmed	7 ± 1	6 ± 1	3 ± 1 [*]	7 ± 1 [*]
O ₂ consumption body	Control	0.22 ± 0.02	0.24 ± 0.02	0.22 ± 0.02	0.31 ± 0.02
mmol.kg ⁻¹ .min ⁻¹	Dexmed	0.21 ± 0.01	0.19 ± 0.02	0.19 ± 0.01	0.22 ± 0.02 [#]
Cortisol	Control		438 ± 40	405 ± 46	389 ± 52
nmol/L	Dexmed		439 ± 53	400 ± 80	402 ± 81
Norepinephrine	Control		116 (115 - 211)	180 (175 - 348)	577 (305-609) [*]
pg/ml	Dexmed		114 (54 - 178)	61 (27 - 173) [#]	126 (51-286) [#]
Epinephrine	Control		435 (320 - 799)	395 (238 - 475)	1909 (136-3489) [*]
pg/ml	Dexmed		281 (179 - 363)	84 (45 - 404)	158 (91-1448) [#]

Data are mean ± SEM, except plasma catecholamines which are presented as median (25 – 75% interval). Pre-stenosis and Stenosis values are measured just before, and just after application of the coronary stenosis. Stop values are measured just prior to stopping the anesthetics, Emergence values are median values of all time points during emergence. Pre-drug = before starting study drug (dexmedetomidine or placebo). SSE = systolic shortening of the ejection period. ^{*} = P < 0.05 compared to preceding measurement in the same group, [#] = P < 0.05, Control group vs. Dexmed group.

Figure 4. Stability of plasma concentrations of dexmedetomidine (mean $\pm$ SEM, $n = 8$ dogs) in relation to target plasma concentration of 0.5 ng/ml. P = before coronary stenosis. St = coronary Stenosis. S = Stop anesthesia (about 35 minutes after starting dexmedetomidine). R = first emergence period measurement at start of spontaneous Respiration. 2,3,4, . . . = emergence period measurements

prevented only an increase in plasma catecholamines compared to the preceding intraoperative measurements. The time to regain spontaneous breathing after stopping the anesthetics, as a measure of emergence, tended to be longer in the Dexmed group, but this was not statistically significant (Dexmed group: 30 ± 6 , Control Group: 16 ± 2 min; 95% CI for the difference between groups = -3 to $+29$ min, $P > 0.2$).

Effects of dexmedetomidine prior to emergence.

Prior to emergence the prevalence of myocardial lactate release was 57% lower in the Dexmed group than in the Control group (95% CI = 20% to 94%, $P = 0.03$, Stop values Fig. 2B). Simultaneously, dexmedetomidine decreased plasma concentrations of norepinephrine by 66%, decreased myocardial oxygen demand (PWI) by 29% (Table 2) and increased the endo-/epicardial blood flow ratio by 45% (Table 1).

Experimental model

Intra-operative procedures were the same in both groups. First, application of the stenosis resulted in a similar decrease in myocardial oxygenation. This is because: 1) myocardial lactate release was absent in both groups (Control Group: -0.1 ± 0.1 ; Dexmed group -0.2 ± 0.0 mmol/ L (CV – A) [lactate], $P = 0.16$, Fig. 2A stenosis values), 2) endocardial flow decreased similarly (Dexmed group: 59

$\pm 6\%$, Control group: $66 \pm 8\%$ decrease; $P > 0.5$, Table 1), and 3) baseline stenosis values were similar for all variables except EDP (stenosis values Table 1, 2, Fig. 2A). Second, the duration of surgery and anesthesia was the same in both groups because the time between 'stenosis' and 'stop anesthesia' measurements was 81 ± 8 minutes in the Dexmed group, and 76 ± 9 minutes in the Control Group (95% CI = -19 to + 20 minutes, $P > 0.5$). Finally, intra-operative hemodilution resulted in a similar hemoglobin (Table 1)

Plasma concentrations of dexmedetomidine were stable and close to our target of 0.5 ng/ml (Fig. 4), and no animal in either group required additional buprenorphine.

Discussion

In the current study the α_2 -agonist dexmedetomidine decreased myocardial ischemic load in dogs with a coronary stenosis and emerging from anesthesia. This anti-ischemic effect of dexmedetomidine was associated with a decreased sympathetic tone and improved myocardial oxygen balance. The unique feature of our study was that we used invasive measurements of myocardial oxygenation of the area of risk that are not obtainable from human studies. Our data therefore may help explain clinical findings that perioperative infusion of an α_2 -agonist has potential to limit postoperative myocardial ischemia⁷.

A decrease in myocardial ischemic load is a clinically relevant outcome measure because it has been shown that several periods of myocardial ischemia have a cumulative effect and can cause subendocardial necrosis in dogs¹⁹. In accordance, in humans prolonged duration of ST-segment depression leads to myocardial damage as measured by cardiac troponin-1 levels²⁰ and is associated with adverse cardiac outcome¹⁰. If dexmedetomidine can decrease the incidence of myocardial ischemia during emergence remains unknown from the current study because it was not powered for this outcome measure (e.g. to detect differences in incidence of myocardial ischemia with power: 0.80 and $\alpha = 0.05$, 62 dogs in each group would have been necessary.) However, the importance of decreasing the incidence of myocardial ischemia, in addition to its load, remains unknown.

The decrease in emergence-related myocardial ischemic load from dexmedetomidine may be explained from its sympatholytic effects, improving the myocardial oxygen supply/demand ratio. In accordance with previous studies in humans⁶ and in dogs²¹, dexmedetomidine had sympatholytic effects during the emergence period, as indicated by a decrease in plasma catecholamines and heart rate. These effects coincided with a redistribution of supply to the vulnerable endocardium as indicated by an increased endo-/ epicardial

blood flow ratio. Although relatively large doses of α_2 -adrenergic agonists may produce coronary vasoconstriction¹¹, the redistribution of blood flow toward the endocardium indicates that the sympatholytic and heart rate-lowering effects of dexmedetomidine most likely prevailed at the dose used. Coronary artery thrombosis may also decrease myocardial blood flow, and thus supply. However, this is an unlikely event in the current study, because dogs are not prone to coronary atherosclerosis, and we did not observe any macroscopic intracoronary thrombi at dissection afterwards.

Other determinants of myocardial oxygen supply, plasma hemoglobin values and arterial oxygen tension, were not different between both groups, and therefore are not likely to confound the observed differences in myocardial lactate release. Hemoglobin values were 6–7 mmol/L after hemodilution. These values are generally accepted for almost all surgical patients²², and as such do not lead to myocardial ischemia. However, if the vasodilating capacity of the coronary artery is limited, moderate hemodilution may increase the risk of myocardial ischemia²³. This effect was considered ethically advantageous because it reduced the number of animals required.

Of the hemodynamic factors potentially involved in the genesis of emergence-related myocardial ischemia, dexmedetomidine decreased heart rate. A low heart rate is of pivotal importance in reducing myocardial ischemia because it improves supply from a prolonged diastolic perfusion time and is the most important determinant of myocardial oxygen demand²⁴.

Thus, the decrease in myocardial ischemic load from dexmedetomidine in the current study most likely results from its sympatholytic effects, mitigating emergence-related tachycardia and improving myocardial oxygen balance.

The beneficial effect of dexmedetomidine started intra-operatively because it decreased the prevalence of myocardial ischemia prior to emergence. This coincided with a decrease in demand, as indicated by the PWI, and with an improved endo/epicardial blood flow ratio. The finding that dexmedetomidine decreased myocardial oxygen requirements during the intra-operative period is in accordance with our previous studies in halothane-anesthetized dogs^{11,25}. We started the infusion of dexmedetomidine intra-operatively to obtain stable plasma concentrations of dexmedetomidine at the start of the emergence period. This approach also may have clinical relevance because it has been shown recently in vascular surgery patients that most ischemic events occur between 50 minutes before and 60 minutes after the end of surgery²⁰.

A critical aspect of our study is the methodology to create a stable coronary stenosis because small changes in diameter may cause large changes in coronary flow. However, immediately after application of the stenosis the relative decrease in poststenotic endocardial flow was the same in both groups. Also, major

kinking of the plastic screw occluder is unlikely because no sudden decreases of the coronary flow or myocardial shortening signals were observed. Most importantly, it is unlikely that potential variations in diameter of the stenosis explain the differences in myocardial ischemic load between both groups because the probability of these variations is the same in both groups.

In conclusion, a stable plasma concentration of dexmedetomidine of 0.5 ng/ml in dogs with a artificial coronary stenosis decreases the myocardial ischemic load during the first 2 hours of emergence from halothane anesthesia. This effect of dexmedetomidine can be explained by its sympatholytic and heart rate-lowering effects improving myocardial oxygen balance. Although extrapolation of our findings to the clinical setting should be performed with care, our study suggests that perioperative infusion of α_2 adrenergic-receptor agonists may offer a pharmacologic means of decreasing the ischemic load on the myocardium during emergence.

Acknowledgments

The authors want to thank Ruud Kruger, Theo van der Nagel, Anita Rousseau, and Jean Willigers for their technical assistance, and A. Kester for his statistical advice.

References

1. Mangano DT, Browner WS, Hollenberg M, et al. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. *N. Engl. J. Med.* 1990;323:1781-8.
2. Warltier DC, Pagel PS, Kersten JR. Approaches to the prevention of perioperative myocardial ischemia. *Anesthesiology* 2000;92:253-9.
3. Maze M. Alpha-2 adrenoreceptor agonists: Defining the role in clinical anesthesia. *Anesthesiology* 1991;74:581-605.
4. Talke P, Li J, Jain U, et al. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. *Anesthesiology* 1995;82:620-33.
5. Talke P, Richardson CA, Scheinin M, Fisher DM. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. *Anesth Analg* 1997;85:1136-42.
6. Talke P, Chen R, Thomas B, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. *Anesth Analg* 2000;90:834-9.
7. McSPI. Perioperative sympatholysis. Beneficial effects of the α_2 - adrenoceptor agonist mivazerol on hemodynamic stability and myocardial ischemia. *Anesthesiology* 1997;86:346-63.
8. Oliver MF, Goldman L, Julian DG, Holme I. Effect of mivazerol on perioperative cardiac complications during non- cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). *Anesthesiology* 1999;91:951-61.
9. Fleisher LA, Zielski MM, Schulman SP. Perioperative ST-segment depression is rare and may not indicate myocardial ischemia in moderate-risk patients undergoing noncardiac surgery. *J Cardiothorac Vasc Anesth* 1997;11:155-9.

10. Landesberg G, Luria MH, Cotev S, et al. Importance of long-duration postoperative ST-segment depression in cardiac morbidity after vascular surgery. *The Lancet* 1993;341:715-19.
11. Lawrence CJ, Prinzen FW, Lange de S. The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand. *Anesth Analg* 1996;82:544-50.
12. Flacke WE, Flacke JW, Bloor BC, et al. Effects of Dexmedetomidine on systemic and coronary hemodynamics in the anesthetized dog. *J of Cardiothorac and Vasc Anesthesia* 1993;7:41-9.
13. Flecknell PA. Anaesthesia of animals for biomedical research. *Brit J Anaesth* 1993;71:885-94.
14. Van Oosterhout MF, Willigers HM, Reneman RS, Prinzen FW. Fluorescent microspheres to measure organ perfusion: validation of a simplified sample processing technique. *Am J Physiol* 1995;269:H725-33.
15. Hoorn van der FAJ, Boomsma, Man in het Veld AJ, Schalekamp MADH. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. *J. Chromatogr.* 1989;487:17-28.
16. Vuorilehto L, Salonen JS, Anttila M. Picogram level determination of medetomidine in dog serum by capillary gas chromatography with negative ion chemical ionisation mass spectrometry. *J. Chromatogr.* 1989;497:282-7.
17. Rooke GA, Feigl EO. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. *Circ Res* 1982;50:273-86.
18. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. *Br. Med. J.* 1990;300:230-5.
19. Geft IL, Fishbein MC, Ninomiya K, et al. Intermittent brief periods of ischemia have a cumulative effect and may cause myocardial necrosis. *Circulation* 1982;66:1150-3.
20. Landesberg G, Mosseri M, Zahger D, et al. Myocardial infarction after vascular surgery: the role of prolonged stress-induced, ST depression-type ischemia. *J Am Coll Cardiol* 2001;37:1839-45.
21. Proctor LT, Schmeling WT, Roerig D, et al. Oral dexmedetomidine attenuates hemodynamic responses during emergence from general anesthesia in chronically instrumented dogs. *Anesthesiology* 1991;74:108-14.
22. Practice Guidelines for blood component therapy: A report by the American Society of Anesthesiologists. Task Force on Blood Component Therapy. *Anesthesiology* 1996;84:732-47.
23. Crystal GJ, Salem MR. Myocardial oxygen consumption and segmental shortening during selective coronary hemodilution in dogs. *Anesth Analg* 1988;67:500-8.
24. Indolfi C, Ross JJ. The role of heart rate in myocardial ischemia and infarction: Implications of myocardial perfusion-contraction matching. *Prog. Cardiovasc. Dis.* 1993;36:61-74.
25. Roekaerts PM, Prinzen FW, De Lange S. Beneficial effects of dexmedetomidine on ischaemic myocardium of anesthetized dogs. *Br J Anaesth* 1996;77:427-9.

CHAPTER 5

Comparison of the effects of dexmedetomidine and esmolol on myocardial oxygen consumption in dogs

Henriëtte M. Willigers, Frits W. Prinzen and Paul M. Roekaerts.

European journal of anaesthesiology 2004; **21**: 957–66. With small modifications.

Summary

Background and objective: The beta-adrenergic blocker esmolol and the α_2 -adrenergic agonist dexmedetomidine have the potential to decrease perioperative myocardial ischaemia. The pathophysiologic mechanisms involved in these anti-ischaemic properties have not been thoroughly studied. We compared the effects of esmolol and dexmedetomidine on two haemodynamic indices of overall myocardial oxygen demand and on directly measured myocardial oxygen consumption.

Methods: Eleven mongrel dogs were instrumented to measure aortic and left ventricular pressure, aortic and left anterior coronary artery flow, and myocardial wall thickening.

Variables related to myocardial oxygen metabolism were also determined. Measurements were performed during four sequential experimental conditions (control 1, esmolol, control 2, dexmedetomidine).

Results: Esmolol and dexmedetomidine decreased haemodynamic indices of myocardial oxygen demand to a similar extent: esmolol decreased the rate-pressure-product by $16 \pm 3\%$ and the pressure-work-index by $16 \pm 3\%$, dexmedetomidine decreased the rate-pressure-product by $26 \pm 3\%$ and the pressure-work-index by $16 \pm 7\%$. However, neither drug had an effect on myocardial oxygen consumption, a direct measure of myocardial oxygen demand. Sympatholytic doses of esmolol and of dexmedetomidine had different haemodynamic effects. Dexmedetomidine had a more pronounced bradycardic effect than esmolol ($P = 0.01$) and increased systolic aortic pressure by $15 \pm 4\%$. Esmolol decreased systolic aortic pressure by $8 \pm 2\%$, and decreased indices of myocardial contractility ($dPdT_{\max}$ and regional myocardial area decrease).

Conclusions: Esmolol and dexmedetomidine decreased haemodynamic indices of myocardial oxygen demand to a similar extent but neither drug decreased directly measured myocardial oxygen demand.

Keywords: Sympatholytics, Adrenergic Beta-Antagonists, Esmolol; Sympatholytics, Adrenergic Alpha-Agonists, Dexmedetomidine; Heart, Coronary Circulation, Drug Effects; Myocardium, Metabolism; Heart, Myocardial Contraction

Introduction

Perioperative sympatholysis from beta-adrenergic blockers and from alpha₂-adrenergic agonists has the potential to decrease the risk of postoperative myocardial ischaemia and of cardiac death¹. Therefore, the American Heart Association guidelines recommend consideration of the use of either one of these two classes of sympatholytic drugs in patients having or at risk for coronary artery disease². However, the pathophysiologic mechanisms involved in the anti-ischaemic effects of these drugs have not been studied intensively. It is likely that the postoperative increase in myocardial oxygen demand is an important cause of myocardial ischaemia in patients having significant coronary artery disease. This is because this category of patients has a reduced capacity to increase coronary blood flow in response to an increase in myocardial oxygen demand. Both the short-acting beta blocker esmolol and the most specific alpha₂ agonist dexmedetomidine have been shown to suppress postoperative increases in blood pressure and heart rate, two important determinants of myocardial oxygen demand³⁻⁶. Therefore it is likely that these drugs decrease myocardial ischemia from a decrease in myocardial oxygen demand. However, the effects of these drugs on myocardial oxygen demand are unknown, probably because of the invasive nature of the measurements involved. Also, the haemodynamic effects of an alpha₂-agonist and a beta-blocker have not been compared into detail.

The aim of this study was to determine and to compare the effects of the beta₁-blocker esmolol and the alpha₂-agonist dexmedetomidine on myocardial oxygen demand and on various haemodynamic indices of myocardial oxygen demand. Because of the invasiveness of the measurement of myocardial oxygen demand, these studies were performed in chloralose anaesthetized dogs.

Materials and methods

Animal preparation and instrumentation

Eleven adult mongrel dogs (31 ± 1.9 kg) were studied with the approval of the Animal Care Committee of the University. Anaesthesia was induced with sodium thiopental 25 mg kg⁻¹ intravenously; the dogs were intubated and ventilated with oxygen 30% in nitrous oxide. Halothane (inspired concentration 1–1.5%) was added to suppress somatic responses and to maintain haemodynamic stability during thoracotomy and instrumentation. The chest was opened through the left fifth intercostal space and the heart was suspended in a pericardial cradle. The rectal temperature of the dogs was kept between 37° C and 39° C by means of a thermostatically regulated heating mattress and a

warmed operating room (24° C). Heart rate and rhythm were monitored using ECG lead II.

Catheters were inserted into a femoral artery and the vein next to the left anterior descending (LAD) coronary artery for arterial and coronary venous blood sampling respectively. The coronary venous catheter was assumed to drain the region of the myocardium supplied by the LAD artery. Pressure sensors (Sentron 180 S, Cordis, Roden, the Netherlands) were inserted through the right femoral artery into the ascending aorta and left ventricle. Ultrasonic transit-time flow probes (Transonic Systems, Ithaca, NY) were placed around the aortic root and around the LAD artery just proximal to the first diagonal branch. A pulmonary artery catheter (Baxter) was introduced via the right jugular vein into the pulmonary artery and connected to a thermodilution cardiac output computer (Baxter Edwards SAT 2). The cardiac output measurements, obtained by averaging triplicate thermodilution values, were compared at regular intervals with the ultrasonic aortic flow measurements. Three inductive coils were sutured to the left lateral epicardium in an equilateral triangle configuration to measure epicardial area decrease, an index of myocardial wall thickening.

Study protocol

As soon as instrumentation was completed, nitrous oxide and halothane were discontinued. A chloralose loading dose of 40 mg kg⁻¹ was then administered, followed by a maintenance infusion of 8 mg kg⁻¹ h⁻¹. The dogs were ventilated with 40% oxygen in air to normocarbina.

After a stabilization period of at least 60 minutes, the following 4 successive experimental conditions were studied in each dog:

1. Control 1
2. Esmolol: twenty minutes after starting esmolol HCl infusion (Ohmeda Inc., NJ, USA)
3. Control 2: twenty minutes after stopping the esmolol infusion
4. Dexmedetomidine: twenty minutes after starting dexmedetomidine infusion (Orion Corporation, Farnos Research, Turku, Finland) .

After the Control 1 measurements had been performed, the dose of isoprenaline necessary to increase heart rate by more than 20% was determined as the tachycardic dose in each dog.

After heart rate and other haemodynamic variables had returned to control 1 values, esmolol was given as a loading dose of 0.5 mg kg⁻¹ min⁻¹ for two minutes, followed by a continuous infusion of 0.3 mg kg⁻¹ min⁻¹. To check that the beta₁-

adrenergic blockade from esmolol was adequate, the response to the tachycardic dose of isoprenaline was tested before stopping the esmolol infusion.

Dexmedetomidine was given as a loading dose of $1 \mu\text{g kg}^{-1}$ over twenty minutes, followed by a continuous infusion of $1.5 \mu\text{g kg}^{-1} \text{ hour}^{-1}$ in NaCl 0.9%. We aimed for a target plasma concentration of dexmedetomidine above 0.5 ng ml^{-1} , because this concentration reduces sympathetic tone effectively in dogs⁷ and in humans⁵. Because the pharmacokinetics of dexmedetomidine in dogs were unknown at the time of the study, we used an infusion regimen advised by Orion Corporation (Turku, Finland) and based on the pharmacokinetic set in the STANPUMP software⁸.

During each experimental condition the following variables were measured:

1. haemodynamic indices: heart rate, systolic and diastolic aortic pressure, left ventricular pressure, aortic flow and myocardial wall thickening.
2. variables related to myocardial oxygen metabolism: Arterial and LAD coronary venous blood gas tensions, LAD coronary flow and, arterial haemoglobin content.

To measure LAD flow relative to myocardial weight, the perfusion area of the LAD was delineated by injecting methylene blue dye in the LAD at the end of each experiment. Then the dogs were euthanized by a pentobarbital overdose, and their hearts were excised. The methylene blue stained portion of the heart was dissected off and weighed.

Data analysis

All haemodynamic and coronary flow signals were preamplified and then digitized with a 16-channel, 12-bit A/D interface in a IBM-compatible PC. Sampling frequency was 200 Hz for each channel. Signals were continuously displayed on the computer screen, and during each experimental measurement period beat to beat values were stored on the hard disk. For each measurement period, the average of each variable was calculated over a stable haemodynamic period of two minutes, i.e. less than 5% heart rate variation. Peak of first derivative of left ventricular pressure ($\text{LV dPdt}_{\text{max}}$) was derived from the left ventricular pressure signal.

Systemic vascular resistance (SVR) was calculated as the quotient of mean aortic pressure and mean aortic blood flow. Coronary vascular resistance (CVR) was calculated as the quotient of mean aortic pressure and mean coronary blood flow.

The following haemodynamic indices of myocardial oxygen demand were measured:

1. The pressure work index $PWI^9 = C1 (SAP \times HR) + C2 (0.8 SAP + 0.2 DAP) \times HR \times SV/BW + 0.57$, in $\mu\text{mol min}^{-1} \text{g}^{-1}$

where

HR = heart rate in beats per minute

SV = stroke volume in ml

SAP = systolic aortic pressure in mmHg

DAP = diastolic aortic pressure in mmHg

BW = body weight in kg

$C1 = 1.63 \times 10^{-4}$

$C2 = 1.30 \times 10^{-4}$

2. The rate pressure product $RPP = \text{heart rate} \times \text{systolic aortic pressure}$.

To study the effects of esmolol and dexmedetomidine on the relation between haemodynamic indices of myocardial oxygen demand (MVO_2) and measured myocardial oxygen consumption, percentage changes in RPP and PWI were plotted against percentage changes in measured MVO_2 .

To measure epicardial deformation, three inductive coils were sutured to the left lateral epicardium. This method for measuring epicardial deformation and its ability to detect changes in regional contractility has been validated in our laboratory^{10,11}. The coils were sutured in an equilateral triangle configuration to measure area decrease, e.g. the reduction in area of the epicardial region enclosed by the coils during the ejection period of the systole. Onset and end of the ejection phase were determined from the cross over of the left ventricular pressure and the ascending aortic pressure and from the dicrotic notch in the aortic pressure signal, respectively. Because the volume of a certain part of the ventricular wall does not change significantly throughout the cardiac cycle, surface area decrease during the ejection phase is related to myocardial wall thickening, and thus regional contractility.

All blood samples were collected on ice. Those to be analysed afterwards were centrifuged at 4 ° C within 15 minutes after sampling to separate plasma and then stored at - 70 ° C. Blood gas tensions were assessed with a blood gas analyser (ABL 3, Radiometer, Copenhagen, Denmark). Haemoglobin content (Hb) and oxygen saturation ($O_{2\text{sat}}$) were assessed with a haemoximeter (OSM-2, Radiometer). The O_2 content (CaO_2 in mmol L^{-1}) was calculated as $\text{Hb} \times O_{2\text{sat}} + 0.0102 \times PO_2$. From this, oxygen extraction was calculated for the territory of myocardium perfused by the LAD, using a standard formula. To assay plasma concentrations of norepinephrine, high performance liquid chromatography with colometric electrochemical detection was used^{12,13}. Plasma concen-

trations of dexmedetomidine were analysed at the pharmacokinetics laboratory of the Orion Corporation.

Statistical analysis

The drugs in the present study were investigated in each dog in the same sequence.

Esmolol and dexmedetomidine were compared with their preceding control values and with each other. To minimize a possible time-effect between esmolol and dexmedetomidine measurements the values found during these measurements were first subtracted from their preceding control value before a statistical comparison was made.

We used the non-parametric Wilcoxon signed rank test because of the relatively small number of experiments. P value ≤ 0.05 was considered statistically significant. Linear regression analysis was used to study the relation between the change in haemodynamic indices of myocardial oxygen demand and change in myocardial oxygen consumption. Data are presented as mean $\pm$ SEM, unless stated otherwise.

Results

The dogs maintained normothermia throughout the study period, and shivering was not observed.

The infusion regimens of esmolol and dexmedetomidine had sympatholytic effects. Esmolol abolished the tachycardic response to isoprenaline in all dogs. The dose of isoprenaline used to test the beta-adrenergic blockade was $0.45 \pm 0.04 \mu\text{g kg}^{-1}$. The infusion of dexmedetomidine resulted in plasma concentrations of $1.1 \pm 0.3 \text{ ng ml}^{-1}$. Dexmedetomidine decreased plasma norepinephrine concentration from $0.52 \pm 0.15 \text{ nmol L}^{-1}$ to $0.06 \pm 0.03 \text{ nmol L}^{-1}$ ($P < 0.02$).

Esmolol and dexmedetomidine decreased haemodynamic indices of myocardial oxygen demand to a similar extent: esmolol decreased the RPP by $16 \pm 3\%$ and the PWI by $16 \pm 3\%$, dexmedetomidine decreased the RPP by $26 \pm 3\%$ and the PWI by $16 \pm 7\%$ (Fig. 2). However, these similar decreases in demand resulted from different haemodynamic effects (fig 1). Dexmedetomidine had a more pronounced bradycardic effect than esmolol ($P = 0.01$). The effects on systolic aortic pressure were opposite with these two drugs: dexmedetomidine increased systolic aortic pressure by $15 \pm 4\%$ whereas esmolol decreased systolic aortic pressure by $8 \pm 2\%$ ($P < 0.01$). The increase in systolic aortic pressure from dexmedetomidine was accompanied by a parallel increase in systemic vascular resistance. The decrease in systolic aortic pressure from esmolol was

Figure 1. The effects of esmolol and dexmedetomidine on; sympathetic tone, haemodynamic parameters and, indices of myocardial contractility in chloralose anaesthetized dogs. Black bars indicate control values and grey bars values during the infusion of the respective drug. E: esmolol; D: dexmedetomidine; HR: heart rate; AOP: aortic pressure; SVR: systemic vascular resistance.

* : $P < 0.05$ vs. preceding control measurement; # : $P < 0.05$ esmolol vs. dexmedetomidine

Figure 2. The effects of esmolol and dexmedetomidine on haemodynamic indices of myocardial oxygen demand and on myocardial oxygen consumption, a direct measure of myocardial oxygen demand, in chloralose anesthetized dogs. Black bars indicate control values and grey bars values during the infusion of the respective drug. E: esmolol; D: dexmedetomidine; PWI: pressure work index; RPP: rate pressure product.

* : $P < 0.05$ vs preceding control measurement; # : $P < 0.05$ esmolol vs dexmedetomidine

Figure 3. The relation between changes (vs. preceding control value for each experiment) in haemodynamic indices of myocardial oxygen demand and in myocardial oxygen consumption in the presence of esmolol (Esmo) and in the presence of dexmedetomidine (Dexmed). No significant linear relationship was found.

accompanied by a decrease in indices of myocardial contractility, dPdtmax and regional myocardial area decrease (Fig.1). The decrease in myocardial contractility after esmolol resulted in a marginal decrease in cardiac output compared to Control 1 ($12 \pm 4\%$ decrease, $P = 0.05$) but not compared to dexmedetomidine ($P = 0.17$).

In contrast to their suppressive effect on haemodynamic indices of myocardial oxygen demand, neither drug decreased measured myocardial oxygen consumption (Fig. 2). To study this finding into more detail we plotted changes in myocardial oxygen consumption as a function of changes in RPP and PWI (haemodynamic indices of demand). No linear relationship was observed (Fig. 3).

Esmolol and dexmedetomidine maintained myocardial oxygen delivery by different mechanisms (Table 1). Dexmedetomidine: increased blood haemoglobin concentration, increased myocardial oxygen extraction, increased coronary vascular resistance, and tended to decrease coronary flow ($P = 0.13$). Esmolol maintained blood haemoglobin concentration and coronary flow, and

Table 1. The effects of esmolol and dexmedetomidine on determinants of myocardial oxygen consumption and delivery in chloralose anaesthetised dogs.

	Control 1	Esmolol	Control 2	Dexmede- tomidine
Arterial				
Haemoglobin mmol L ⁻¹	8.2 ± 0.3	8.3 ± 0.3	7.7 ± 0.2	9.0 ± 0.4 ^{*#}
pH	7.47 ± 0.02	7.44 ± 0.02 [*]	7.40 ± 0.01	7.45 ± 0.03 [#]
PO ₂ kPa	33.4 ± 5.8	30.3 ± 5.6	31.5 ± 5.6	35.7 ± 5.9
Oxygen content mmol L ⁻¹	8.3 ± 0.3	8.3 ± 0.2	7.8 ± 0.3	9.3 ± 0.4 ^{*#}
PCO ₂ kPa	4.1 ± 0.2	4.2 ± 0.2	4.2 ± 0.1	4.3 ± 0.2
Coronary venous				
pH	7.40 ± 0.02	7.39 ± 0.02	7.35 ± 0.02	7.39 ± 0.03
PO ₂ kPa	2.5 ± 0.1	3.0 ± 0.2 [*]	3.2 ± 0.2	2.8 ± 0.2 ^{*#}
O ₂ content mmol L ⁻¹	2.4 ± 0.2	3.0 ± 0.2 [*]	2.9 ± 0.2	3.0 ± 0.2 [#]
Coronary blood flow ml min ⁻¹ 100g ⁻¹	76 ± 10	78 ± 10	80 ± 11	69 ± 14
Myocardial oxygen delivery mmol min ⁻¹ 100g ⁻¹	0.63 ± 0.07	0.65 ± 0.09	0.63 ± 0.10	0.61 ± 0.10
Arterial-coronary venous oxygen content difference mmol L ⁻¹	5.9 ± 0.3	5.3 ± 0.3 [*]	4.9 ± 0.3	6.3 ± 0.4 ^{*#}
Myocardial oxygen extraction ratio	0.71 ± 0.02	0.64 ± 0.03 [*]	0.63 ± 0.03	0.67 ± 0.02 ^{*#}
Myocardial oxygen consumption mmol min ⁻¹ 100 g ⁻¹	0.45 ± 0.05	0.43 ± 0.06	0.40 ± 0.07	0.42 ± 0.07
Coronary vascular resistance mmHg ml ⁻¹ min ⁻¹ 100g ⁻¹	1.77 ± 0.25	1.57 ± 0.22 [*]	1.62 ± 0.27	2.32 ± 0.43 ^{*#}

decreased coronary vascular resistance and myocardial oxygen extraction. Neither drug affected coronary venous pH.

Thus, esmolol and dexmedetomidine decreased haemodynamic indices of myocardial oxygen demand to a similar extent, but neither drug decreased myocardial oxygen consumption, a direct measure of myocardial oxygen demand.

Discussion

Prophylactic administration of sympatholytic drugs during the emergence period may decrease myocardial ischaemia in certain groups of patients. Theoretically, this beneficial effect is, at least partly, related to their effect on myocardial oxygen demand. The peripherally acting beta-blockers and centrally acting α_2 - agonists are two fundamentally different classes of sympatholytic drugs but their effects on myocardial oxygen demand have not been compared directly. Therefore, we studied in 11 chloralose anaesthetised dogs if a beta blocker and an α_2 agonist have different effects on myocardial oxygen demand and on frequently used haemodynamic indices of myocardial oxygen demand.

An important finding in this study is that both classes of sympatholytic drugs decreased haemodynamic indices of myocardial oxygen demand to a similar extent but did not decrease myocardial oxygen consumption. In this study myocardial oxygen consumption reflected myocardial oxygen demand because the dogs had an unlimited coronary blood flow.

A possible explanation for this finding is that myocardial oxygen consumption measurements may not have been completely accurate. In previous pilot experiments, we observed that measurements of myocardial blood flow using a flow probe and methylene blue to delineate the perfusion area, underestimates myocardial blood flow as measured with microspheres, a gold standard of blood flow measurement. However, the percentage of error was small, systematic and stable. Therefore we concluded that myocardial blood flow measurements using a flow probe can accurately detect a change in oxygen delivery.

A more likely explanation for the discrepancy between myocardial oxygen consumption and haemodynamic indices of myocardial oxygen demand in the current study may be the inaccuracy of haemodynamic indices in predicting myocardial oxygen demand. We studied RPP and PWI because these two indices can be easily calculated in clinical practice from heart rate, systolic pressure and cardiac output. They have been shown to correlate with myocardial oxygen consumption in chloralose anaesthetised dogs⁹ and in humans¹⁴. However, it has been argued that the conclusions from these studies may be false because of methodological pitfalls such as pooling of all data instead of using only single data points for each subject¹⁵. An explanation for the inaccuracy of haemodynamic indices in predicting myocardial oxygen demand may be that they were primarily developed as a clinical useful indices and thus do not include all parameters determining myocardial oxygen demand⁹.

So, we may conclude that neither dexmedetomidine nor esmolol decreased myocardial oxygen demand in the present comparative study in chloralose anaesthetized dogs. This finding is in accordance with previous non-comparative studies. Studies from our laboratory showed that dexmedetomidine does

not affect myocardial oxygen consumption in anaesthetized dogs and goats¹⁶⁻¹⁸ and Sidi et al^{19,20} showed that esmolol does not affect myocardial oxygen demand in anaesthetized dogs^{19,20}

Another important finding in the present comparative study is that the beta blocker and the α_2 agonist had different haemodynamic effects. Esmolol decreased both blood pressure and heart rate. Dexmedetomidine increased blood pressure, but decreased heart rate to a greater extent than esmolol. The decrease in arterial pressure from esmolol seemed to result from its cardiodepressive effects, because esmolol suppressed indices of myocardial contractility without affecting the systemic vascular resistance. Hypotension is a known adverse effect of esmolol and is not fully explained by its beta receptor blocking effect²¹. The decrease in myocardial contractility from esmolol in the present study is in accordance with previous studies in which doses of more than $300 \mu\text{g kg}^{-1} \text{min}^{-1}$ were used²²⁻²⁴. The effects of esmolol on peripheral vascular resistance are equivocal; both an increase²³ and no effect²⁵ have been observed. Dexmedetomidine infusion was associated with an increase in blood pressure and systemic vascular resistance. Generally, dexmedetomidine infusion results in biphasic changes in blood pressure. Initially, blood pressure increases for a short period (i.e. less than 20 minutes). This pressor phase is caused by stimulation of α_2 -adrenergic receptors in peripheral vessel walls. Over time the central sympatholytic effects predominate with a decline in blood pressure^{7,26}. In the present study, blood pressure was still significantly increased approximately one hour after starting the infusion of dexmedetomidine, despite a significant decrease in plasma norepinephrine concentration. This implies a much longer duration of the vasoconstrictive phase which may be explained by the species studied and by the anaesthetic technique used in our experiments. It has been shown that the peripheral vasoconstrictive effect of dexmedetomidine is more pronounced in dogs than in humans^{27,28}. The importance of the anaesthetic technique when studying the effects of dexmedetomidine were already pointed out in a previous study from our laboratory¹⁸. In the present study, we used α -chloralose anaesthesia because it is known to have no major effect on central neuroregulation and on oxygen metabolism^{29,30}. However, α -chloralose is also known to potentiate the pressor effects of α_2 agonists³¹.

The heart rate lowering effect of dexmedetomidine was more pronounced than that of esmolol. In accordance, a case of tachycardia in a cardiac surgical patient has been reported which was unresponsive to esmolol but resolved after dexmedetomidine³². The ability of α_2 -agonists to decrease heart rate has been attributed to their central sympatholytic effect, as well as to a decrease in norepinephrine release at the peripheral neuroeffector junction³³. The more pronounced bradycardic effect of dexmedetomidine suggests that an additional

vagomimetic effect may be involved in producing bradycardia. This is because the heart rate reduction induced by almost complete beta₁-receptor blockade during esmolol infusion was the maximum which could be obtained from sympatholysis alone. It could be argued that the infusion protocol of esmolol in the present experiments did not result in adequate beta₁-receptor blockade. However, baseline plasma norepinephrine concentrations, and thus beta-adrenergic stimulation, were low in these chloralose anaesthetized dogs. Also, we used $0.45 \pm 0.04 \mu\text{g kg}^{-1}$ of isoprenaline to test beta₁-adrenergic blockade, this is in the higher range of the doses of isoprenaline used in other studies on the beta-blocking effects of esmolol, e.g. $0.125 - 0.5 \mu\text{g kg}^{-1}$ ³⁴⁻³⁶. Third, it has been shown that the infusion of only one third of the dose of esmolol used in the current study already blocks 70% of the cardiac beta₁-receptors³⁶.

Esmolol and dexmedetomidine did not affect myocardial oxygen consumption, however they affected coronary vascular resistance and the relative contribution of the individual parameters of myocardial oxygen delivery. Esmolol decreased myocardial oxygen extraction and coronary vascular resistance (CVR) which suggests that esmolol has coronary vasodilating properties. In contrast, dexmedetomidine increased fractional oxygen extraction and CVR¹⁶⁻¹⁸. It has been suggested that these effects of dexmedetomidine indicate that its alpha₂-adrenergic coronary vasoconstrictive effects result in a relative shortage of oxygen delivery⁷. However, our findings indicate a possible alternative explanation. Dexmedetomidine increased myocardial oxygen extraction secondary to an increase in haemoglobine and arterial O₂ content, and not secondary to a decrease in coronary venous O₂ content. Indications that the increase in myocardial oxygen extraction was not associated with a critical shortage of myocardial oxygen delivery when giving dexmedetomidine are:

1. oxygen extraction was still far below maximal³⁷
2. coronary venous pH did not decrease
3. dexmedetomidine suppressed haemodynamic indices of myocardial oxygen demand.

Conversely, the observed increase in arterial O₂ content and myocardial oxygen extraction from dexmedetomidine did not increase myocardial oxygen delivery because coronary blood flow tended to decrease.

The increase in haemoglobin from dexmedetomidine is an interesting feature of this study. The most likely explanation for this finding is that alpha₂-receptor activation from dexmedetomidine caused recruitment of erythrocytes from splenic stores. A previous study in dogs showed the effects of alpha-adrenoreceptor activation on the splenic capsule and splanchnic capacitance vasculature³⁸, and there is evidence that these effects are alpha₂-receptor rather than alpha₁-receptor mediated³⁹. Also in humans alpha-adrenergic induced

blood volume shifts from the spleen and increases in hematocrit have been described^{40,41}. Another possible explanation for the increase in haemoglobin concentration is a transcapillary fluid shift from the intravascular space in those organs where venous vasoconstriction outstands arterial vasoconstriction. This mechanism has already been demonstrated in rats⁴². We believe that this explanation is less likely, because the expected decrease in end-diastolic pressure associated with a fluid shift, was not observed in our experiments. The increase in haemoglobin concentration associated with the administration of dexmedetomidine can also, at least in part, explain the measured increase in coronary vascular resistance. This is because viscosity, of which haematocrit is the major determinant, contributes to vascular resistance⁴³.

A limitation of this study is that the results obtained are restricted to dogs; there may be relevant species difference in the effect of sympatholytic drugs on myocardial oxygen consumption. However, myocardial oxygen consumption in the current study was similar to that reported in awake and in anaesthetized humans¹⁴.

A methodological limitation of the current study is that the drugs were always investigated in the same sequence in each experiment; first esmolol, then dexmedetomidine. This was done because of the relatively long plasma half-life of dexmedetomidine (2 hours) compared to the very short plasma half-life of esmolol (9 minutes). However, we applied statistical methods to minimize the possible time effect associated with a sequential study design.

A final limitation is that we studied only one dose of each drug and therefore cannot exclude that higher doses are needed to decrease myocardial oxygen consumption. However, the dose used resulted in adequate sympatholysis for each drug.

In conclusion, peripheral sympatholysis from a beta blocker and central sympatholysis from an α_2 -agonist decrease haemodynamic indices of myocardial oxygen demand to a similar extent, but do not decrease myocardial oxygen consumption in chloralose anaesthetized dogs.

Acknowledgements

The authors thank A. Kester for statistical advice and Orion Corporation, Farnos Research, Turku, Finland, for financial support and plasma concentration measurements of dexmedetomidine.

References

- 1 Stevens RD, Burri H, Tramer MR. Pharmacologic Myocardial Protection in Patients Undergoing Noncardiac Surgery: A Quantitative Systematic Review. *Anesth Analg* 2003; **97**: 623-33.

- 2 Eagle KA, Berger PB, Calkins H et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary. *Anesth Analg* 2002; **94**: 1052–64.
- 3 Urban MK, Markowitz SM, Gordon MA, Urquhart BL, Kligfield P. Postoperative prophylactic administration of beta-adrenergic blockers in patients at risk for myocardial ischemia. *Anesth Analg* 2000; **90**: 1257–61.
- 4 Raby KE, Brull SJ, Timimi F et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. *Anesth Analg* 1999; **88**: 477–82.
- 5 Talke P, Li J, Jain U et al. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group. *Anesthesiology* 1995; **82**: 620–33.
- 6 Talke P, Chen R, Thomas B et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. *Anesth Analg* 2000; **90**: 834–9.
- 7 Flacke WE, Flacke JW, Bloor BC, McIntee DF, Sagan M. Effects of Dexmedetomidine on systemic and coronary hemodynamics in the anesthetized dog. *J of Cardiothorac and Vasc Anaesthesia* 1993; **7**: 41–9.
- 8 Dyck JB, Maze M, Haack C et al. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. *Anesthesiology* 1993; **78**: 821–8.
- 9 Rooke GA, Feigl EO. Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting. *Circ Res* 1982; **50**: 273–86.
- 10 Arts T, Reneman RS. Measurement of deformation of canine epicardium in vivo during cardiac cycle. *Am J Physiol* 1980; **239**: H432–7.
- 11 Arts T, Veenstra PC, Reneman RS. Epicardial deformation and left ventricular wall mechanics during ejection in the dog. *Am. J. Physiol.* 1982; **243**: H379–H90.
- 12 Scheinin M, Karhuvaara S, Ojala Karlsson P, Kallio A, Koulu M. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. *Life Sci* 1991; **49**: 75–84.
- 13 Koulu M, Scheinin M, Kaartinen A et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. *Br. J. clin. Pharmacol.* 1989; **27**: 243–55.
- 14 Hoeft A, Sonntag H, Stephan H, Kettler D. Validation of myocardial oxygen demand indices in patients awake and during anaesthesia. *Anesthesiology* 1991; **75**: 49–56.
- 15 Kal JE, Van Wezel HB, Vergroesen I. A critical appraisal of the rate pressure product as index of myocardial oxygen consumption for the study of metabolic coronary flow regulation. *Int J Cardiol* 1999; **71**: 141–8.
- 16 Roekaerts PM, Prinzen FW, De Lange S. Beneficial effects of dexmedetomidine on ischaemic myocardium of anesthetized dogs. *Br J Anaesth* 1996; **77**: 427–9.
- 17 Lawrence CJ, Prinzen FW, Lange de S. The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand. *Anesth Analg* 1996; **82**: 544–50.
- 18 Lawrence CJ, Prinzen FW, De Lange S. Hemodynamic and coronary vascular effects of dexmedetomidine in the anesthetized goat. *Acta Anaesthesiol Scand* 1997; **41**: 830–6.
- 19 Sidi A, Rush W. Decreased regional lactate production and output due to intracoronary continuous infusion of esmolol during acute coronary occlusion in dogs. *J Cardiothorac Vasc Anesth* 1991; **5**: 237–42.

- 20 Sidi A, Davis RF. Esmolol decreases the adverse effects of acute coronary artery occlusion on myocardial metabolism and regional myocardial blood flow in dogs. *Anesth. analg.* 1988; **67**: 124-30.
- 21 Deegan R, Wood AJ. Beta-receptor antagonism does not fully explain esmolol-induced hypotension. *Clin Pharmacol Ther* 1994; **56**: 223-8.
- 22 Jacobs JR, Maier GW, Rankin JS, Reves JG. Esmolol and left ventricular function in the awake dog. *Anesthesiology* 1988; **68**: 373-8.
- 23 Shah N, Del Valle O, Edmondson R et al. Esmolol infusion during nitroprusside-induced hypotension: impact on hemodynamics, ventricular performance, and venous admixture. *J Cardiothorac Vasc Anesth* 1992; **6**: 196-200.
- 24 Strum DP, Pinsky MR. Esmolol-induced regional wall motion abnormalities do not affect regional ventricular elastances. *Anesth Analg* 2000; **90**: 252-61.
- 25 Girard D, Shulman BJ, Thys DM et al. The safety and efficacy of esmolol during myocardial revascularisation. *Anesthesiology* 1986; **65**: 157-64.
- 26 Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. *Anesthesiology* 1993; **78**: 813-20.
- 27 Schmeling WT, Kampine JP, Roerig DL, Warltier DC. The effects of the stereoisomers of the α_2 -Adrenergic agonist medetomidine on systemic and coronary hemodynamics in conscious dogs. *Anesthesiology* 1991; **75**: 499-511.
- 28 Kallio A, Scheinin M, Koulu M et al. Effects of dexmedetomidine, a selective α_2 -adrenoceptor agonist, on hemodynamic control mechanisms. *Clin Pharmacol Ther* 1989; **46**: 33-42.
- 29 Citters Van RL, Franklin DL, Rushmer RF. Left Ventricular Dynamics in Dogs During Anaesthesia with Alpha-Chloralose and Sodium Pentobarbital. *The american journal of cardiology* 1964: 349-54.
- 30 Covert RF, Schreiber MD, Leff AR et al. Oxygen metabolism and catecholamine secretion during chloralose anaesthesia in lambs. *J of Developmental Physiology* 1992; **17**: 125-32.
- 31 Covert RF, Drummond WH, Gimotty PA. Chloralose alters circulatory response to α -receptor stimulation and blockade. *Am. J. Physiol.* 1988; **255**: H419-H25.
- 32 Ruesch S, Levy JH. Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery. *Anaesth Analg* 2002; **95**: 316-8.
- 33 Maze M, Tranquilli W. Alpha-2 adrenoceptor agonists: defining the role in clinical anaesthesia. *Anesthesiology* 1991; **74**: 581-605.
- 34 Quon CY, Gorczynsky RJ. Pharmacodynamics and onset of action of esmolol in anesthetized dogs. *The journal of pharmacology and experimental therapeutics* 1986; **237**: 912-8.
- 35 Gorczynski RJ, Shaffer JE, Lee RJ. Pharmacology of ASL-8052, a novel α -adrenergic receptor antagonist with an ultrashort duration of action. *Journal of Cardiovascular Pharmacology* 1983; **5**: 668-77.
- 36 Gorczynski RJ, Murthy VS, Hwang TF. α -blocking and hemodynamic effects of ASL-8052. *Journal of cardiovascular pharmacology* 1984; **6**: 1048-59.
- 37 Daniell HB. Coronary flow alterations on myocardial contractility, oxygen extraction, and oxygen consumption. *Am J Physiol* 1973; **225**: 1020-5.
- 38 Modin A, Pernow J, Lundberg JM. Neuropeptide Y and differential sympathetic control of splenic blood flow and capacitance function in the pig and dog. *Acta Physiol Scand* 1993; **147**: 15-25.
- 39 Supple EW, Graham RM, Powell WJ, Jr. Direct effects of alpha 2-adrenergic receptor stimulation on intravascular systemic capacity in the dog. *Hypertension* 1988; **11**: 352-9.

- 40 Flamm SD, Taki J, Moore R et al. Redistribution of regional and organ blood volume and effect on cardiac function in relation to upright exercise intensity in healthy human subjects. *Circulation* 1990; **81**: 1550-9.
- 41 Laub M, Hvid Jacobsen K, Hovind P et al. Spleen emptying and venous hematocrit in humans during exercise. *J Appl Physiol* 1993; **74**: 1024-6.
- 42 Trippodo NC. Total circulatory capacity in the rat. Effects of epinephrine and vasopressin on compliance and unstressed volume. *Circ Res* 1981; **49**: 923-31.
- 43 Fan FC, Chen RY, Schuessler GB, Chien S. Effects of hematocrit variations on regional hemodynamics and oxygen transport in the dog. *Am J Physiol* 1980; **238**: H545-22.

CHAPTER 6

The effects of esmolol and dexmedetomidine on myocardial oxygen consumption during sympathetic stimulation in dogs

Henriëtte M. Willigers, Frits W. Prinzen and Paul M.H.J. Roekaerts.

J Cardiothorac Vasc Anesth 2006; **20**: 364–70. With small modifications.

Abstract

Objective: To compare the potential of the β_1 -adrenergic receptor blocker esmolol and the α_2 -adrenergic receptor agonist dexmedetomidine to suppress the cardiovascular and neuro-endocrine response to a sympathetic stimulus

Design: Experimental study.

Setting: Laboratory of University.

Participants: Eleven anesthetized dogs.

Interventions: Catheters for arterial and coronary venous blood sampling and calculation of myocardial oxygen consumption were inserted. Pressure sensors were placed in the aorta, in the left ventricle and in a carotid artery. Flow probes were placed around the aortic root and around the left anterior descending coronary artery. Esmolol was infused (loading dose 1 mg/kg, infusion $0.3 \text{ mg}^{-1} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$), and the adequacy of β -blockade was checked. Dexmedetomidine infusion was started more than 30 minutes after stopping esmolol (loading dose dexmedetomidine $1 \text{ } \mu\text{g/kg}$, infusion $1.5 \text{ } \mu\text{g}^{-1} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}$). Occlusion of both carotid arteries was used as a sympathetic stimulus before and during infusion of esmolol and before and during infusion of dexmedetomidine.

Measurements and Main Results: The variables were measured just before and during sympathetic stimulation, and changes were calculated. Both drugs suppressed the increase in dPdT_{max} . Dexmedetomidine suppressed the increase in plasma norepinephrine; and the increase in systemic vascular resistance (dexmedetomidine: $4 \pm 4\%$, esmolol: $25 \pm 19\%$; increase, $P = 0.02$). Esmolol attenuated the heart rate response (esmolol: $2 \pm 2\%$ increase, dexmedetomidine: $20 \pm 18\%$ increase; $P = 0.02$). However, dexmedetomidine decreased baseline heart rate more than esmolol; therefore, the absolute maximal heart rate during sympathetic stimulation was lower in the presence of dexmedetomidine (dexmedetomidine 119 ± 14 , esmolol $141 \pm 15 \text{ beats min}^{-1}$; $P = 0.01$). Neither drug suppressed the increase in myocardial oxygen consumption.

Conclusions: Both dexmedetomidine and esmolol have the potential to suppress some of the cardiovascular and neuro-endocrine changes to a sympathetic stimulus but neither drug suppressed the increase in myocardial oxygen consumption.

Introduction

Sympatholytic drugs such as beta-adrenergic blockers and alpha₂-adrenergic agonists have a beneficial effect on cardiac outcome in selected surgical patients^{1,2}, and therefore the American College of Cardiology / American Heart Association guidelines recommend consideration of administration of one of these drugs during the perioperative period³. One reason for the beneficial effect of sympatholytic drugs on cardiac outcome is that they suppress the increase in myocardial oxygen consumption associated with sympathetic stimulation. In accordance, it has been shown that beta-blockade suppresses the increase in myocardial oxygen consumption in exercising dogs⁴, and the alpha₂-agonist dexmedetomidine suppresses the increase in heart rate and myocardial lactate release during emergence from anesthesia in dogs⁵.

To date, there are no comparative studies on the potential of beta-blockers and alpha₂-adrenergic agonists to decrease perioperative cardiac complications⁶. Clinical studies in which the sympatholytic potential of these drugs were compared suggest that alpha₂-agonists may be superior^{7,8}. This is because the central acting alpha₂-agonists attenuate the heart rate, blood pressure, and plasma catecholamine response to sympathetic stimulation, whereas the peripheral acting beta-blockers only attenuate the heart rate response. However, it remains unknown if this more complete sympatholytic action of alpha₂-agonists translates into a more complete suppression of the sympathetic mediated increase in myocardial oxygen consumption. This is because myocardial oxygen consumption was not measured in these studies.

Therefore the purpose of the current study was to compare the potential of the alpha₂-agonist dexmedetomidine and the beta₁-blocker esmolol to suppress the cardiovascular effects and the increase in myocardial consumption associated with a sympathetic stimulus. Because of the invasive nature of the measurements the study was done in anesthetised dogs. Carotid sinus hypotension from bicarotid occlusion was used as a sympathetic stimulus because this is a well known stimulus^{9,10} and because it induced the most reliable and reversible hemodynamic changes and increases in myocardial oxygen consumption of all sympathetic stimuli tested in our pilot experiments. The other sympathetic stimuli tested were; application of capsaicin on the stomach¹¹, in the knee¹², and on the epicardium¹³.

In each animal, the effects of esmolol and of dexmedetomidine on sympathetic induced changes in: plasma norepinephrine levels, hemodynamic variables, hemodynamic indices of demand, and myocardial oxygen consumption were measured.

Methods

Animal Preparation and Instrumentation

Eleven adult mongrel dogs (31 ± 6 kg) were studied with the approval of the Animal Care Committee of the University. The dogs were anesthetized with sodium thiopental 25 mg kg^{-1} intravenously; intubated, and ventilated with oxygen 30% in nitrous oxide. Halothane (inspired concentration 1–1.5%) was added to maintain hemodynamic stability during thoracotomy and instrumentation. The rectal temperature of the dogs was kept between 37°C and 39°C by means of a thermostatically regulated heating mattress and a warmed operating room. Heart rate and rhythm were monitored using ECG lead II.

The chest was opened through the left fifth intercostal space and catheters were inserted into the femoral artery and into the coronary vein accompanying the left anterior descending (LAD) artery for arterial and left ventricular coronary venous blood sampling respectively. Pressure sensors (Sentron 180 S, Cordis, Roden, the Netherlands) were inserted through a femoral artery into the ascending aorta and left ventricle. Ultrasonic transit-time flow probes (Transonic Systems, Ithaca, NY) were placed around the aortic root and around the LAD artery just proximal to the first diagonal branch. A pulmonary artery catheter (Baxter) was introduced via the right jugular vein into the pulmonary artery and connected to a thermodilution cardiac output computer (Baxter Edwards SAT 2, Irvine, CA) to compare cardiac output measurements derived from the ultrasonic aortic flow probe with the thermodilution cardiac output measurements.

To be able to induce reversible bicarotid occlusion, both common carotid arteries were dissected free over a distance of 1.5 cm and care was taken to ensure that nerve branches from the vagosympathetic trunk remained intact. Umbilical tape was placed loosely around each carotid artery, and the two ends of the ties were passed through stiff plastic tubing to form a snare occluder. Carotid pressure distal to the occluder was measured with a catheter (Bardicath, Bard Limited, Murray Hill, NJ) introduced into the cranial thyroid artery and connected to a pressure transducer (Baxter 43-600F).

Study Protocol

As soon as instrumentation was completed, nitrous oxide and halothane were discontinued. A loading dose of 40 mg kg^{-1} chloralose was administered, followed by a maintenance infusion of $8 \text{ mg kg}^{-1} \text{ h}^{-1}$. The animals were ventilated with 30% oxygen in air to normocarbia. After a stabilization period of at

Figure. 1. The study protocol in 11 chloralose-anesthetized dogs. BL, baseline; BCO, bicarotid occlusion; Esmo, esmolol; Dex, dexmedetomidine.

least 60 minutes, 4 successive experimental conditions were studied in each dog (fig.1).

Esmolol (Ohmeda Inc., NJ, USA) was given as a loading dose of $0.5 \text{ mg kg}^{-1} \text{ min}^{-1}$ for two minutes, followed by a continuous infusion of $0.3 \text{ mg kg}^{-1} \text{ min}^{-1}$. To check that the β_1 -adrenergic blockade from esmolol was adequate, the response to the tachycardiac dose of isoprenaline was tested during the esmolol infusion. The tachycardiac dose of isoprenaline was defined as the dose necessary to increase heart rate by more than 20% during control 1.

Dexmedetomidine (Orion Corporation, Farmos Research, Turku, Finland) was given as a loading dose of $1 \text{ } \mu\text{g kg}^{-1}$ over twenty minutes, followed by a continuous infusion of $1.5 \text{ } \mu\text{g kg}^{-1} \text{ h}^{-1}$. With this infusion we aimed at a plasma concentration of dexmedetomidine above 0.5 ng.mL^{-1} based on the pharmacokinetic set in the STANPUMP software (Department of Anesthesia, Stanford University, Palo Alto, CA)¹⁴.

Carotid sinus hypotension from bicarotid occlusion was used as a sympathetic stimulus as described in previous studies^{9,10}. Baseline measurements were performed 20 minutes after start of each condition, and bicarotid occlusion (BCO) measurements were performed after maximum changes from BCO had stabilized, which was approximately after one minute of occlusion.

The following variables were measured:

1. Carotid pressure distal to the occlusion.
2. Hemodynamic indices: heart rate, aortic pressure, left ventricular pressure, and cardiac output.
3. Plasma concentration of norepinephrine.
4. Variables related to left ventricular myocardial oxygen metabolism: LAD coronary venous blood gases, LAD coronary flow, and arterial blood gases and hemoglobin content.

To calculate LAD flow relative to myocardial weight, the perfusion area of the LAD was delineated by injecting methylene blue dye in the LAD at the end of each experiment¹⁵. Then, the dogs were killed by a pentobarbital overdose and their hearts were excised. The methylene-blue stained portion of the heart was dissected and weighed.

Data Analysis

All hemodynamic and coronary flow signals were preamplified and then digitized with a 16-channel, 12-bit A/D interface in an IBM-compatible PC. Sampling frequency was 200 Hz for each channel. The signals were continuously displayed on the computer screen during the experiment and beat-to-beat values were stored on the hard disk during each period of measurement. From these values the mean value over a stable hemodynamic period of two minutes, i.e. less than 5% heart rate variation, was calculated afterwards. Peak of first derivative of left ventricular pressure (LV dPdt_{max}) was derived from the left ventricular pressure signal. Systemic vascular resistance (SVR) was calculated as the quotient of mean aortic pressure and mean aortic blood flow. Coronary vascular resistance (CVR) was calculated as the quotient of mean aortic pressure and mean coronary blood flow.

The Rate Pressure Product (RPP), which is a frequent used index of myocardial oxygen demand, was calculated as; $RPP = \text{heart rate} \times \text{systolic aortic pressure}$.

Arterial plasma norepinephrine concentrations were analyzed with high performance liquid chromatography with colorimetric electrochemical detection^{16,17}. Plasma concentrations of dexmedetomidine were determined by gas chromatography-mass spectrometry¹⁸ at Farnos research, Turku, Finland. All blood samples were collected on ice. Those to be analyzed afterwards were centrifuged at 4 ° C within 15 minutes after sampling and stored as plasma at -70° C. Arterial and coronary venous blood gas tensions were assessed with a blood gas analyzer (ABL 3, Radiometer, Copenhagen, Denmark). Hemoglobin content (Hb) and oxygen saturation (O₂sat) were assessed with a hemoxymeter (OSM-2, Radiometer). The O₂ content (in mmol L⁻¹) was calculated as $Hb \times O_{2}sat + 0.0102 \times PO_2$. From this, oxygen extraction was calculated for the territory of myocardium perfused by the LAD, using a standard formula.

Statistical Analysis

The focus of the current study was on the effect of sympatholytic drugs on sympathetic induced cardiovascular responses. Therefore BCO-induced

responses were calculated as the difference between the value measured during BCO and the baseline value, and from this the percentage change from baseline was also calculated. Responses in presence of esmolol or dexmedetomidine were compared to each other and to their preceding control responses. A methodological limitation of the study was that the drugs always had to be investigated in the same sequence in each experiment because of the very short plasma half-life of esmolol and the long plasma half-life of dexmedetomidine. To minimize a possible time-effect of the comparison between esmolol and dexmedetomidine, the corresponding control values were first subtracted from the values found in presence of esmolol or dexmedetomidine. Based on our pilot experiments the present study was powered to detect a suppression of the BCO mediated increase in myocardial oxygen consumption of minimally 50% (power: 0.80 and $\alpha = 0.05$). Because of the number of experiments were too few to presume a standard distribution the non-parametric Wilcoxon signed rank test was used as a statistical test. Data are presented as mean $\pm$ standard deviation, unless stated otherwise.

Results

Baseline experimental conditions

Throughout the study period, all dogs maintained body temperature and shivering was not observed. Dexmedetomidine infusion resulted in plasma concentration of dexmedetomidine of 1.1 ± 0.9 ng ml⁻¹.

The change in baseline values from administration of dexmedetomidine or esmolol (Table 1) has been discussed in a previous publication¹⁹. The infusion protocols used resulted in sympatholysis because dexmedetomidine decreased plasma norepinephrine concentration more than 80% (table 1) and esmolol abolished the tachycardic response to isoprenaline in all experiments. The mean tachycardic dose of isoprenaline used to test the beta-adrenergic blockade was 0.45 ± 0.04 μ g kg⁻¹. Esmolol did not decrease the baseline plasma norepinephrine concentration.

Effect of Bicarotid Occlusion during Control Conditions

An example of the effect of BCO during control conditions is plotted in figure 2. Occlusion of the carotid arteries resulted in a significant decrease in carotid pressure (Control 1; decrease $22 \pm 11\%$, Control 2; decrease $15 \pm 8\%$ ($P = 0.12$, Control 1 *vs* Control 2). Simultaneously, plasma norepinephrine concentration, heart rate, systolic aortic pressure, SVR, dPdT_{max}, RPP, coronary flow and myocardial oxygen consumption increased (Fig. 3 and 4, grey bars). The effects of BCO were not statistically different between both control measurements,

Table 1: Baseline values (Mean $\pm$ SD) measured just before sympathetic stimulation during each experimental condition in chloralose anesthetized dogs.

Variable	Control 1	Esmolol	Control 2	Dexmedetomidine
Heart rate beats min ⁻¹	160 $\pm$ 20	138 $\pm$ 13 [*]	150 $\pm$ 18	101 $\pm$ 20 ^{*#}
Systolic aortic pressure mm Hg	127 $\pm$ 20	127 $\pm$ 18	128 $\pm$ 12	139 $\pm$ 25
dPdT _{max} mmHg sec ⁻¹	2093 $\pm$ 347	1442 $\pm$ 276 [*]	1706 $\pm$ 285	1465 $\pm$ 265 ^{*#}
Cardiac output L min ⁻¹	4.2 $\pm$ 1.9	2.7 $\pm$ 1.0 [*]	2.8 $\pm$ 0.9	2.0 $\pm$ 0.7 [*]
Systemic vascular resistance mmHg min. L ⁻¹	37 $\pm$ 22	51 $\pm$ 16	50 $\pm$ 18	76 $\pm$ 32 [*]
Pressure work index mmol min ⁻¹ 100g ⁻¹	0.67 $\pm$ 0.16	0.52 $\pm$ 0.09 [*]	0.56 $\pm$ 0.08	0.45 $\pm$ 0.07 [*]
Rate pressure product mmHg beats min ⁻¹	20270 $\pm$ 3272	17556 $\pm$ 3254 [*]	19176 $\pm$ 2876	13823 $\pm$ 2261 [*]
Norepinephrine nmol L ⁻¹	0.36 $\pm$ 0.24	0.50 $\pm$ 0.37	0.67 $\pm$ 0.55	0.11 $\pm$ 0.15 ^{*#}
O ₂ consumption mmol min ⁻¹ 100g ⁻¹	0.44 $\pm$ 0.11	0.38 $\pm$ 0.14	0.38 $\pm$ 0.15	0.35 $\pm$ 0.11
Coronary flow mL min ⁻¹ 100g ⁻¹	85 $\pm$ 23	72 $\pm$ 26	71 $\pm$ 24	52 $\pm$ 17
Coronary vascular resistance mm Hg ml ⁻¹ min ⁻¹ 100g ⁻¹	1.69 $\pm$ 0.98	1.94 $\pm$ 0.79	1.98 $\pm$ 0.88	2.92 $\pm$ 1.43 [#]

* P < 0.05 esmolol or dexmedetomidine compared to preceding control; # P < 0.05 esmolol compared to dexmedetomidine.

Figure 2. Representative recordings of the effects of bicarotid occlusion (BCO) in one of the dogs.

Figure 3. Bar graphs showing the effect of bicarotid occlusion as a sympathetic stimulus on heart rate, SVR, dPdT_{max}, and norepinephrine plasma concentrations in anesthetized dogs. Data represent percentage changes (mean $\pm$ standard error) during both control measurements (C1, C2; grey bars) and in presence of esmolol or dexmedetomidine (Esmo, Dex; black bars). * $P < 0.05$; esmolol or dexmedetomidine versus preceding control measurement. # $P < 0.05$ esmolol versus dexmedetomidine measurement.

except for heart rate which increased more ($P = 0.01$) and for SVR ($P = 0.03$) which increased less during Control 1 than during Control 2.

Thus, during control conditions BCO stimulated the sympathetic nervous system and this resulted in a parallel increase of myocardial oxygen consumption and hemodynamic indices of myocardial oxygen demand.

Figure 4. Bar graphs showing the effect of bicarotid occlusion as a sympathetic stimulus on the Rate Pressure Product, myocardial oxygen consumption, flow in LAD coronary artery, and coronary vascular resistance in anesthetized dogs. Data represent percentage changes (mean $\pm$ standard error) during both control measurements (C1, C2; grey bars) and in presence of esmolol or dexmedetomidine (Esmo, Dex; black bars). * $P < 0.05$; esmolol or dexmedetomidine versus preceding control measurement. # $P < 0.05$ esmolol versus dexmedetomidine measurement.

Effect of Bicarotid Occlusion in Presence of Esmolol and Dexmedetomidine

Esmolol and dexmedetomidine had different effects on several sympathetic mediated hemodynamic responses. (black bars, Fig. 3 and 4). First, esmolol, but not dexmedetomidine, attenuated the increase in heart rate ($P = 0.02$, esmolol *vs* dexmedetomidine). However, the absolute maximal heart rate during BCO was lower in presence of dexmedetomidine (dexmedetomidine 119 ± 14 , esmolol 141 ± 15 beats min^{-1} ; $P = 0.01$). This can be explained was because dexmedetomidine reduced the baseline heart rate more than esmolol (Table 1). In contrast, dexmedetomidine but not esmolol suppressed the increase in plasma norepinephrine concentration and the increase in SVR (Fig. 3). Both drugs

suppressed the increase in $dPdT_{\max}$ ($P = 0.16$, esmolol vs dexmedetomidine). However, despite their effects on hemodynamic responses; neither esmolol nor dexmedetomidine suppressed the sympathetic mediated increase in myocardial oxygen consumption and coronary flow. Simultaneously, coronary vascular resistance remained unchanged during BCO in presence of esmolol but decreased in presence of dexmedetomidine ($P = 0.03$ esmolol *vs* dexmedetomidine). Myocardial oxygen extraction remained unaffected (data not shown).

Thus, dexmedetomidine but not esmolol suppressed the BCO-related increase in plasma norepinephrine concentration and SVR. In contrast, esmolol, but not dexmedetomidine, suppressed the increase in heart rate. However, neither drug suppressed the increase in myocardial oxygen consumption.

Discussion

In this study in dogs we compared the potential of a β_1 - blocker and an α_2 - agonist to suppress the hemodynamic changes and increase in myocardial oxygen consumption associated with a sympathetic stimulus. The results of the current study confirms and extends findings of previous studies. Although in different ways, both drugs, at a sympatholytic dose, suppressed hemodynamic responses to sympathetic stimulation. However, neither drug affected the increase in myocardial oxygen consumption associated with a sympathetic stimulus to a significant extend.

Until now, few studies have compared the effects of a β -blocker and an α_2 -agonist on the hemodynamic and neuroendocrine consequences of a sympathetic stimulus. In these studies, the α_2 -agonist clonidine suppressed the sympathetic mediated increase in blood pressure and in plasma catecholamines better than the β -blocker esmolol^{7,8}, which is in accordance with our findings. In contrast to our findings, clonidine suppressed the heart rate response to a similar extend as the β -blocker. This discrepancy in findings may be the result of different measurements: indeed, in one of these studies²⁰, not the heart rate response, but the maximal heart rate in presence of an α_2 -agonist was measured. This heart rate was found to be lower than the maximal heart rate during control which is also in accordance with the current findings. Furthermore, these studies differed from the present experiments in several essential ways; they were performed in humans, inhalation anesthesia was used, the less selective α_2 -agonist clonidine was studied, and the stress stimuli used in these studies were “intubation” and “increase in desflurane concentration”.

It is not likely that the maintained heart rate response in presence of dexmedetomidine resulted from an increase in sympathetic tone. First; this is

because the plasma concentration of norepinephrine did not increase, and second; the maximal heart rate remained lower than the maximal heart rate in presence of β_1 -blockade. We hypothesize that the increase in heart rate during sympathetic stimulation in presence of dexmedetomidine resulted from a decrease of an increased parasympathetic tone. In accordance with parasympathomimetic effects of dexmedetomidine, a study in dogs showed that the vagus nerve plays an important role in the anti-arrhythmic effects of dexmedetomidine²¹.

The current study extends the findings of previous studies because the effects of a beta-blocker and an α_2 -agonist on sympathetic mediated increases in myocardial oxygen consumption were measured in addition to changes in hemodynamic variables. We found that, despite suppression of several hemodynamic responses, neither esmolol nor dexmedetomidine suppressed the increase in myocardial oxygen consumption associated with a sympathetic stimulus. There are several possible explanations for this finding.

First, the sympathetic stimulus could be too weak. In the current study carotid hypotension from bicarotid occlusion was used as a sympathetic stimulus which increased the rate-pressure-product by 40% and the myocardial oxygen consumption by approximately 30%. In accordance, previous work from our laboratory has shown that the decrease in myocardial energy requirements from dexmedetomidine depends on baseline heart rate and blood pressure²². Also, it has been shown that beta-blockade blunts the increase in myocardial oxygen consumption in exercising dogs⁴ but it does not suppress the increase in myocardial oxygen consumption related to administration of cocaine in conscious dogs²³. In accordance with these experimental studies in animals, a study in humans showed that beta-blockade had unpredictable effects on myocardial ischemia from mental-stress²⁴, but reliably reduced myocardial ischemia from exercise-stress. Exercise is one of the most severe physiologic stressors for the cardiovascular system increasing the rate-pressure-product and myocardial oxygen consumption more than 150%^{25,26}, and it has been shown that betablockade limits the exercise induced increase in myocardial oxygen consumption by reducing increases in heart rate and in myocardial contractility²⁵. Cocaine increased the rate-pressure-product by only 70%²³ indicating that this stimulus has less hemodynamic consequences than exercise. However, measuring the effects of sympatholytic drugs on a stimulus which does not result in a large hemodynamic response seems to be clinically relevant because mental activities are as potent as physical activities in triggering daily life ischemia²⁷.

A second possible explanation for the lack of effect of dexmedetomidine and esmolol on myocardial oxygen consumption was that the present study was not powered to detect a suppression of the BCO related increase in myocardial

oxygen consumption of less than 50%. Therefore it cannot be excluded that esmolol and dexmedetomidine suppressed sympathetic mediated increases in myocardial oxygen consumption to a lesser extent.

A final explanation may be that the doses of esmolol and dexmedetomidine used were not adequate. However, the infusion regimens of both esmolol and dexmedetomidine resulted in adequate sympatholysis in all experiments, as evidenced by blunting the isoprenaline-mediated tachycardic response and the significant decrease in plasma norepinephrine concentrations, respectively. Also, infusion of one-third of the dose of esmolol used in the current study blocked 70% of the beta-receptors in another study²⁸, and a plasma concentration of dexmedetomidine above 0.5 ng.mL⁻¹ is known to reduce sympathetic tone effectively in dogs²⁹ and in humans³⁰.

The current complex experimental study enabled comparison of the effects of a beta₁-blocker and an alpha₂-agonist on sympathetic mediated changes in coronary hemodynamics. In presence of dexmedetomidine, sympathetic stimulation induced a decrease in coronary vascular resistance indicating that dexmedetomidine maintains adaptive coronary vascular responses to an increase in myocardial oxygen demand. Alpha₂-agonists have been shown to enhance the release of endothelium-derived relaxing factor (ERDF) in the coronary circulation³¹, but ERDF was not measured in the current study. It could be argued that a shortage of myocardial oxygen supply explains the sympathetic mediated decrease in CVR in presence of dexmedetomidine. However, we found no indication for this because myocardial oxygen extraction and coronary venous PH remained unchanged.

In contrast to the decrease in CVR in presence of dexmedetomidine, the sympathetic mediated increase in coronary flow was associated with an unchanged CVR in presence of esmolol. In a previous study CVR increased during sympathetic stimulation in presence of betablockade⁴. However, in that study a non-selective beta blocker was studied in contrast to the beta₁-adreno-receptor antagonist studied in the current study.

The results of this study must be interpreted within the constraints of several limitations. First, extrapolation of these data from dogs to humans should be undertaken with caution. Second, a time effect in addition to a pharmacological effect on the BCO-response can not be excluded. However, BCO had similar effects for most variables during both control measurements and we applied statistical methods to minimize a possible time-effect. Finally, anesthesia may have influenced our measurements. However, chloralose anesthesia was used because this is known to have relatively little influence on central neuro-regulation³² and oxygen metabolism³³.

In summary, the effects of dexmedetomidine and esmolol on the neuro-humoral and hemodynamic consequences of sympathetic stimulation in chloralose-anesthetized dogs were in accordance with their respective central and peripheral sympatholytic actions. However, neither drug had a significant effect on the increase in myocardial oxygen consumption and coronary flow associated with the applied sympathetic stimulus.

References

- 1 Auerbach AD, Goldman L. $\{\beta\}$ -Blockers and Reduction of Cardiac Events in Noncardiac Surgery: Scientific Review. *JAMA* 2002; **287**: 1435–44.
- 2 Wijeysondera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. *Am J Med* 2003; **114**: 742–52.
- 3 Eagle KA, Berger PB, Calkins H et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Anesth Analg* 2002; **94**: 1052–64.
- 4 Heyndrickx GR, Pannier JL, Muylaert P, Mabilde C, Leusen I. Alteration in myocardial oxygen balance during exercise after beta-adrenergic blockade in dogs. *J Appl Physiol* 1980; **49**: 28–33.
- 5 Willigers HM, Prinzen FW, Roekaerts PM, de Lange S, Durieux ME. Dexmedetomidine Decreases Perioperative Myocardial Lactate Release in Dogs. *Anesth Analg* 2003; **96**: 657–64.
- 6 Stevens RD, Burri H, Tramer MR. Pharmacologic Myocardial Protection in Patients Undergoing Noncardiac Surgery: A Quantitative Systematic Review. *Anesth Analg* 2003; **97**: 623–33.
- 7 Zalunardo MP, Zollinger A, Szelloe P et al. [Cardiovascular stress protection following anesthesia induction. Comparison of clonidine and esmolol]. *Anaesthesist* 2001; **50**: 21–5.
- 8 Weiskopf RB, Eger Eld, Noorani M, Daniel M. Fentanyl, esmolol, and clonidine blunt the transient cardiovascular stimulation induced by desflurane in humans. *Anesthesiology* 1994; **81**: 1350–5.
- 9 Kirchheim H, Gross R. Hemodynamics of the carotid sinus reflex elicited by bilateral carotid occlusion in the conscious dog: Effect of α - or β -adrenergic blockade on the reflex response. *Pflugers Arch.* 1971; **327**: 203–24.
- 10 Disalvo J, Parker PE, Scott JB, Haddy FJ. Carotid baroreceptor influence on coronary vascular resistance in the anesthetized dog. *Am. J. Physiology* 1971; **221**(1): 156–60.
- 11 Martin SE, Pilkington DM, Longhurst JC. Coronary vascular responses to chemical stimulation of abdominal visceral organs. *Am J Physiol* 1989; **256**: H735–H44.
- 12 Sato Y, Schaible HG, Schmidt RF. Reactions of cardiac postganglionic sympathetic neurons to movements of normal and inflamed knee joints. *Journal of the Autonomic Nervous System* 1984; **12**: 1–13.
- 13 Staszewska-Woolly J, Luk DE, Nolan NN. Cardiovascular reflexes mediated by capsaicin sensitive cardiac afferent neurones in the dog. *Cardiovascular Research* 1986; **20**: 897–906.
- 14 Dyck JB, Maze M, Haack C et al. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. *anesthesiology* 1993; **78**: 821–8.
- 15 Hasegawa S, Kusuoka H, Fukuchi K et al. 14 C-deoxyglucose imaging overestimates myocardial viability in subacute infarction of rats. *Nuclear medicine communications* 2002; **23**: 209–17.

- 16 Scheinin M, Karhuvaara S, Ojala Karlsson P, Kallio A, Koulu M. Plasma 3,4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG) are insensitive indicators of alpha 2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. *Life Sci* 1991; **49**: 75-84.
- 17 Koulu M, Scheinin M, Kaartinen A et al. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. *Br. J. clin. Pharmac.* 1989; **27**: 243-55.
- 18 Vuorilehto L, Salonen JS, Anttila M. Picogram level determination of medetomidine in dog serum by capillary gas chromatography with negative ion chemical ionisation mass spectrometry. *Journal of Chromatography* 1989; **497**: 282-7.
- 19 Willigers HM, Prinzen FW, Roekaerts PM. Comparison of the effects of dexmedetomidine and esmolol on myocardial oxygen consumption in dogs. *European journal of anaesthesiology* 2004; **21**: 957-66.
- 20 Zalunardo MP, Zollinger A, Spahn DR, Seifert B, Pasch T. Preoperative clonidine attenuates stress response during emergence from anesthesia. *J Clin Anesth* 2000; **12**: 343-9.
- 21 Kamibayashi T, Hayashi Y, Mammoto T et al. Role of the vagus nerve in the antidysrhythmic effect of dexmedetomidine on halothane/epinephrine dysrhythmias in dogs. *Anesthesiology* 1995; **83**: 992-9.
- 22 Lawrence CJ, Prinzen FW, Lange de S. The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand. *Anesth Analg* 1996; **82**: 544-50.
- 23 Shannon RP, Stambler BS, Komamura K, Ihara T, Vatner SE. Cholinergic modulation of the coronary vasoconstriction induced by cocaine in conscious dogs [see comments]. *Circulation* 1993; **87**: 939-49.
- 24 Bairy CN, Krantz DS, DeQuattro V, Berman DS, Rozansky A. Effect of beta-blockade on low heart rate-related ischemia during mental stress. *JACC* 1991; **17**: 1388-95.
- 25 Colin P, Ghaleh B, Monnet X et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. *American journal of physiology. Heart and circulatory physiology* 2003; **284**: H676-82.
- 26 Heyndrickx GR, Muylaert P, Pannier JL. alpha-Adrenergic control of oxygen delivery to myocardium during exercise in conscious dogs. *Am J Physiol* 1982; **242**: H805-9.
- 27 Krantz DS, Kop WJ, Santiago HT, Gottdiener JS. Mental stress as a trigger of myocardial ischemia and infarction. *Cardiology clinics* 1996; **14**: 271-87.
- 28 Gorczynski RJ, Murthy VS, Hwang TE. beta-blocking and hemodynamic effects of ASL-8052. *Journal of cardiovascular pharmacology* 1984; **6**: 1048-59.
- 29 Flacke WE, Flacke JW, Bloor BC, McIntee DE, Sagan M. Effects of Dexmedetomidine on systemic and coronary hemodynamics in the anesthetized dog. *J of Cardiothorac and Vasc Anesthesia* 1993; **7**: 41-9.
- 30 Talke P, Li J, Jain U et al. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group. *Anesthesiology* 1995; **82**: 620-33.
- 31 Coughlan MG, Lee JG, Bosnjak ZJ et al. Direct coronary and cerebral vascular responses to dexmedetomidine. *Anesthesiology* 1992; **77**: 998-1006.
- 32 Citters Van RL, Franklin DL, Rushmer RF. Left Ventricular Dynamics in Dogs During Anesthesia with Alpha-Chloralose and Sodium Pentobarbital. *The american journal of cardiology* 1964: 349-54.
- 33 Covert RF, Schreiber MD, Leff AR et al. Oxygen metabolism and catecholamine secretion during chloralose anesthesia in lambs. *J of Developmental Physiology* 1992; **17**: 125-32.

CHAPTER 7

Contrasting baroreceptor effects of esmolol and dexmedetomidine in dogs

Henriette M. M. Willigers, Leon A. F. Ledoux, Paul M.H.J. Roekaerts and Frits W. Prinzen

Submitted to: *J Cardiothorac Vasc Anesth*

Abstract

Background: Beta-blockers and α_2 -agonists decrease cardiac complications partly from their effects on baroreceptors. However, these effects have not been compared directly.

Methods: Sequential measurements were performed in chloralose-anaesthetized dogs during: Control 1, Esmo (esmolol (β_1 -blocker)), Control 2, and Dexmed (dexmedetomidine (α_2 -agonist)). We measured: 1) Heart Rate and Arterial Pressure Variability (HRV and APV) using fast Fourier transformation, 2) plasma norepinephrine and arterial pressure response (pressure gain) to a decrease in carotid artery pressure, and 3) the linear HR-pressure relationship to changes in aortic pressure (cardiac baroreflex sensitivity), and minimal and maximal HR plateau.

Results: Both sympatholytic drugs suppressed the maximal HR plateau. Compared to Esmo, Dexmed: 1) maintained the cardiac baroreflex sensitivity better (slope: -0.7 (0.3) versus -0.1 (0.2) (bpm/mmHg), $P = 0.02$), 2) increased the (vagal) high frequency component of HRV (62 (17) versus 43 (17) dB, $P = 0.05$), 3) lowered the minimal HR plateau (77 (8) versus 126 (18) bpm), $P = 0.02$), and 4) decreased the low frequency component of APV (54 (8) versus 61 (11) dB, $P = 0.02$). In contrast Esmo tended to maintain the pressure gain better than Dexmed (1.35 (0.92) versus 0.59 (0.67), $P = 0.07$).

Conclusions: Dexmed and Esmo have similar cardiac sympatholytic effects but Dexmed has an additional vagomimetic and vascular sympatholytic effect. As a result Dexmed maintains cardiac baroreflex sensitivity at lower heart rates and improves arterial pressure stability, but Esmo maintains baroreceptor-mediated vasoconstriction.

Introduction

The mechanisms by which sympatholytic drugs decrease postoperative cardiac complications are still being explored. There are indications from animal¹ and human research² that these drugs improve myocardial oxygen balance from their ceiling effect on sympathetic mediated tachycardic and hypertensive responses. Recently, evidence has emerged that their effects on autonomic nervous system mediated cardiovascular control may also be important in decreasing cardiac complications³. This is because impaired cardiovascular control, which is known to occur after surgery⁴, is a predictor for adverse cardiac outcome in certain groups of patients⁵. The use of either a beta-adrenergic blocker or an alpha₂-adrenergic agonist is advised for pharmacological perioperative symptholysis⁶. This is because it remains unknown which of these groups of sympatholytic drugs is superior in decreasing cardiac complications. To our knowledge, also differences in baroreceptor mediated cardiovascular control of these groups of drugs have not been studied. Our hypothesis is that beta-blockers and alpha₂-agonists have different effects on baroreceptor mediated cardiovascular control because of their respective peripheral and central modes of action. Therefore, we compared esmolol, a short acting beta₁-blocker, to dexmedetomidine, the most specific alpha₂-agonist available, within chloralose-anaesthetized dogs. Autonomic nervous system tone and baroreceptor mediated cardiovascular control was evaluated from; the power of frequency spectra of heart rate and aortic pressure variability, plasma norepinephrine concentrations, the response to a decrease in carotid artery pressure, and cardiac baroreflex sensitivity.

Materials and methods

Instrumentation

Eleven adult Mongrel dogs (31(7) kg) were studied with the approval of the Animal Care and Use Committee at the University of Maastricht, the Netherlands. The current study was part of our previous study focussing on the effects of esmolol and dexmedetomidine on sympathetic mediated increases in myocardial oxygen consumption⁷. Details of instrumentation in these dogs have been described in our previous paper. In short; anaesthesia was induced with sodium thiopental 25 mg kg⁻¹ intravenously, the trachea was intubated and the lungs were ventilated with 30% oxygen in nitrous oxide. Anaesthesia was maintained with halothane (inspired concentration 1–1.5%). The rectal temperature of the dogs was kept between 37° C and 39° C by means of a thermostatically regulated heating mattress. Heart rate and rhythm were monitored using limb lead II of the electrocardiogram. To monitor aortic and left ventricular pressure,

pressure sensors (Sentron 180 S, Cordis, Roden, the Netherlands) were inserted through the right femoral artery into the left ventricle and ascending aorta. Ultrasonic transit-time flow probes (Transonic Systems, Ithaca, NY) were placed around the aortic root and around the LAD artery. Catheters were inserted into the femoral artery and into the left anterior descending (LAD) coronary vein for arterial and coronary venous blood sampling respectively.

Both common carotid arteries were dissected free, taking care that nerve branches from the vagosympathetic trunk remained intact. Umbilical tape was placed loosely around each carotid artery and the two ends of the ties were passed through stiff plastic tubing to form a snare occluder. Carotid pressure distal to the occluder was measured with a catheter (Bardicath, Bard Limited) introduced into the cranial thyroid artery and connected to a pressure transducer (Baxter 43–600F). Balloon tipped catheters (8 Fr, occlusion balloon catheter, Medi-tech, Boston Scientific Cooperation) were introduced into the femoral artery and vein and pushed up into the descending aorta and inferior caval vein respectively to change the arterial pressure for evaluation of cardiac baroreflex sensitivity.

Protocol

Once surgery was complete, nitrous oxide and halothane were discontinued and chloralose (bolus: 40 mg kg^{-1} , maintenance $8 \text{ mg kg}^{-1} \text{ h}^{-1}$) was infused intravenously. After a stabilization period of at least 60 minutes measurements were performed during the following sequential experimental conditions in each dog: Control 1, Esmo (during esmolol infusion), Control 2, and Dex (during dexmedetomidine infusion). This sequence was chosen because esmolol has a much shorter half live than dexmedetomidine (9 minutes versus 2.3 hours).

Esmolol (Ohmeda Inc., NJ, USA) was given as a loading dose of 1 mg kg^{-1} in two minutes, followed by an infusion of $0.3 \text{ mg kg}^{-1} \text{ min}^{-1}$. To check that the β_1 -adrenergic blockade from esmolol was adequate, the response to the tachycardiac dose of isoprenaline was tested during the esmolol infusion. The tachycardiac dose of isoprenaline was defined as the dose necessary to increase heart rate by more than 20% during control 1.

Dexmedetomidine (Orion Corporation, Farnos Research, Turku, Finland) was given as a loading dose of $1 \mu\text{g kg}^{-1}$ over twenty minutes, followed by a continuous infusion of $1.5 \mu\text{g kg}^{-1} \text{ h}^{-1}$.

The study protocol is shown in figure 1. At least 20 minutes after the start of each experimental condition different tests of baroreceptor function were done. First, arterial pressure and heart rate data of a stable hemodynamic period of at least five minutes were stored for off-line spectral analysis of spontaneous heart

Figure 1. Flow chart of our study protocol in chloralose-anesthetized dogs. HRV, heart rate and arterial pressure variability; BL, baseline; BCO, bicarotid occlusion; BST, cardiac barosensitivity test; Esmo, esmolol; Dex, dexmedetomidine

rate and aortic pressure variability, as measures of cardiac autonomic balance and arterial pressure stability. Then, the effect of a decrease in carotid artery pressure from bilateral carotid artery occlusion on aortic pressure, and plasma norepinephrine concentration was measured to evaluate the efferent sympathetic vascular effects of baroreceptor stimulation. Finally, the effect of arterial pressure variation on the heart rate response was measured to test cardiac baroreceptor sensitivity. At the end of the protocol the dogs were killed by an overdose of pentobarbital.

Data analysis and measurements

Hemodynamic data

All hemodynamic signals were preamplified and then digitized with a 16-channel, 12-bit A/D interface in an IBM-compatible PC. Sampling frequency was 200Hz for each channel. Beat-to-beat values of hemodynamic data were stored on the hard disk during each period of measurement for off line analysis.

Spontaneous Heart Rate Variability (HR Variability) and Aortic Pressure Variability (AOP Variability). Heart rate and systolic aortic pressure variability were measured to quantify cardiac sympathovagal balance and pressure lability respectively^{8,9}. Details of the method of spectral analysis have been published previously⁸. This method was chosen because it referred to a study in both dogs and humans and spectral analysis of our data confirmed that the frequency peaks of heart rate and arterial pressure variability were within the suggested predetermined frequency bands. In short: an artefact-free stationary time series of

approximately 400 beats was selected from the ECG (lead II) signal. In case of a non-sinus beat, this beat was discarded and replaced by the interpolated value. Beat to beat systolic arterial pressure was calculated from the peak of the aortic pressure signal. Spectral components and associated power of the heart rate and arterial pressure data were computed using a computer program based on Fast Fourier analysis. From these computed spectra the power (dB) of total frequency (TF: 0.02 – 0.35 Hz), low frequency (LF: 0.02 – 0.12 Hz), and high frequency (HF: 0.25 – 0.35 Hz) was calculated for each experimental period.

Blood samples

All blood samples were collected on ice, centrifuged at 4° C, and stored as plasma at –70°C.

Plasma concentrations of dexmedetomidine were determined by gas chromatography–mass spectrometry¹⁰ at Farnos research, Turku, Finland.

Plasma norepinephrine concentrations were measured as an indicator of sympathetic tone and were analyzed with high performance liquid chromatography with colorimetric electrochemical detection¹¹.

Bilateral Carotid artery Occlusion (BCO). To evaluate carotid baroreceptor function, both common carotid arteries were occluded for 3 minutes as described previously^{12, 13} and we measured; the carotid pressure distal to the occlusion, heart rate, aortic pressure, and plasma norepinephrine concentrations. Responses were calculated as the difference between the value measured during carotid occlusion (after maximal changes had stabilized) and the value measured immediately before carotid occlusion. The gain of the carotid pressure response, as a measure of the baroreceptor mediated vascular response, was calculated as the ratio of the increase in systolic aortic pressure to the decrease in systolic carotid artery pressure.

Cardiac Baroreceptor Sensitivity Test (cardiac BST): Arterial pressure was randomly varied within a range of 50 mmHg above and below baseline by inflating the intravascular balloons. The number of pressure changes for each test was approximately 9, and their duration was approximately 30 seconds. The resulting heart rates and arterial pressures were stored for off line analysis. The mean value of systolic aortic pressure and heart rate (sinus rhythm) over the final 10–15 s of each pressure change were calculated. The gain of cardiac baroreceptor reflex sensitivity was calculated as the slope of the regression line relating systolic arterial pressure (mmHg) to heart rate (beats per min (bpm)). Additionally, the maximal and minimal heart rate values obtained during each test were calculated as measures of sympathetic and parasympathetic cardiac modulation

respectively. Cardiac BST was not repeated during control 2 because this would increase the length of the experiment too much.

Statistical analysis

Cardiac BST data from two out of the eleven dogs were missing because of technical problems. These two dogs were excluded from our analysis because cardiac BST was our main outcome measure. Power analysis indicated that the present study was powered to detect a 50% difference in baroslope changes (power: 0.80 and $\alpha = 0.05$). Because of the relatively low number of experiments the non-parametric Wilcoxon signed rank test was used to analyse the data. The effects of esmolol and dexmedetomidine were compared to each other and to their preceding control measurements. To minimize a possible time-effect in comparing esmolol and dexmedetomidine values, statistical testing was done on values from which their preceding control values were subtracted. For analysis of the cardiac BST, for which Control 2 measurement was not done, repeated measures analysis (Friedman test) followed by Wilcoxon Signed Ranked test and Bonferroni correction was used. A P-value of ≤ 0.05 was considered statistically significant. Data are presented as mean (SD), unless stated otherwise.

Results

Baseline experimental conditions

Esmolol infusion did not affect plasma norepinephrine concentrations (table 1), and resulted in adequate beta-adrenergic blockade because it abolished the response to the tachycardic dose isoprenaline (mean dose $0.45 (0.04) \mu\text{g kg}^{-1}$) in all experiments. The infusion scheme of dexmedetomidine resulted in dexmedetomidine plasma concentrations of $0.94 (0.33 - 3.49) \text{ ng mL}^{-1}$ (median (range)), and was associated with a decrease in plasma norepinephrine concentrations of more than 75% (Table 1). During baseline dexmedetomidine decreased heart rate more than esmolol but neither drug affected arterial pressure (Table 1).

Heart rate and arterial pressure variability.

Neither drug affected total spectral frequency power of heart rate and arterial pressure variability (data not shown). Dexmedetomidine increased the power of the HF component of heart rate variability and this was associated with a decrease in power of the LF component of systolic arterial pressure variability. In contrast, esmolol did not affect power of any of the frequency spectra (Fig. 2).

Table 1: Baseline values and effect of bicarotid occlusion (BCO) (mean (SD))during the sequential study periods. BCO-effect = BCO value minus baseline value.

Variable		Control 1	Esmolol	Control 2	Dexmedetomidine
Norepinephrine nmol L ⁻¹	Baseline	0.36 (0.24)	0.50 (0.39)	0.67 (0.55)	0.11 (0.15) ^{*#}
	BCO-effect	0.28 (0.25)	0.16 (0.20)	0.09 (0.09)	-0.06 (0.12) [*]
Heart rate beats min ⁻¹	Baseline	160 (20)	138 (13) [*]	150 (18)	101 (20) ^{*#}
	BCO-effect	12 (6)	3 (3) [*]	7 (2)	18 (15) [#]
Syst Aortic pressure mmHg	Baseline	127 (20)	127 (18)	128 (12)	139 (25)
	BCO-effect	36 (19)	26 (10)	32 (6)	14 (9) [*]
Syst Carotid pressure mmHg	BCO-effect	- 31 (18)	-24 (9)	-21 (12)	-34 (15) [#]

★ P ≤ 0.05 compared to preceding control; # P ≤ 0.05 esmolol compared to dexmedetomidine.

Bilateral Carotid artery Occlusion

Dexmedetomidine, but not esmolol, suppressed the carotid baroreceptor mediated increase in plasma concentration of norepinephrine and the increase in systolic arterial pressure (table 1, BCO effect). Simultaneously, carotid artery pressure distal to the carotid occlusion decreased more in presence of dexmedetomidine than in presence of esmolol (table 1). This suppression of the carotid baroreceptor mediated vasopressor response from dexmedetomidine in contrast to the maintained response from esmolol is shown in figure 3 as their different effects on the calculated pressure gain (ratio of the increase in systolic aortic pressure to the decrease in systolic carotid artery pressure).

Cardiac Barosensitivity Test

The range of arterial pressures used to test cardiac barosensitivity was similar during each study period (Control 1: 78 – 178 mmHg, Esmo: 70 – 170 mmHg, Dexmed: 81 – 181 mmHg, P > 0.05). However, the resulting slope and range of heart rate responses were different during each period of measurement as can be seen in a typical example (Fig. 4). Esmolol almost abolished the slope of cardiac barosensitivity; in contrast, dexmedetomidine maintained this slope (Fig 5, upper panel). Dexmedetomidine and esmolol suppressed the maximal heart rate

Figure 2. Individual changes in power of Low Frequency (LF) and High Frequency (HF) heart rate variability (upper and middle panels) and LF arterial pressure variability (lower panels). Esmo :during esmolol infusion, Dexmed: during dexmedetomidine infusion * = $P \leq 0.05$ compared to preceding control measurement. # = $P \leq 0.05$ Dexmed compared to Esmo. Dexmedetomidine increased HF heart rate variability and depressed LF arterial pressure variability compared to esmolol. dexmedetomidine

Figure 3. Individual changes in arterial pressure gain calculated as the ratio of the increase in systolic arterial pressure to the decrease in systolic carotid pressure during bicarotid artery occlusion. Dexmedetomidine decreased this gain compared to the preceding control measurement in all experiments. Esmo: during esmolol infusion, Dexmed: during dexmedetomidine infusion. * = $P \leq 0.05$ compared to preceding control measurement.dexmedetomidine

Figure 4. Example of changes in cardiac baroreceptor sensitivity during the sequential experimental conditions in one of the dogs. White dots: baseline values, black dots: values measured during induced pressure changes. Esmolol (esmo) almost abolished the slope relating heart rate responses (y-axis) to changes in systolic arterial pressure (x-axis). Dexmedetomidine maintained this slope at lower heart rate values compared to control.

plateau in response to a decrease in arterial pressure to a similar extend (Fig. 5, middle panel). However, only dexmedetomidine decreased the minimum heart rate plateau to an increase in arterial pressure (Fig. 5, lower panel). As a result, dexmedetomidine but not esmolol maintained the heart rate range in response to arterial pressure variation (heart rate range: Control 1: 58 (34), Esmo: 17 (14), Dexmed: 55 (18) bpm). Of notice, some dogs developed severe nodal or ventric-

Figure 5. Effects of esmolol (esmo) and dexmedetomidine (dexmed) on cardiac barosensitivity. Data indicate individual results of the slope of the regression line relating heart rate to systolic arterial pressure (upper panel), maximal heart rate response (middle panel), and minimal heart rate response (lower panel). * = $P < 0.05$ compared to control. # = $P < 0.05$ dexmed compared to esmo. dexmedetomidine

ular brady-arrhythmias upon maximal inflation of the aortic balloon in presence of dexmedetomidine. However, these arrhythmias resolved spontaneously after deflating the balloon, and only tests without arrhythmias were included in the analysis.

Discussion

This is the first comparative study of two different classes of sympatholytic drugs on different measures of baroreceptor function. Arterial baroreflex function is an important regulatory system in maintaining cardiovascular stability, and consists of a cardiac and a vascular effector limb. The current study in chloralose-anaesthetized dogs shows several important differences between the α_2 -agonist dexmedetomidine and the β_1 -antagonist esmolol on arterial baroreflex function.

The most important difference was that dexmedetomidine but not esmolol maintained cardiac baroreceptor gain, as indicated by their effects on the cardiac barosensitivity slope. This maintained cardiac baroreceptor gain from dexmedetomidine is in accordance with previous studies in dogs¹⁴ and human volunteers¹⁵. However, the depressed baroreceptor gain from esmolol contrasts with previous findings which indicate that beta-blockade either has no effect¹⁶ or even improves cardiac baroreflex function⁹. Differences in methods may explain these contrasting results because in these previous studies cardiac barosensitivity was assessed from rapid changes in arterial pressure, which measures mainly vagally mediated heart rate changes¹⁷. In contrast, we studied cardiac barosensitivity from “steady state” pressure changes, which measures both the sympathetic and parasympathetic mediated component of the heart rate response.

Our data suggest that the differences in cardiac baroreceptor sensitivity between esmolol and dexmedetomidine may be explained from their effects on cardiac vagal tone. Both drugs decreased the sympathetic controlled maximal heart rate plateau to a similar extent, but only dexmedetomidine increased cardiac vagal tone. This is indicated by a lower minimum heart rate plateau during cardiac barosensitivity testing, and by the increase in power of the HF component of heart rate variability, an accurate measure of cardiac vagal tone at rest¹⁸. As a result dexmedetomidine maintained the operating range of the baroreflex system. In contrast, the pure sympatholytic effect of esmolol decreased the range and thus the slope of heart rate responses. Our findings fit well with recent observations in mice¹⁹ and humans²⁰ suggesting that the beneficial effect of α_2 -agonists on baroreceptor sensitivity is mediated by the parasympathetic nervous system. The mechanisms by which α_2 -agonists enhance this parasympathetic mediated heart rate control are not known but they may directly influence α_2 -adrenoreceptors in the vagal nuclei of the medulla oblongata²¹. Previous data on parasympathetic effects from beta blockade are equivocal, showing that beta blockade either increases^{16,22} or, in accordance with the current findings, has no parasympathetic effect^{18,19}. These conflicting results may be explained by the various conditions determining the

vagal HF component of heart rate variability such as; baseline autonomic tone²³, acute versus chronic beta blockade⁸, and the specific beta-blocker studied²⁴.

The increased vagal tone and maintenance of baroreceptor gain of dexmedetomidine resulted in an improved hemodynamic stability, as indicated by its suppression of the LF power of arterial pressure variability⁹. In accordance, it has been shown that rapid cardiac vagal modulation is the most important mechanism for correcting high frequency, small magnitude, blood pressure variations²⁵. Also, the α_2 -agonist clonidine has been shown to have a hemodynamic stabilizing effect during the recovery period in patients with hypertension³.

These differences in cardiac autonomic control between dexmedetomidine and esmolol may be clinically relevant because indices of impaired cardiovascular control have been shown to be independent predictors of adverse outcome after myocardial infarction²⁶ or after noncardiac surgery⁵. However, extrapolation from animal studies should be done with caution.

In addition to these different effects on the cardiac limb of the baroreceptor reflex, the current study indicates that dexmedetomidine and esmolol had also different effects on the vascular effector limb. Their effects on arterial pressure gain and plasma norepinephrine response during carotid artery occlusion indicate that dexmedetomidine suppressed and esmolol maintained the sympathetic mediated vasopressor response. The conclusions of previous studies on the effects of α_2 -agonists on sympathetic mediated increases of vascular tone are equivocal. In accordance with the current study, dexmedetomidine attenuated the vasoconstrictor response to hypotension in rabbits²⁷ and clonidine decreased the slope of the arterial pressure – sympathetic nerve activity relationship in human volunteers²⁰. It is likely that this reduced sympathetic vasopressor response results from their effects at α_2 -receptors in vasomotor centres in the brainstem²⁸, and at pre- and post sympathetic ganglia²⁹. In contrast, α_2 -agonists have been shown to maintain adaptive sympathetic vasopressor responses during potential major decreases in blood pressure such as sepsis³⁰ or vessel unclamping during liver transplantation³¹. These contrasting effects of α_2 -agonists on sympathetic vasopressor responses may be explained because central pathways different from baroreceptor pathways are involved during hypovolemic episodes³². In the current study beta-blockade did not affect the sympathetic vasopressor response which is in accordance with findings in human volunteers showing that propranolol does not attenuate the increase in sympathetic nerve activity during orthostatic stress³³.

The results of this study must be interpreted within the constraints of several limitations. First, it is likely that anaesthesia affected our results. However, chloralose anaesthesia is used widely for neurophysiological experiments and

offers stable hemodynamics³⁴. The presence of anesthesia and controlled ventilation also prevented uncontrolled emotional stress responses and irregular respiration, which are known to interfere with neurophysiological measurements. Another limitation is that the counter regulatory response from the aortic baroreceptors depressed the arterial pressure response during carotid occlusion³⁵, thus interfering with the calculation of the pressure gain. However it is likely that this confounding factor had a similar effect during all periods of measurement.

In conclusion, in accordance with our hypothesis we found that an α_2 -agonist and a beta-blocker had different baroreceptor effects. Dexmedetomidine maintained baroreceptor mediated heart rate responses and improved baseline arterial pressure stability from its vagomimetic effect but decreased vascular responsiveness from its central sympatholytic effect. In contrast, peripheral cardiac sympatholysis from esmolol depressed the cardiac effector limb of the baroreceptor but maintained central sympathetic mediated vascular responsiveness.

References

- 1 Willigers HM, Prinzen FW, Roekaerts PM, de Lange S, Durieux ME. Dexmedetomidine Decreases Perioperative Myocardial Lactate Release in Dogs. *Anesth Analg* 2003; 96: 657-64.
- 2 Wärltier DC, Pagel PS, Kersten JR. Approaches to the prevention of perioperative myocardial ischemia. *Anesthesiology* 2000; 92: 253-9.
- 3 Parlow JL, Begou G, Sagnard P et al. Cardiac baroreflex during the postoperative period in patients with hypertension: effect of clonidine. *Anesthesiology* 1999; 90: 681-92.
- 4 Amar D, Fleisher M, Pantuck CB et al. Persistent alterations of the autonomic nervous system after noncardiac surgery. *Anesthesiology* 1998; 89: 30-42.
- 5 Filipovic M, Jeger R, Probst C et al. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. *J Am Coll Cardiol* 2003; 42: 1767-76.
- 6 Eagle KA, Berger PB, Calkins H et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary *Anesth Analg* 2002; 94: 1052-64.
- 7 Willigers HM, Prinzen FW, Roekaerts PM. The effects of esmolol and dexmedetomidine on myocardial oxygen consumption during sympathetic stimulation in dogs. *J Cardiothorac Vasc Anesth* 2006; 20: 364-70.
- 8 Pagani M, Lombardi F, Guzzetti S et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. *Circ Res* 1986; 59: 178-93.
- 9 Formes KJ, Wray DW, O Yurvati AH, Weiss MS, Shi X. Sympathetic cardiac influence and arterial blood pressure instability. *Autonomic neuroscience basic and clinical* 2005; 118: 116-24.
- 10 Vuorilehto L, Salonen JS, Anttila M. Picogram level determination of medetomidine in dog serum by capillary gas chromatography with negative ion chemical ionisation mass spectrometry. *Journal of Chromatography* 1989; 497: 282-7.

- 11 Hoorn van der FAJ, Boomsma, Man in het Veld AJ, Schalekamp MADH. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. *Journal of Chromatography* 1989; 487: 17-28.
- 12 Disalvo J, Parker PE, Scott JB, Haddy FJ. Carotid baroreceptor influence on coronary vascular resistance in the anesthetized dog. *Am. J. Physiology* 1971; 221(1): 156-60.
- 13 Kirchheim H, Gross R. Hemodynamics of the carotid sinus reflex elicited by bilateral carotid occlusion in the conscious dog: Effect of α - or β -adrenergic blockade on the reflex response. *Pflugers Arch.* 1971; 327: 203-24.
- 14 Devcic AD, Schmeling WT, Kampine JP, Warltier DC. Oral dexmedetomidine preserves baroreceptor function and decreases anesthetic requirements of halothane-anesthetized dogs. *Anesthesiology* 1994; 81: 419-30.
- 15 Hogue CW, Jr., Talke P, Stein PK et al. Autonomic nervous system responses during sedative infusions of dexmedetomidine. *Anesthesiology* 2002; 97: 592-8.
- 16 Cogliati C, Colombo S, Ruscone TG et al. Acute beta-blockade increases muscle sympathetic activity and modifies its frequency distribution. *Circulation* 2004; 110: 2786-91.
- 17 Kingwell BA, McPherson GA, Korner PI. Assessment of gain of tachycardia and bradycardia responses of cardiac baroreflex. *Am J Physiol* 1991; 260: H1254-H63.
- 18 Hayano J, Sakakibara Y, Yamada A et al. Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects. *Am J Cardiol* 1991; 67: 199-204.
- 19 Tank J, Jordan J, Diedrich A et al. Clonidine improves spontaneous baroreflex sensitivity in conscious mice through parasympathetic activation. *Hypertension* 2004; 43: 1042-7.
- 20 Tank J, Diedrich A, Szczech E, Luft FC, Jordan J. Alpha-2 adrenergic transmission and human baroreflex regulation. *Hypertension* 2004; 43: 1035-41.
- 21 Robertson HA, Leslie RA. Noradrenergic alpha 2 binding sites in vagal dorsal motor nucleus and nucleus tractus solitarius: autoradiographic localization. *Can J Physiol Pharmacol* 1985; 63: 1190-4.
- 22 Melenovsky V, Simek J, Sperl M, Malik J, Wichterle D. Relation between actual heart rate and autonomic effects of beta blockade in healthy men. *Am J Cardiol* 2005; 95: 999-1002.
- 23 Goldberger JJ, Challapalli S, Tung R, Parker MA, Kadish AH. Relationship of heart rate variability to parasympathetic effect. *Circulation* 2001; 103: 1977-83.
- 24 Minami N, Yoshikawa T, Kataoka H et al. Effects of exercise and beta-blocker on blood pressure and baroreflexes in spontaneously hypertensive rats. *Am J Hypertens* 2003; 16: 966-72.
- 25 Wray DW, Formes KJ, Weiss MS et al. Vagal cardiac function and arterial blood pressure stability. *Am J Physiol Heart Circ Physiol* 2001; 281: H1870-80.
- 26 La Rovere MT, Bigger Jr JT, Marcus FI et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. *The Lancet* 1998; 351: 478-84.
- 27 Blake DW. Dexmedetomidine and hemodynamic responses to simulated hemorrhage in experimental heart failure. *Anesth Analg* 2000; 91: 1112-7.
- 28 Li G, Wang X, Abdel Rahman AA. Neuronal norepinephrine responses of the rostral ventrolateral medulla and nucleus tractus solitarius distinguish the I1- from the alpha2-receptor-mediated hypotension in conscious SHR. *J Cardiovasc Pharmacol* 2005; 46: 52-62.
- 29 McCallum JB, Boban N, Hogan Q et al. The mechanism of alpha2-adrenergic inhibition of sympathetic ganglionic transmission. *Anesth Analg* 1998; 87: 503-10.
- 30 Dodd-o JM, J BM, Dorman T, Rosenfeld BA. Preserved sympathetic response to hypotension despite perioperative α_2 agonist administration. *Anesth Analg* 1997; 84: 1208-10.

- 31 De Kock M, Laterre PF, Van Obbergh L, Carlier M, Lerut J. The effects of intraoperative intravenous clonidine on fluid requirements, hemodynamic variables, and support during liver transplantation: a prospective, randomized study. *Anesth Analg* 1998; 86: 468-76.
- 32 Potts PD, Ludbrook J, Gillman Gaspari TA, Horiuchi J, Dampney RA. Activation of brain neurons following central hypervolaemia and hypovolaemia: contribution of baroreceptor and non-baroreceptor inputs. *Neuroscience* 2000; 95: 499-511.
- 33 Jacobsen T, Converse R, Jr, Victor R. Contrasting effects of propranolol on sympathetic nerve activity and vascular resistance during orthostatic stress. *Circulation* 1992; 85: 1072-6.
- 34 Cox RH. Influence of chloralose anesthesia on cardiovascular function in trained dogs. *American Journal of Physiology* 1972; 223: 660-7.
- 35 Brunner MJ, Greene AS, Kallman CH, Shoukas AA. Interaction of canine carotid sinus and aortic arch baroreflexes in the control of total peripheral resistance. *Circ Res* 1984; 55: 740-50.

CHAPTER 8

General discussion

General discussion

Based on the findings in the current thesis there are three major topics which deserve further discussion:

1. Strategies to modulate the perioperative stress response: improving knowledge.
2. Choosing the optimal sympatholytic drug to decrease perioperative myocardial ischemia.
3. Decreasing the stress response, what is the goal ?

Strategies to modulate the perioperative stress response: improving knowledge

The introduction of anesthesia and the associated reduction in the perioperative stress response was a major step forward in improving morbidity and mortality after surgery. However, modern surgery is still associated with adverse outcome related to the surgical stress response. This is mainly due to adverse cardiac outcome during the first weeks to months after surgery. At this moment clinical studies do not allow definitive conclusions regarding the effectiveness of anesthetic strategies on cardiac outcome. This can be explained by: 1) the low incidence of adverse cardiac outcome, 2) the presence of confounding factors and, 3) the difficulty in defining and thus measuring adverse cardiac outcome. Therefore great efforts will be needed to overcome these difficulties in studying the effectiveness of anesthetic techniques on cardiac outcome. An alternative way to increase our knowledge on the relationship between anesthetic strategies and adverse outcome is to study the effect of anesthetic strategies on the stress response to surgery instead of studying their effect on cardiac outcome. Our study in chapter 3 of this thesis is an example of this strategy. In this study the effect of an opioid based anesthetic technique and an epidural technique on the early postoperative stress response were compared. Our main finding was that the plasma concentration of epinephrine was higher and that of the pro-inflammatory cytokine IL-6 was lower in presence of an opioid based anesthetic compared to an epidural based anesthetic. These findings highlight the potential of anesthetic techniques to modulate both the neuro-endocrine and the immunological homeostatic responses to surgery. However, it is difficult to define the implications of our findings. Firstly, this is because all patients had an uneventful recovery. A second difficulty in interpreting our results is that we measured relatively few markers of the stress response. For example, we did not measure cortisol, anti-inflammatory cytokines, and lymphocyte function. Finally, because

Figure 1

Schematic presentation of different factors which modify outcome after surgery indirectly from their effects on the stress response to tissue injury.

of large inter-individual variations in markers of the stress response it is difficult to compare our findings to those in other studies having different study designs .

To increase our knowledge on anesthetic modulation of the stress response as such we need an enormous amount of data. One possibility is to create an extensive database of patients having surgery. This database should include serial measurements of different markers of the stress response and variables such as surgical procedure, anesthetic technique, and co-morbidity of the patient. In this way we may identify factors, including anesthetic strategy, associated with an excessive or inadequate stress response (fig.1). The resulting knowledge may help to define the optimal perioperative strategy for an individual patient. For example, our findings in chapter 3 suggest that an opioid-based technique is superior in decreasing the inflammatory response to surgery whereas an epidural based technique has superior sympatholytic effects. If this suggestion is confirmed in such a database then we may use an opioid technique if the inflammatory response is to be suppressed, and an epidural technique if decreasing sympathetic activation is important for an individual patient. In the future genetic data may be added as a variable to such a database. This is because there is increasing evidence that differences in genetic expression or genetic polymorphisms are responsible for more than 50% of the individual differences

in the stress response². For instance, genetic variants in cytokine and leukocyte-endothelial interaction pathways are independently associated with severity of myocardial necrosis after cardiac surgery³. Also, it has been identified that a single-nucleotide polymorphism of the α_2 -adrenoreceptor contributes to autonomic nervous system responsiveness⁴.

Choosing the optimal sympatholytic drug to decrease myocardial ischemia after surgery

Clinical studies indicate that sympatholytic drugs decrease perioperative myocardial ischemia. An important draw-back of these studies is the absence of an accepted gold standard indicator for the diagnosis of perioperative myocardial ischemia or myocardial infarction⁵. This beneficial effect of sympatholytic drugs on myocardial ischemia may result from suppressing shear stress on unstable coronary plaques thus decreasing plaque rupture and coronary thrombosis. Also, they may attenuate potentially dangerous mismatches in myocardial oxygen demand and supply in presence of a severe stable coronary stenosis. However, these two potential mechanisms are difficult to separate in patients. In this context, the results of our study in dogs on the anti-ischemic effects of perioperative sympatholysis are important (chapter 4). The experimental model used in this study excluded coronary plaque rupture as a cause of myocardial ischemia because coronary artery stenosis resulted from an occluder applied around a coronary artery. In this way we were able to show that profound perioperative sympatholysis has the potential to decrease myocardial ischemia purely from its effect on myocardial oxygen balance. Another important aspect of this study in dogs is that myocardial ischemia was diagnosed using its gold standard indicator: myocardial lactate release.

The American Heart Association advised the use of either an α_2 -agonist or a beta-blocker for perioperative pharmacological sympatholysis⁶. Central sympatholysis produced by an α_2 -agonist may have a potential advantage over the use of a beta-blocker because of the ability of the α_2 -agonist to attenuate the adverse effects of sympathetic nervous stimulation mediated by peripheral α - as well as β receptors. However, there are no clinical studies in which the potential anti-ischemic effects of α_2 -agonists are directly compared to those of beta-blockers⁷. The main drawback of performing such a comparative study is the enormous number of patients needed. At this moment the first adequately powered randomised controlled trial on perioperative beta-blockers (POISE trial) plans to recruit 10.000 patients⁸. It is likely that many more patients are needed to find a difference between two potentially effective

sympatholytic therapies. Therefore it is unlikely that both sympatholytic therapies have clinically relevant different anti-ischemic effects.

This leaves us with the question: should we use α_2 -agonists or beta-blockers for perioperative pharmacological sympatholysis? The results of the experimental studies in this thesis do not give a definite answer to this question. However, they clearly show several differences between both classes of drugs which may help to answer this question. Firstly, findings from this thesis suggest that an α_2 -agonist decreases heart rate more than a beta-blocker (chapter 7). This was explained by the additional vagomimetic action of the α_2 -agonist in contrast to the pure cardiac sympatholytic effect of the beta-blocker. In accordance with our findings, a case report indicated that dexmedetomidine was more successful than esmolol in treating intraoperative tachycardia⁹. The effect of a drug on heart rate seems to be important for its effect on myocardial ischemia. This is because in our study in dogs emerging from anesthesia (chapter 4) a decreased heart rate from pharmacological sympatholysis was associated with and an improved myocardial blood flow through a stenotic coronary artery. Also clinical studies show the importance of heart rate in decreasing myocardial ischemia. In a study in patients having vascular surgery the use of beta-blockers to keep the heart rate below the pre-operative measured ischemic threshold markedly reduced postoperative myocardial ischemia¹⁰. In another study, a tight heart rate control with beta-blockers was associated with reduced perioperative myocardial ischemia and troponin T¹¹. Myocardial oxygen balance may also improve from a decrease in myocardial oxygen demand. However, the findings in our study in dogs emerging from anesthesia suggest that sympatholysis has no significant effect on myocardial oxygen demand (chapter 4). Also, our findings in chapter 5 and 6 suggest that neither an α_2 -agonist nor a beta-blocker has an important effect on myocardial oxygen demand. In these studies in dogs, myocardial oxygen demand was measured from its effect on myocardial oxygen consumption in presence of an unlimited coronary blood flow. This measurement of demand is more accurate than a hemodynamic index of demand, such as rate pressure product, which is generally used in clinical studies (chapter 5). Thus, it is likely that, in presence of a critical coronary artery stenosis, the heart rate lowering effect of sympatholytic drugs improves myocardial oxygen balance from an increase in myocardial oxygen supply. Therefore, these findings present a reason to study the heart rate lowering effects of beta-blockers and α_2 -agonists during the period early after surgery.

Secondly, our findings suggest that an α_2 -agonist, in contrast to a beta-blocker suppresses stress related increases in systemic vascular resistance (SVR) (chapter 6). An increase in SVR is an important component of the hemodynamic response to mental stress. It is likely that mental stress from

anxiety and pain is part of the postoperative stress. There are indications that increases in SVR may cause myocardial ischemia in patients having left ventricular dysfunction. It has been shown that beta-blockers may be harmful in patients having mental-stress induced myocardial ischemia¹². Therefore, an α_2 -agonist may be a more appropriate sympatholytic drug than a beta-blocker in these patients. Additionally, α_2 -agonists may decrease mental stress from their sedative and anxiolytic properties.

Finally, the findings in this thesis indicate that α_2 -agonists and beta-blockers have different effects on baroreceptor mediated cardiovascular control. This difference may be important because indices of impaired cardiovascular control are independent predictors of adverse outcome after surgery¹³. First, we found that the α_2 -agonist dexmedetomidine maintained baroreceptor sensitivity and baseline hemodynamic stability better than the beta-blocker esmolol (chapter 4). Additionally, the increase in cardiac vagal tone from the α_2 -agonist was associated with an improved ability to correct high frequency, small magnitude, blood pressure variations¹⁴. A second difference regarding cardiovascular control mechanisms was that the α_2 -agonist, in contrast to the beta-blocker, suppressed the sympathetic vasoconstrictor response. However, the clinical relevance of this potential disadvantageous effect of an α_2 -agonist is difficult to predict. There is, on the one hand, a large body of clinical experience of perioperative use of α_2 -agonists and no major complications have so far been published. Additionally, several case-reports have shown that α_2 -agonists maintain adaptive sympathetic vasopressor responses during potential major decreases in blood pressure such as sepsis¹⁵ or from vessel unclamping during liver transplantation¹⁶. An explanation for this maintained sympathetic response in the presence of an α_2 -agonist is that central pathways different from baroreceptor pathways are involved during hypovolemic episodes¹⁷. On the other hand, there is evidence that suppression of sympathetic mediated compensatory mechanisms may be disadvantageous in some patient groups. For example, the Moxonidine Congestive Heart Failure Trial (MOXCON) showed that moxonidine, a centrally active sympatholytic imidazoline agonist, increased mortality by more than 50% in patients having severe heart failure^{18,19}. Also, the beta-Blocker Evaluation of Survival Trial (BEST) showed that powerful sympatholysis increased mortality in patients having severe heart failure²⁰. These two trials caution against unbounded sympatholysis and may present a reason to study the relation between perioperative sympatholysis and potential shock states. Thus, the main findings from our comparative experimental studies on autonomic nervous system modulation of an α_2 -agonist and a beta-blocker were:

1. The vagomimetic effect of the α_2 -agonist resulted in a lower heart rate.

2. In contrast to the beta-blocker, the α_2 -agonist maintained baroreceptor mediated heart rate responses.
3. The α_2 -agonist suppressed the increase in vascular resistance to a stress stimulus more effectively.

In conclusion, the findings in this thesis suggest that an α_2 -agonist may be more appropriate than a beta-blocker for perioperative sympatholysis. However, studies in patients are needed before more firm advice can be given.

Decreasing the stress response, what is the goal ?

One view is that the stress response to surgery should be maximally suppressed because it may have adverse effects and is not necessary for survival in hospitalised surgical patients ²¹.

Another view is not to intervene aggressively in the stress response. The stress response was programmed in higher organisms to provide homeostatic adjustments to cold, volume loss, hypoglycaemia, and infection. In accordance with this view, Cannon showed 70 years ago that total sympathectomized cats were unable to defend themselves against various stresses such as hypoxia, temperature changes and hemorrhage²². The over-aggressive use of therapies to decrease the stress response may be harmful in patients as well. For example, the use of opioids in intensive care patients may have detrimental effects such as increased haemodynamic instability during shock, and suppression of host immune responses²³. Also, some patients have a defective stress-response secondary to their illness, and suppressing the stress response in these patients may have detrimental effects. For example, Rivers and colleagues²⁴ reported that a significant number of patients who needed vasopressor therapy early after surgery had signs of adrenal insufficiency. The administration of the stress hormone hydrocortisone decreased vasopressor requirement and improved survival in these patients. Finally, there are strong indications that intense sympatholytic therapy may be detrimental in patients having severe cardiac failure^{18 20}.

In conclusion, to improve perioperative outcome the surgical team should aim to control the stress response in relation to the individual patient. However, precise control of the different components of the surgical stress response is not possible at this moment. Also, it is difficult to predict which patients are at risk of an inappropriate stress response. Therefore, controlling the stress response in relation to the individual patient is a major task in future perioperative medicine. At this moment, we have to continue our current practice of aiming at a profound suppression of the stress response to surgery. However, we must realize that this strategy places large responsibility on care providers to monitor and protect their patients during the perioperative period.

References

- 1 Nathan C. Points of control in inflammation. *Nature* 2002; **420**: 846–52.
- 2 Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. *Ann N Y Acad Sci* 1998; **851**: 311–35.
- 3 Podgoreanu MV, White WD, Morris RW et al. Inflammatory gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery. *Circulation* 2006; **114**: I275–81.
- 4 Finley JC, Jr., O’Leary M, Wester D et al. A genetic polymorphism of the α_2 -adrenergic receptor increases autonomic responses to stress. *Journal of applied physiology Bethesda, Md.* 1985 2004; **96**: 2231–9.
- 5 Fleisher LA, Zielski MM, Schulman SP. Perioperative ST-segment depression is rare and may not indicate myocardial ischemia in moderate-risk patients undergoing noncardiac surgery. *J Cardiothorac Vasc Anesth* 1997; **11**: 155–9 .
- 6 Eagle KA, Berger PB, Calkins H et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Anesth Analg* 2002; **94**: 1052–64.
- 7 Wijeyesundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. *Am J Med* 2003; **114**: 742–52.
- 8 Devereaux PJ, Beattie WS, Choi PT et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. *BMJ Clinical research*; **331**: 313–21.
- 9 Ruesch S, Levy JH. Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery. *Anesth Analg* 2002; **95**: 316–8, table of contents.
- 10 Raby KE, Brull SJ, Timimi F et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. *Anesthesia and analgesia* 1999; **88**: 477–82.
- 11 Feringa HH, Bax JJ, Boersma E et al. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients. *Circulation ISE: 1524 4539* 2006; **114**: I344–9.
- 12 Bairy CN, Krantz DS, DeQuattro V, Berman DS, Rozansky A. Effect of beta-blockade on low heart rate-related ischemia during mental stress. *JACC* 1991; **17**: 1388–95.
- 13 Filipovic M, Jeger R, Probst C et al. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. *J Am Coll Cardiol* 2003; **42**: 1767–76.
- 14 Wray DW, Formes KJ, Weiss MS et al. Vagal cardiac function and arterial blood pressure stability. *Am J Physiol Heart Circ Physiol* 2001; **281**: H1870–80.
- 15 Dodd-o JM, J BM, Dorman T, Rosenfeld BA. Preserved sympathetic response to hypotension despite perioperative α_2 agonist administration. *anesth analg* 1997; **84**: 1208–10.
- 16 De Kock M, Laterre PF, Van Obbergh L, Carlier M, Lerut J. The effects of intraoperative intravenous clonidine on fluid requirements, hemodynamic variables, and support during liver transplantation: a prospective, randomized study. *Anesthesia and analgesia* 1998; **86**: 468–76.
- 17 Potts PD, Ludbrook J, Gillman Gaspari TA, Horiuchi J, Dampney RA. Activation of brain neurons following central hypervolaemia and hypovolaemia: contribution of baroreceptor and non-baroreceptor inputs. *Neuroscience* 2000; **95**: 499–511.
- 18 Coats AJ. Heart Failure 99 — the MOXCON story. *International journal of cardiology* 1999; **71**: 109–11.

- 19 Cohn JN, Pfeffer MA, Rouleau J et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). *Eur J Heart Fail* 2003; **5**: 659–67.
- 20 Bristow MR, Krause-Steinrauf H, Nuzzo R et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. *Circulation* 2004; **110**: 1437–42.
- 21 Kehlet H. Labat lecture 2005: surgical stress and postoperative outcome—from here to where? *Reg Anesth Pain Med* 2006; **31**: 47–52.
- 22 Cannon WB. *The Wisdom of the body*. New York: Norton, W. W, 1932.
- 23 Molina PE. Opioids and opiates: analgesia with cardiovascular, haemodynamic and immune implications in critical illness. *J Intern Med* 2006; **259**: 138–54.
- 24 Rivers EP, Gaspari M, Saad GA et al. Adrenal insufficiency in high-risk surgical ICU patients. *Chest* 2001; **119**: 889–96.